# Patent

## Title
Human microRNAs and methods for inhibiting same

## Abstract

The invention relates to isolated DNA or RNA molecules comprising at least ten contiguous bases having a sequence in a microRNA shown in SEQ ID NOs: 1-94; 281-374; 467-481; 497-522; or 549, except that up to thirty percent of the bases may be wobble bases, and up to 10% of the contiguous bases may be non-complementary. The invention further relates to modified single stranded microRNA molecules, isolated single stranded anti-microRNA molecules and isolated microRNP molecules. In another embodiment, the invention relates to a method for inhibiting microRNP activity in a cell.

## Background
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a National Phase application of International Application No. PCT/US06/16767 filed May 1, 2006, which claims priority based on U.S. Provisional Application No. 60/714,519 filed Apr. 29, 2005, which are incorporated herein by reference.
This application asserts priority to U.S. Provisional Application Ser. No. 60/714,519 filed on Apr. 29, 2005, the specification of which is hereby incorporated by reference in its entirety.


The invention described in this application was made with funds from the National Institutes of Health/NIGMS, Grant Numbers 1 P01 GM073047-01 and 1 R01 GM068476-01. The United States government has certain rights in this invention.


BACKGROUND OF THE INVENTION
MicroRNAs are typically small RNA molecules of generally about nineteen to twenty-five nucleotides in length. These microRNAs are non-coding RNAs which are cleaved from hairpin precursors. Several microRNAs have been identified in the genomes of a wide range of multicellular life forms.
MicroRNAs in animals are found in diverse genomic locations. Typically, most microRNAs are encoded in intergenic regions. Other microRNAs are hosted within the introns of mRNAs or within non-coding RNA transcripts.
Many microRNAs are conserved in sequence between distantly related organisms, and exhibit tissue-specific or developmental stage-specific expression. The conservation of the sequence between organisms indicates that microRNAs may play important roles in biological processes.
MicroRNA molecules have been reported to control gene expression in a sequence specific manner in a wide variety of organisms by blocking translation after partially hybridizing to the non-coding 3′ region of mRNAs of target genes. The genes targeted by microRNAs largely remain to be characterized.
However, there is growing evidence that microRNAs are implicated in various diseases and illnesses. For instance, Drosophila microRNAs have been shown to target genes involved in apoptosis. Also, B-cell chronic lymphocytic leukemia has been linked to the deletion of two microRNAs.
Therefore, it is important to elucidate the mechanisms involved in mediating genes which play a role in the regulation of various diseases and illnesses. Thus, there is a need for materials and methods that can help elucidate the function of regulators, such as microRNAs, in various diseases and illnesses.
Further, due to the ability of microRNAs to induce RNA degradation or repress translation of mRNA which encode important proteins, there is also a need for novel molecules that inhibit microRNA-induced cleavage or promote expression by inhibiting translational repression of target mRNAs.
SUMMARY OF THE INVENTION
In one embodiment, the invention relates to an isolated DNA or RNA molecule comprising at least ten contiguous bases having a sequence in a microRNA shown in SEQ ID NOs:1-94, except that up to thirty percent of the bases may be wobble bases, and up to 10% of the contiguous bases may be non-complementary.
In another embodiment, the invention relates to a modified single stranded microRNA molecule comprising a minimum of ten moieties and a maximum of fifty moieties on a molecular backbone, the molecular backbone comprising backbone units, each moiety comprising a base bonded to a backbone unit, wherein at least ten contiguous bases have the same sequence as a contiguous sequence of bases in a microRNA molecule shown in SEQ ID NOs:1-94, except that up to thirty percent of the bases pairs may be wobble base pairs, and up to 10% of the contiguous bases may be additions, deletions, mismatches, or combinations thereof; no more than fifty percent of the contiguous moieties contain deoxyribonucleotide backbone units, and at least one moiety is not an unmodified deoxyribonucleotide moiety or an unmodified ribonucleotide moiety.
In a further embodiment, the invention relates to an isolated single stranded anti-microRNA molecule comprising a minimum of ten moieties and a maximum of fifty moieties on a molecular backbone, the molecular backbone comprising backbone units, each moiety comprising a base bonded to a backbone unit, each base forming a Watson-Crick base pair with a complementary base, wherein at least ten contiguous bases have a sequence complementary to a contiguous sequence of bases in any one of the microRNA molecules shown in SEQ ID NOs; 1-94, except that up to thirty percent of the base pairs may be wobble base pairs, and up to 10% of the contiguous bases may be additions, deletions, mismatches, or combinations thereof; no more than fifty percent of the contiguous moieties contain deoxyribonucleotide backbone units; and the molecule is capable of inhibiting microRNP activity.
In yet another embodiment, the invention relates to a method for inhibiting microRNP activity in a cell, the microRNP comprising a microRNA molecule, the method comprising introducing into the cell a single-stranded anti-microRNA molecule according to claim 18, wherein the anti-microRNA is complementary to the microRNA molecule.
In yet a further embodiment, the invention relates to an isolated microRNP comprising an isolated DNA or RNA molecule described herein.
In another embodiment, the invention relates to an isolated microRNP comprising an isolated single stranded microRNA molecule described herein.
In another embodiment, the invention relates to an isolated DNA or RNA molecule comprising at least ten contiguous bases having a sequence in a microRNA shown in SEQ. ID. NOs:281-374, except that up to thirty percent of the bases may be wobble bases, and up to 10% of the contiguous bases may be wobble bases, and up to 10% of the contiguous bases may be non-complementary.
In another embodiment, the invention relates to an isolated DNA or RNA molecule comprising at least ten contiguous bases having a sequence in a microRNA shown in SEQ. ID. NOs:467-481, except that up to thirty percent of the bases may be wobble bases, and up to 10% of the contiguous bases may be wobble bases, and up to 10% of the contiguous bases may be non-complementary.
In another embodiment, the invention relates to an isolated DNA or RNA molecule comprising at least ten contiguous bases having a sequence in a microRNA shown in SEQ. ID. NOs:497-522, except that up to thirty percent of the bases may be wobble bases, and up to 10% of the contiguous bases may be wobble bases, and up to 10% of the contiguous bases may be non-complementary.
In another embodiment, the invention relates to an isolated DNA or RNA molecule comprising at least ten contiguous bases having a sequence in a microRNA shown in SEQ. D. NO:549, except that up to thirty percent of the bases may be wobble bases, and up to 10% of the contiguous bases may be wobble bases, and up to 10% of the contiguous bases may be non-complementary.
In another embodiment, the invention relates to a modified single stranded microRNA molecule comprising a minimum of ten moieties and a maximum of fifty moieties on a molecular backbone, the molecular backbone comprising backbone unites, each moiety comprising a base bonded to a backbone unit, wherein at least ten contiguous bases have the same sequence as a contiguous sequence of based in a microRNA molecule shown in SEQ. D. NOs: 281-374, except that up to thirty percent of the base pairs may be wobble base pairs, and up to 10% of the contiguous bases may be additions, deletions, mismatches, or combinations thereof; no more than fifty percent of the contiguous moieties contain deoxyribonucleotide backbone units, and at least one moiety is not an unmodified deoxyribonucleotide moiety or an unmodified ribonucleotide moiety.
In another embodiment, the invention relates to a modified single stranded microRNA molecule comprising a minimum of ten moieties and a maximum of fifty moieties on a molecular backbone, the molecular backbone comprising backbone unites, each moiety comprising a base bonded to a backbone unit, wherein at least ten contiguous bases have the same sequence as a contiguous sequence of bases in a microRNA molecule shown in SEQ. D. NOs:467-481, except that up to thirty percent of the base pairs may be wobble base pairs, and up to 10% of the contiguous bases may be additions, deletions, mismatches, or combinations thereof; no more than fifty percent of the contiguous moieties contain deoxyribonucleotide backbone units, and at least one moiety is not an unmodified deoxyribonucleotide moiety or an unmodified ribonucleotide moiety.
In another embodiment, the invention relates to a modified single stranded microRNA molecule comprising a minimum of ten moieties and a maximum of fifty moieties on a molecular backbone, the molecular backbone comprising backbone unites, each moiety comprising a base bonded to a backbone unit, wherein at least ten contiguous bases have the same sequence as a contiguous sequence of bases in a microRNA molecule shown in SEQ. ID. NOs: 497-522, except that up to thirty percent of the base pairs may be wobble base pairs, and up to 10% of the contiguous bases may be additions, deletions, mismatches, or combinations thereof; no more than fifty percent of the contiguous moieties contain deoxyribonucleotide backbone units, and at least one moiety is not an unmodified deoxyribonucleotide moiety or an unmodified ribonucleotide moiety.
In another embodiment, the invention relates to a modified single stranded microRNA molecule comprising a minimum of ten moieties and a maximum of fifty moieties on a molecular backbone, the molecular backbone comprising backbone unites, each moiety comprising a base bonded to a backbone unit, wherein at least ten contiguous bases have the same sequence as a contiguous sequence of bases in a microRNA molecule shown in SEQ. ID. NO: 549, except that up to thirty percent of the base pairs may be wobble base pairs, and up to 10% of the contiguous bases may be additions, deletions, mismatches, or combinations thereof; no more than fifty percent of the contiguous moieties contain deoxyribonucleotide backbone units, and at least one moiety is not an unmodified deoxyribonucleotide moiety or an unmodified ribonucleotide moiety.
In another embodiment, the invention relates to an isolated single stranded anti-microRNA molecule comprising a minimum of ten moieties and a maximum of fifty moieties on a molecular backbone, the molecular backbone comprising backbone units, each moiety comprising a base bonded to a backbone unit, each base forming a Watson-Crick base pair with a complementary base, wherein at least ten contiguous bases have a sequence complementary to a contiguous sequence of bases in any one of the microRNA molecules shown in SEQ ID NOs; 281-374, except that up to thirty percent of the base pairs may be wobble base pairs, and up to 10% of the contiguous bases may be additions, deletions, mismatches, or combinations thereof; no more than fifty percent of the contiguous moieties contain deoxyribonucleotide backbone units; and the molecule is capable of inhibiting microRNP activity.
In another embodiment, the invention relates to an isolated single stranded anti-microRNA molecule comprising a minimum of ten moieties and a maximum of fifty moieties on a molecular backbone, the molecular backbone comprising backbone units, each moiety comprising a base bonded to a backbone unit, each base forming a Watson-Crick base pair with a complementary base, wherein at least ten contiguous bases have a sequence complementary to a contiguous sequence of bases in any one of the microRNA molecules shown in SEQ ID NOs; 467-481, except that up to thirty percent of the base pairs may be wobble base pairs, and up to 10% of the contiguous bases may be additions, deletions, mismatches, or combinations thereof; no more than fifty percent of the contiguous moieties contain deoxyribonucleotide backbone units; and the molecule is capable of inhibiting microRNP activity.
In another embodiment, the invention relates to an isolated single stranded anti-microRNA molecule comprising a minimum of ten moieties and a maximum of fifty moieties on a molecular backbone, the molecular backbone comprising backbone units, each moiety comprising a base bonded to a backbone unit, each base forming a Watson-Crick base pair with a complementary base, wherein at least ten contiguous bases have a sequence complementary to a contiguous sequence of bases in any one of the microRNA molecules shown in SEQ ID NOs: 497-522, except that up to thirty percent of the base pairs may be wobble base pairs, and up to 10% of the contiguous bases may be additions, deletions, mismatches, or combinations thereof; no more than fifty percent of the contiguous moieties contain deoxyribonucleotide backbone units; and the molecule is capable of inhibiting microRNP activity.
In another embodiment, the invention relates to an isolated single stranded anti-microRNA molecule comprising a minimum of ten moieties and a maximum of fifty moieties on a molecular backbone, the molecular backbone comprising backbone units, each moiety comprising a base bonded to a backbone unit, each base forming a Watson-Crick base pair with a complementary base, wherein at least ten contiguous bases have a sequence complementary to a contiguous sequence of bases in any one of the microRNA molecules shown in SEQ ID NO: 549, except that up to thirty percent of the base pairs may be wobble base pairs, and up to 10% of the contiguous bases may be additions, deletions, mismatches, or combinations thereof; no more than fifty percent of the contiguous moieties contain deoxyribonucleotide backbone units; and the molecule is capable of inhibiting microRNP activity.



DESCRIPTION OF THE FIGURES
FIG. 1 shows the modified nucleotide units discussed in the specification. B denotes any one of the following nucleic acid bases: adenosine, cytidine, guanosine, thymine, or uridine
FIG. 2: Conservation patterns of known and predicted human microRNAs. The conservation patterns are based on the UCSC phastCons scores (http://genome.ucsc.edu). The chromosomal regions of the microRNAs with additional 3000 flanking nucleotides on both sides are presented. The chromosomal coordinates follow the build 34 assembly (hg16) of the human genome from UCSC (http://genome.ucsc.edu/). For simplicity the X-axis displays the relative positions. Known microRNAs are designated by their Rfam name omitting the “hsa” prefix. The predicted microRNAs fall into two categories: verified predictions—these predictions were verified experimentally in this study. New predictions—these predictions have not been verified. The microRNA orientation is marked by an arrow. A: example of a microRNA prediction that extends a known pair cluster. B: Unraveling a new multi-member cluster. (The figures are not plotted to scale, and therefore the conserved region width is a function of the length of the presented region; the longer the region, the narrower is the presented profile).



DETAILED DESCRIPTION OF THE INVENTION
MicroRNA Molecules
In one embodiment, the invention relates to an isolated single stranded microRNA molecule having any one of SEQ. ID. NOs:1-94.
In another embodiment, the invention relates to an isolated single stranded microRNA molecule having any one of SEQ. ID. NOs: 281-374.
In yet another embodiment, the invention relates to an isolated single stranded microRNA molecule having any one of SEQ. ID. NOs: 467-481.
In a further embodiment, the invention relates to an isolated single stranded microRNA molecule having any one of SEQ. ID. NOs: 497-522.
In yet a further embodiment, the invention relates to an isolated single stranded microRNA molecule having any one of SEQ. ID. NO: 549
MicroRNA molecules are known in the art (see, for example, Bartel, Cell, 2004, 116, 281-297 for a review on microRNA molecules). The definitions and characterizations of microRNA molecules in the article by Bartel is hereby incorporated by reference. Such molecules are derived from genomic loci and are produced from specific microRNA genes.
Mature microRNA molecules are processed from precursor transcripts that form local hairpin structures. The hairpin structures are typically cleaved by an enzyme known as Dicer, generating thereby one microRNA duplex. See the above reference by Bartel.
Usually, one of the two strands of a microRNA duplex is packaged in a microRNA ribonucleoprotein complex (microRNP). A microRNP in, for example, humans, also includes the proteins eIF2C2/Argonaute (Ago)2, the helicase Gemin3, and Gemin 4. Other members of the Argonaute protein family, such as Ago1, 3, and 4, also associate with microRNAs and form microRNPs.
In humans, microRNP containing Ago2 typically guide microRNA cleavage of a target RNA sequence. MicroRNP complexes containing other Ago proteins (e.g., Ago 1, 3, and 4) generally repress translation of target mRNAs.
In one embodiment, the invention relates to an isolated DNA or RNA molecule comprising at least ten contiguous bases having a sequence shown in SEQ ID NOs:1-94 in Table A, and equivalents thereof. Preferably, the isolated DNA or RNA molecule comprises at least thirteen, more preferably at least fifteen, and even more preferably at least twenty contiguous bases.
In another embodiment, the invention relates to an isolated DNA or RNA molecule comprising at least ten contiguous bases having a sequence shown in SEQ ID NOs:281-374 in Table A2, and equivalents thereof. Preferably, the isolated DNA or RNA molecule comprises at least thirteen, more preferably at least fifteen, and even more preferably at least twenty contiguous bases.
In yet another embodiment, the invention relates to an isolated DNA or RNA molecule comprising at least ten contiguous bases having a sequence shown in SEQ ID NOs:467-481 in Table A4, and equivalents thereof. Preferably, the isolated DNA or RNA molecule comprises at least thirteen, more preferably at least fifteen, and even more preferably at least twenty contiguous bases.
In a further embodiment, the invention relates to an isolated DNA or RNA molecule comprising at least ten contiguous bases having a sequence shown in SEQ ID NOs:497-522 in Table A6, and equivalents thereof. Preferably, the isolated DNA or RNA molecule comprises at least thirteen, more preferably at least fifteen, and even more preferably at least twenty contiguous bases.
In yet a further embodiment, the invention relates to an isolated DNA or RNA molecule comprising at least ten contiguous bases having a sequence shown in SEQ ID NO:549 in Table A8, and equivalents thereof. Preferably, the isolated DNA or RNA molecule comprises at least thirteen, more preferably at least fifteen, and even more preferably at least twenty contiguous bases.







TABLE A







MicroRNAs Sequences.










Name
Mature MicroRNA (5′ → 3′)






miR-20b-5p
CAAAGUGCUCAUAGUGCAGGUAG




(SEQ. ID. NO: 1)


 



miR-18b
UAAGGUGCAUCUAGUGCAGUUAG




(SEQ. ID. NO: 2)


 



miR-843
CAACUAGACUGUGAGCUUCUAG




(SEQ. ID. NO: 3)


 



miR-867
UCGAGGAGCUCACAGUCUAGAC




(SEQ. ID. NO: 4)


 



miR-504
GUGCAUUGCUGUUGCAUUGC 




(SEQ. ID. NO: 5)


 



miR-720a
UGGCAGUGUAUUGUUAGCUGGU




(SEQ. ID. NO: 6)


 



miR-720b
AGGCAGUGUAUUGUUAGCUGGC




(SEQ. ID. NO: 7)


 



miR-92b
UAUUGCACUCGUCCCGGCCUCC




(SEQ. ID. NO: 8)


 



miR-429
UAAUACUGUCUGGUAAAACCGU




(SEQ. ID. NO: 9)


 



miR-822
GUGUGCGGAAAUGCUUCUGCUA




(SEQ. ID. NO: 10)


 



miR-755#
AAAUCUCUGCAGGCAAAUGUGA




(SEQ. ID. NO: 11)


 



miR-301b
CAGUGCAAUGAUAUUGUCAAAGCA




(SEQ. ID. NO: 12)


 



miR-864
AAAAGCUGAGUUGAGAGGG 




(SEQ. ID. NO: 13)


 



miR-374b
AUAUAAUACAACCUGCUAAGUG 




(SEQ. ID. NO: 14)


 



miR-619
UUUCCGGCUCGCGUGGGUGUGU




(SEQ. ID. NO: 15)


 



miR-20b-3p
ACUGUAGUAUGGGCACUUCCAG




(SEQ. ID. NO: 16)


 



miR-329
AACACACCUGGUUAACCUCUUU 




(SEQ. ID. NO: 17)


 



miR-421
AUCAACAGACAUUAAUUGGGCG




(SEQ. ID. NO: 18)


 



miR-431
UGUCUUGCAGGCCGUCAUGCAG




(SEQ. ID. NO: 19)


 



miR-433
AUCAUGAUGGGCUCCUCGGUGU




(SEQ. ID. NO: 20)


 



miR-451
AAACCGUUACCAUUACUGAGUU 




(SEQ. ID. NO: 21)


 



miR-452
UGUUUGCAGAGGAAACUGAGAC




(SEQ. ID. NO: 22)


 



miR-453
AGGUUGUCCGUGGUGAGUUCGC




(SEQ. ID. NO: 23)


 



miR-500
UAGUGCAAUAUUGCUUAUAGGGU




(SEQ. ID. NO: 24)


 



miR-604
UGCGGGGCUAGGGCUAACAGCA




(SEQ. ID. NO: 25)


 



miR-610
CAUGCCUUGAGUGUAGGACCGU




(SEQ. ID. NO: 26)


 



miR-618
UUAAUAUGUACUGACAAAGCGU 




(SEQ. ID. NO: 27)


 



miR-620
AUGUUGGGAGCGGGCAGGUUGG




(SEQ. ID. NO: 28)


 



miR-631#
UCCGAGCCUGGGUCUCCCUCUU




(SEQ. ID. NO: 29)


 



miR-723-3p#
CGUGGGCCUGAUGUGGUGCUGG




(SEQ. ID. NO: 30)


 



miR-723-5p#
AGUACCACGUGUCAGGGCCACA 




(SEQ. ID. NO: 31)


 



miR-730#
AAACAUUCGCGGUGCACUUCUU




(SEQ. ID. NO: 32)


 



miR-732#
AAAGGAUUCUGCUGUCGGUCCC 




(SEQ. ID. NO: 33)


 



miR-800a
AAUCGUACAGGGUCAUCCACUU




(SEQ. ID. NO: 34)


 



miR-800b
AAUCAUACAGGGACAUCCAGUU 




(SEQ. ID. NO: 35)


 



miR-803
UAUGUGCCUUUGGACUACAUCG




(SEQ. ID. NO: 36)


 



miR-805
UUUUGCGAUGUGUUCCUAAUAU 




(SEQ. ID. NO: 37)


 



miR-814
GCAGGAACUUGUGAGUCUCC 




(SEQ. ID. NO: 38)


 



miR-815
AAUGGCGCCACUAGGGUUGUGC




(SEQ. ID. NO: 39)


 



miR-816
UUGGGGAAACGGCCGCUGAGUG




(SEQ. ID. NO: 40)


 



miR-817
CUGUAUGCCCUCACCGCUCAGC




(SEQ. ID. NO: 41)


 



miR-818
AGGGGGAAAGUUCUAUAGUCCU




(SEQ. ID. NO: 42)


 



miR-819
UCCAUUACACUACCCUGCCUCU




(SEQ. ID. NO: 43)


 



miR-821
GCGGCGGCGGCGGAGGCUGCUG




(SEQ. ID. NO: 44)


 



miR-892
CGGCGGCGGCGGCGGCGGCUGU




(SEQ. ID. NO: 45)


 



miR-824
GGAGAAAUUAUCCUUGGUGUGU




(SEQ. ID. NO: 46)


 



miR-825-3p
UUGUGACAGAUUGAUAACUGAA




(SEQ. ID. NO: 47)


 



miR-825-5p
UCGGGGAUCAUCAUGUCACGAG




(SEQ. ID. NO: 48)


 



miR-826
AUUGACACUUCUGUGAGUAGAG




(SEQ. ID. NO: 49)


 



miR-828-5p
AUGCUGACAUAUUUACUAGAGG




(SEQ. ID. NO: 50)


 



miR-828-3p
UCUAGUAAGAGUGGCAGUCGAA




(SEQ. ID. NO: 51)


 



miR-829-5p
GAGCUUAUUCAUAAAAGUGCAG




(SEQ. ID. NO: 52)


 



miR-829-3p
UAAUUUUAUGUAUAAGCUAGUC 




(SEQ. ID. NO: 53)


 



miR-831
UGGGGCGGAGCUUCCGGAGGCC




(SEQ. ID. NO: 54)


 



miR-832
CCAUGGAUCUCCAGGUGGGUCA




(SEQ. ID. NO: 55)


 



miR-834
UGAAGGUCUACUGUGUGCCAGG




(SEQ. ID. NO: 56)


 



miR-835-5p
AGGAAGCCCUGGAGGGGCUGGA




(SEQ. ID. NO: 57)


 



miR-835-3p
UCCGGUUCUCAGGGCUCCACCU




(SEQ. ID. NO: 58)


 



miR-837
ACCAGGAGGCUGAGGCCCCUCA




(SEQ. ID. NO: 59)


 



miR-838
UCAGGCUCAGUCCCCUCCCGAU




(SEQ. ID. NO: 60)


 



miR-839-5p
UCCUGUACUGAGCUGCCCCGA 




(SEQ. ID. NO: 61)


 



miR-839-3p
CGGGGCAGCUCAGUACAGGAU 




(SEQ. ID. NO: 62)


 



miR-840-5p
UCGACCGGACCUCGACCGGCU 




(SEQ. ID. NO: 63)


 



miR-840-3p
CUCGGCGUGGCGUCGGUCGUGG




(SEQ. ID. NO: 64)


 



miR-841
UUUGAAAGGCUAUUUCUUGGUC




(SEQ. ID. NO: 65)


 



miR-842
CGAAAACAGCAAUUACCUUUGC 




(SEQ. ID. NO: 66)


 



miR-845
AAAGCAUGCUCCAGUGGCGCA 




(SEQ. ID. NO: 67)


 



miR-846
CGGCUCUGGGUCUGUGGGGAGC




(SEQ. ID. NO: 68)


 



miR-847
CAGAGAGGACCACUAUGGCGGG




(SEQ. ID. NO: 69)


 



miR-848
AUUGCCAUCCCCUAUGGACCAG




(SEQ. ID. NO: 70)


 



miR-849
UGUCUACUACUGGAGACACUGG




(SEQ. ID. NO: 71)


 



miR-850
UUAGGGCCCUGGCUCCAUCUCC




(SEQ. ID. NO: 72)


 



miR-851
GUGAACGGGCGCCAUCCCGAGG




(SEQ. ID. NO: 73)


 



miR-852
UCAGCAAACAUUUAUUGUGUGC




(SEQ. ID. NO: 74)


 



miR-853
UGGGAUCUCCGGGGUCUUGGUU




(SEQ. ID. NO: 75)


 



miR-854
CUGCCCUGGCCCGAGGGACCGA




(SEQ. ID. NO: 76)


 



miR-855-5p
UGAGUGUGUGUGUGUGAGUGUG




(SEQ. ID. NO: 77)


 



miR-855-3p
CACGCUCAUGCACACACCCACA 




(SEQ. ID. NO: 78)


 



miR-857
AAGGCAGGGCCCCCGCUCCCCG




(SEQ. ID. NO: 79)


 



miR-869
UGGUGGGCCGCAGAACAUGUGC




(SEQ. ID. NO: 80)


 



miR-871-5p
CGGGUCGGAGUUAGCUCAAGCGG




(SEQ. ID. NO: 81)


 



miR-871-3p
CUAUCUGUCCAUCUCUGUGCUG




(SEQ. ID. NO: 82)


 



miR-883
UGAAACAUACACGGGAAACCUC 




(SEQ. ID. NO: 83)


 



miR-884
AUUCUGCAUUUUUAGCAAGUUC




(SEQ. ID. NO: 84)


 



miR-885
GCGACCCAUACUUGGUUUCAGA




(SEQ. ID. NO: 85)


 



miR-886
AACAUCACAGCAAGUCUGUGCU




(SEQ. ID. NO: 86)


 



miR-887-5p
UAUACCUCAGUUUUAUCAGGUG




(SEQ. ID. NO: 87)


 



miR-887-3p
CCUGGAAACACUGAGGUUGUGU




(SEQ. ID. NO: 88)


 



miR-888
AGACCCUGGUCUGCACUCUAUC




(SEQ. ID. NO: 89)


 



miR-889
AGUGGGGAACCCUUCCAUGAGG




(SEQ. ID. NO: 90)


 



miR-890
GUGUUGAAACAAUCUCUACUGA




(SEQ. ID. NO: 91)


 



miR-891
AUGGAUUUCUUUGUGAAUCACC




(SEQ. ID. NO: 92)


 



miR-893
AAGACGGGAGGAAAGAAGGGAA




(SEQ. ID. NO: 93)


 



miR-894
GUGACAUCACAUAUACGGCAGC




(SEQ. ID. NO: 94)
















TABLE A1





MicroRNA Hairpin Precursor Sequences.















>hsa-mir-18b


CUUGUGUUAAGGUGCAUCUAGUGCAGUUAGUGAAGCAGCUUAGAAUCUACUGCC


CUAAAUGCCCCUUCUGGCACAGG (SEQ. ID. NO: 95)


 


>hsa-mir-20b


GAUAAGAUUGGGUCCUAGUAGUACCAAAGUGCUCAUAGUGCAGGUAGUUUUGGC


AUGACUCUACUGUAGUAUGGGCACUUCCAGUACUCUUGGAUAACAAAUCUCUUG (SEQ. ID. NO: 96)


UUG


 


>hsa-mir-301b


GGGGUCCCCCCUGCUGGCCGCAGGUGCUCUGACGAGGUUGCACUACUGUGCUCUG


AGAAGCAGUGCAAUGAUAUUGUCAAAGCAUCUGGGACCAGCCUUGGGGAUCUC (SEQ. ID. NO: 97)


 


>hsa-mir-329-1


GGUACCUGAAGAGAGGUUUUCUGGGUUUCUGUUUCUUUAAUGAGGACGAAACAC


ACCUGGUUAACCUCUUUUCCAGUAUC (SEQ. ID. NO: 98)


 


>hsa-mir-329-2


GUGGUACCUGAAGAGAGGUUUUCUGGGUUUCUGUUUCUUUAUUGAGGACGAAAC


ACACCUGGUUAACCUCUUUUCCAGUAUCAA (SEQ. ID. NO: 99)


 


>hsa-mir-374b


ACUCGGAUGGAUAUAAUACAACCUGCUAAGUGUCCUAGCACUUAGCAGGUUGUA


UUAUCAUUGUCCGUGU (SEQ. ID. NO: 100)


 


>hsa-mir-421


CACAUUGUAGGCCUCAUUAAAUGUUUGUUGAAUGAAAAAAUGAAUCAUCAACAG


ACAUUAAUUGGGCGCCUGCUCUGUG (SEQ. ID. NO: 101)


 


>hsa-mir-500


CCAGAUCCUAGAACCCUAUCAAUAUUGUCUCUGCUGUGUAAAUAGUUCUGAGUA


GUGCAAUAUUGCUUAUAGGGUUUUGGUGUUUGG (SEQ. ID. NO: 102)


 


>hsa-mir-504


GGCGGCCCCGCGGUGCAUUGCUGUUGCAUUGCACGUGUGUGAGGCGGGUGCAGU


GCCUCGGCAGUGCAGCCCGGAGCCGGC (SEQ. ID. NO: 103)


 


>hsa-mir-604


GGGUUGGGCAAGGUGCGGGGCUAGGGCUAACAGCAGUCUUACUGAAGGUUUCCU


GGAAACCACGCACAUGCUGUUGCCAC (SEQ. ID. NO: 104)


 


>hsa-mir-610


CUCCAUGCCUUGAGUGUAGGACCGUUGGCAUCUUAAUUACCCUCCCACACCCAAG


GCUUGCA (SEQ. ID. NO: 105)


 


>hsa-mir-618


(SEQ. ID. NO: 106)


UUAUUGUGAAAUAUGUCAUUAAUAUGUACUGACAAAGCGUAUCUGUGUAAUAAA


 


UAUGCUUUUUGUCAGUACAUGUUAAUGGUAUAUUUCAUAACAA


 


>hsa-mir-619


GCGGCUGCUGGACCCACCCGGCCGGGAAUAGUGCUCCUGGUUGUUUCCGGCUCGC


GUGGGUGUGUCGGCGGCGGG (SEQ. ID. NO: 107)


 


>hsa-mir-620


CGCCCCCACGUGGCCCCGCCCCCUGAGGCCGGCGCUGCCGCCAUGUUGGGAGCGG


GCAGGUUGGGAGCG (SEQ. ID. NO: 108)


 


>hsa-mir-631


GGGGCGGGAGGGGGGUCCCCGGUGCUCGGAUCUCGAGGGUGCUUAUUGUUCGGU


CCGAGCCUGGGUCUCCCUCUUCCCCCC (SEQ. ID. NO: 109)


 


>hsa-mir-720A


UGCUCUGGAUACCUGUGUGUGAUGAGCUGGCAGUGUAUUGUUAGCUGGUUGAAU


AUGUGAAUGGCAUCGGCUAACAUGCAACUGCUGUCUUAUUGCAUAUACAAUGAA


CAUCAGAGUG (SEQ. ID. NO: 110)


 


>hsa-mir-720b


UGAAUCAGGUAGGCAGUGUAUUGUUAGCUGGCUGCUUGGGUCAAGUCAGCAGCC


ACAACUACCCUGCCACUUGCUUCU (SEQ. ID. NO: 111)


 


>hsa-mir-723


GCCACCUUCCGAGCCUCCAGUACCACGUGUCAGGGCCACAUGAGCUGGGCCUCGU


GGGCCUGAUGUGGUGCUGGGGCCUCAGGGGUCUG (SEQ. ID. NO: 112)


 


>hsa-mir-730


GCGGUACUUAAUGAGAAGUUGCCCGUGUUUUUUUCGCUUUAUUUGUGACGAAAC


AUUCGCGGUGCACUUCUUUUUCAGUAUCCU (SEQ. ID. NO: 113)


 


>hsa-mir-732


CCAACGUCAGGGAAAGGAUUCUGCUGUCGGUCCCACUCCAAAGUUCACAGAAUGG


GUGGUGGGCACAGAAUCUGGACUCU (SEQ. ID. NO: 114)


 


>hsa-mir-429


CGGCCGAUGGGCGUCUUACCAGACAUGGUUAGACCUGGCCCUCUGUCUAAUACUG


UCUGGUAAAACCGUCCAUCCGCUG (SEQ. ID. NO: 115)


 


>hsa-mir-754


UGCUUCUGUGUGAUAUGUUUGAUAUUGGGUUGUUUAAUUAGGAACCAACUAAAU


GUCAAACAUAUUCUUACAGCAGCA (SEQ. ID. NO: 116)


 


>hsa-mir-755


GCAGACUGGAAAAUCUCUGCAGGCAAAUGUGAUGUCACUGAGGAAAUCACACAC


UUACCCGUAGAGAUUCUACAGUCUGA (SEQ. ID. NO: 117)


 


>hsa-mir-800A


CUUUCUUUUCCGUGCUAACCUUUGGUACUUGGAGAGUGGUUAUCCCUGUCCUGU


UCGUUUUGCUCAUGUCGAAUCGUACAGGGUCAUCCACUUUUUCAGUAUCAAGAG


CGC (SEQ. ID. NO: 118)


 


>hsa-mir-800b


UGAAGAGUGGUUAUCCCUGCUGUGUUCGCUUAAUUUAUGACGAAUCAUACAGGG


ACAUCCAGUUUUUCA (SEQ. ID. NO: 119)


 


>hsa-mir-803


CCCUGGCGUGAGGGUAUGUGCCUUUGGACUACAUCGUGGAAGCCAGCACCAUGCA


GUCCAUGGGCAUAUACACUUGCCUCAAGG (SEQ. ID. NO: 120)


 


>hsa-mir-805-2


GAUGCUAAACUAUUUUUGCGAUGUGUUCCUAAUAUGUAAUAUAAAUGUAUUGGG


GACAUUUUGCAUUCAUAGUUUUGUAUC (SEQ. ID. NO: 121)


 


>hsa-mir-451


CUUGGGAAUGGCAAGGAAACCGUUACCAUUACUGAGUUUAGUAAUGGUAAUGGU


UCUCUUGCUAUACCCAGA (SEQ. ID. NO: 122)


 


>hsa-mir-433


CCGGGGAGAAGUACGGUGAGCCUGUCAUUAUUCAGAGAGGCUAGAUCCUCUGUG


UUGAGAAGGAUCAUGAUGGGCUCCUCGGUGUUCUCCAGG (SEQ. ID. NO: 123)


 


>hsa-mir-431


UCCUGCUUGUCCUGCGAGGUGUCUUGCAGGCCGUCAUGCAGGCCACACUGACGGU


AACGUUGCAGGUCGUCUUGCAGGGCUUCUCGCAAGACGACAUCCUCAUCACCAAC


GACG (SEQ. ID. NO: 124)


 


>hsa-mir-452


GCUAAGCACUUACAACUGUUUGCAGAGGAAACUGAGACUUUGUAACUAUGUCUC


AGUCUCAUCUGCAAAGAAGUAAGUGCUUUGC (SEQ. ID. NO: 125)


 


>hsa-mir-453


GCAGGAAUGCUGCGAGCAGUGCCACCUCAUGGUACUCGGAGGGAGGUUGUCCGU


GGUGAGUUCGCAUUAUUUAAUGAUGC (SEQ. ID. NO: 126)


 


>hsa-mir-814


GUGCAUUUGCAGGAACUUGUGAGUCUCCUAUUGAAAAUGAACAGGAGACUGAUG


AGUUCCCGGGAACAC (SEQ. ID. NO: 127)


 


>hsa-mir-815


CUAUGCACUGCACAACCCUAGGAGAGGGUGCCAUUCACAUAGACUAUAAUUGAA


UGGCGCCACUAGGGUUGUGCAGUGCACAA (SEQ. ID. NO: 128)


 


>hsa-mir-816


GGGUUUGGGGAAACGGCCGCUGAGUGAGGCGUCGGCUGUGUUUCUCACCGCGGU


CUUUUCCUCCCACUC (SEQ. ID. NO: 129)


 


>hsa-mir-817


CUUGGUGACGCUGUAUGCCCUCACCGCUCAGCCCCUGGGGCUGGCUUGGCAGACA


GUACAGCAUCCAGGGGAGUCAAGGGCAUGGGGCGAGACCAGA (SEQ. ID. NO: 130)


 


>hsa-mir-818-1


GGUAAGGGUAGAGGGAUGAGGGGGAAAGUUCUAUAGUCCUGUAAUUAGAUCUCA


GGACUAUAGAACUUUCCCCCUCAUCCCUCUGCCCUCUACC (SEQ. ID. NO: 131)


 


>hsa-mir-818-2


GUAGAGGGCAGAGGGAUGAGGGGGAAAGUUCUAUAGUCCUGAGAUCUAAUUACA


GGACUAUAGAACUUUCCCCCUCAUCCCUCUACCCUUACCA (SEQ. ID. NO: 132)


 


>hsa-mir-819


GGCCCGCACUCUCUCCAUUACACUACCCUGCCUCUUCUCCAUGAGAGGCAGCGGG


GUGUAGUGGAUAGAGCACGGGUU (SEQ. ID. NO: 133)


 


>hsa-mir-821-1


GCGGCGGCGGCGGAGGCUGCUGCUGGGGCGGCUGCUGCUGGGGCGGCUGCGGCGG


CGGCUGCUGCGGGGGCUGCUGCUGCUGUUGC (SEQ. ID. NO: 134)


 


>hsa-mir-821-2/-3


GCGGCUGCGGCGGCGGCGGAGGCUGCGGCGGCGACCGUGGCAGAGGCGGUGGCGG


AGGCCUCCGUGGCGGAGGCGGAAGC (SEQ. ID. NO: 135)


 


>hsa-mir-822


ACUCUAUAAAUCUAGUGGAAACAUUUCUGCACAAACUAGAUUCUGGACACCAGU


GUGCGGAAAUGCUUCUGCUACAUUUUUAGGGU (SEQ. ID. NO: 136)


 


>hsa-mir-824


GUUUCAUACUUGAGGAGAAAUUAUCCUUGGUGUGUUCGCUUUAUUUAUGAUGAA


UCAUACAAGGACAAUUUCUUUUUGAGUAUCAAAU (SEQ. ID. NO: 137)


 


>hsa-mir-825


UCUCAGACAUCUCGGGGAUCAUCAUGUCACGAGAUACCAGUGUGCACUUGUGACA


GAUUGAUAACUGAAAGGUCUGGGA (SEQ. ID. NO: 138)


 


>hsa-mir-826-2


UUGUCUGUGGUACCCUACUCUGGAGAGUGACAAUCAUGUAUAACUAAAUUUGAU


UGACACUUCUGUGAGUAGAGUAACGCAUGACAC (SEQ. ID. NO: 139)


 


>hsa-mir-826-3


UUGUCUGUGGUACCCUACUCUGGAGAGUGACAAUCAUGUAUAAUUAAAUUUGAU


UGACACUUCUGUGAGUAGAGUAACGCAUGACAC (SEQ. ID. NO: 140)


 


>hsa-mir-828


CUUCCUCAUGCUGACAUAUUUACUAGAGGGUAAAAUUAAUAACCUUCUAGUAAG


AGUGGCAGUCGAAGGGAAG (SEQ. ID. NO: 141)


 


>hsa-mir-829


CAGUCAGAAAUGAGCUUAUUCAUAAAAGUGCAGUAUGGUGAAGUCAAUCUGUAA


UUUUAUGUAUAAGCUAGUCUCUGAUUG (SEQ. ID. NO: 142)


 


>hsa-mir-831-1


GCUCCGCCCCACGUCGCAUGCGCCCCGGGAACGCGUGGGGCGGAGCUUCCGGAGG


CCCCGCUCUGCUGCCGACCCUGUGGAGCGGAGGGUGAAGCCUCCGGAUGCCAGUC


CCUCAUCGCUGGCCUGGUCGCGCUGUGGCGAAGGGGGCGGAGC (SEQ. ID. NO: 143)


 


>hsa-mir-831-2


GCUCCGCCCCACGUCGCAUGCGCCCCGGGAACGCGUGGGGCGGAGCUUCCGGAGG


CCCCGCCCUGCUGCCGACCCUGUGGAGCGGAGGGUGAAGCCUCCGGAUGCCAGUC


CCUCAUCGCUGGCCCGGUCGCGCUGUGGCGAAGGGGGCGGAGC (SEQ. ID. NO: 144)


 


>hsa-mir-831-3/-4/-5


CGCUCCGCCCCACGUCGCAUGCGCCCCGGGAAAGCGUGGGGCGGAGCUUCCGGAG


GCCCCGCCCUGCUGCCGACCCUGUGGAGCGGAGGGUGAAGCCUCCGGAUGCCAGU


CCCUCAUCGCUGGCCCGGUCGCGCUGUGGCGAAGGGGGCGGAGC (SEQ. ID. NO: 145)


 


>hsa-mir-832


AUUGUUCGACACCAUGGAUCUCCAGGUGGGUCAAGUUUAGAGAUGCACCAACCU


GGAGGACUCCAUGCUGUUGAGCUGU (SEQ. ID. NO: 146)


 


>hsa-mir-834


CAGGGCUUUGUACAUGGUAGGCUUUCAUUCAUUCGUUUGCACAUUCGGUGAAGG


UCUACUGUGUGCCAGGCCCUG (SEQ. ID. NO: 147)


 


>hsa-mir-835


CUGGCAGGCCAGGAAGAGGAGGAAGCCCUGGAGGGGCUGGAGGUGAUGGAUGUU


UUCCUCCGGUUCUCAGGGCUCCACCUCUUUCGGGCCGUAGAGCCAG (SEQ. ID. NO: 148)


 


>hsa-mir-837


AGAGGAGGGUCUCCUCGAGGGGUCUCUGCCUCUACCCAGGACUCUUUCAUGACCA


GGAGGCUGAGGCCCCUCACAGGCGGCUUCUUACUCU (SEQ. ID. NO: 149)


 


>hsa-mir-838


UCGUCAGGCUCAGUCCCCUCCCGAUAAACCCCUAAAUAGGGACUUUCCCGGGGGG


UGACCCUGGCUUUUUUGGCGA (SEQ. ID. NO: 150)


 


>hsa-mir-839


CUGACUCCCACCCCGAGUAUCCUGUACUGAGCUGCCCCGAGCUGGGCAGCAUGAA


GGGCCUCGGGGCAGCUCAGUACAGGAUGCCCCAGGGAGGAUGGAGAUCAG (SEQ. ID. NO: 151)


 


>hsa-mir-839-2


CUCCAUCCUCCCUGGGGCAUCCUGUACUGAGCUGCCCCGAGGCCCUUCAUGCUGC


CCAGCUCGGGGCAGCUCAGUACAGGAUACUCGGGGUGGGAGUCAG (SEQ. ID. NO: 152)


 


>hsa-mir-840


UUCAUCAAGACCCAGCUGAGUCACUGUCACUGCCUACCAAUCUCGACCGGACCUC


GACCGGCUCGUCUGUGUUGCCAAUCGACUCGGCGUGGCGUCGGUCGUGGUAGAUA


GGCGGUCAUGCAUACGAAUUUUCAGCUCUUGUUCUGGUGAC (SEQ. ID. NO: 153)


 


>hsa-mir-841


AGAAUCAUCUCUCCCAGAUAAUGGCACUCUCAAACAAGUUUCCAAAUUGUUUGA


AAGGCUAUUUCUUGGUCAGAUGACUCU (SEQ. ID. NO: 154)


 


>hsa-mir-842


CCUAGAUAAGUUAUUAGGUGGGUGCAAAGGUAAUUGCAGUUUUUCCCAUUAUUU


UAAUUGCGAAAACAGCAAUUACCUUUGCACCAACCUGAUGGAGUCCCCCU (SEQ. ID. NO: 155)


 


>hsa-mir-843


GCCCUCAAGGAGCUUACAAUCUAGCUGGGGGUAAAUGACUUGCACAUGAACACA


ACUAGACUGUGAGCUUCUAGAGGGC (SEQ. ID. NO: 156)


 


>hsa-mir-845-1


CGCGAGGCCGGGGUCGAGCGCUUCAGUAGCUCAUGGCUCUGUAGAGUGCGCAUGG


CCAAGCAAAGGAAAGCAUGCUCCAGUGGCGCA (SEQ. ID. NO: 157)


 


>hsa-mir-845-2


AGUAACCACUUAGUGUGUAUUGACUUGUCAGAAUUUUCAGAAUUUAAAGCAUGC


UCCAGUGGCGCA (SEQ. ID. NO: 158)


 


>hsa-mir-846


CGGGGCGCGUCGCCCCCCUCAGUCCACCAGAGCCCGGAUACCUCAGAAAUUCGGC


UCUGGGUCUGUGGGGAGCGAAAUGCAACCCA (SEQ. ID. NO: 159)


 


>hsa-mir-847


UUACUGUGUCAUUGUUGCUGUCAUUGCUACUGAGGAGUACUGACCAGAAUCAUC


UGCAACUCUUAGUUGGCAGAGAGGACCACUAUGGCGGGUAG (SEQ. ID. NO: 160)


 


>hsa-mir-848


UGGGCCAGAUUGCCAUCCCCUAUGGACCAGAAGCCAAGGAUCUCUCUAGUGAUGG


UCAGAGGGCCCAAAUGGCAGGGAUACCCA (SEQ. ID. NO: 161)


 


>hsa-mir-849


GCUUCUGUCUACUACUGGAGACACUGGUAGUAUAAAACCCAGAGUCUCCAGUAA


UGGACGGGAGC (SEQ. ID. NO: 162)


 


>hsa-mir-850


CUGGGUUAGGGCCCUGGCUCCAUCUCCUUUAGGAAAACCUUCUGUGGGGAGUGG


GGCUUCGACCCUAACCCAG (SEQ. ID. NO: 163)


 


>hsa-mir-851


GCAGAUCCUUGGGAGCCCUGUUAGACUCUGGAUUUUACACUUGGAGUGAACGGG


CGCCAUCCCGAGGCUUUGC (SEQ. ID. NO: 164)


 


>hsa-mir-852


AGUAGGCCUCAGUAAAUGUUUAUUAGAUGAAUAAAUGAAUGACUCAUCAGCAAA


CAUUUAUUGUGUGCCUGCU (SEQ. ID. NO: 165)


 


>hsa-mir-853


CCUGGGCUCUGACCUGAGACCUCUGGGUUCUGAGCUGUGAUGUUGCUCUCGAGCU


GGGAUCUCCGGGGUCUUGGUUCAGGG (SEQ. ID. NO: 166)


 


>hsa-mir-854


GGUGUUAGCCCUGCGGCCCCACGCACCAGGGUAAGAGAGACUCUCGCUUCCUGCC


CUGGCCCGAGGGACCGACUGGCUGGGCC (SEQ. ID. NO: 167)


 


>hsa-mir-855


UGGGUGCGGGCGUGUGAGUGUGUGUGUGUGAGUGUGUGUCGCUCCGGGUCCACG


CUCAUGCACACACCCACACGCCCACACUCA (SEQ. ID. NO: 168)


 


>hsa-mir-855


UGGGUGCGGGCGUGUGAGUGUGUGUGUGUGAGUGUGUGUCGCUCCGGGUCCACG


CUCAUGCACACACCCACACGCCCACACUCA (SEQ. ID. NO: 169)


 


>hsa-mir-857


GGGCCCGGCCCCAGGAGCGGGGCCUGGGCAGCCCCGUGUGUUGAGGAAGGAAGGC


AGGGCCCCCGCUCCCCGGGCCU (SEQ. ID. NO: 170)


 


>hsa-mir-864


CCUUCUCUUCUCAGUUCUUCCCCAAGUUAGGAAAAGCUGAGUUGAGAGGG (SEQ. ID. NO: 171)


 


>hsa-mir-151


GUCUCUCUUCAGGGCUCCCGAGACACAGAAACAGACACCUGCCCUCGAGGAGCUC


ACAGUCUAGAC (SEQ. ID. NO: 172)


 


>hsa-mir-869


AAAGAUGGUGGGCCGCAGAACAUGUGCUGAGUUCGUGCCAUAUGUCUGCUGACC


AUCACCUUU (SEQ. ID. NO: 173)


 


>hsa-mir-871-1


UCCUACCCGGGUCGGAGUUAGCUCAAGCGGUUACCUCCUCAUGCCGGACUUUCUA


UCUGUCCAUCUCUGUGCUGGGGUUCGAGACCCGCGGGUGCUUACUGACCCUUUUA


UGCA (SEQ. ID. NO: 174)


 


>hsa-mir-92b


CCGGGCCCCGGGCGGGCGGGAGGGACGGGACGCGGUGCAGUGUUGUUUUUUCCCC


CGCCAAUAUUGCACUCGUCCCGGCCUCCGGCCCCCCCGGCCCCCCGG (SEQ. ID. NO: 175)


 


>hsa-mir-883


GAUACUCGAAGGAGAGGUUGUCCGUGUUGUCUUCUCUUUAUUUAUGAUGAAACA


UACACGGGAAACCUCUUUUUUAGUAUC (SEQ. ID. NO: 176)


 


>hsa-mir-884


AUUUUCAUCACCUAGGGAUCUUGUUAAAAAGCAGAUUCUGAUUCAGGGACCAAG


AUUCUGCAUUUUUAGCAAGUUCUCAAGUGAUGCUAAU (SEQ. ID. NO: 177)


 


>hsa-miR-885


GUGCUCUCCUGGCCCAUGAAAUCAAGCGUGGGUGAGACCUGGUGCAGAACGGGA


AGGCGACCCAUACUUGGUUUCAGAGGCUGUGAGAAUAAC (SEQ. ID. NO: 178)


 


>hsa-mir-886


CCCCUGUGCCUUGGGCGGGCGGCUGUUAAGACUUGCAGUGAUGUUUAACUCCUCU


CCACGUGAACAUCACAGCAAGUCUGUGCUGCUUCCCGUCCCUACGCUGCCUGGGC 


(SEQ. ID. NO: 179)


 


>hsa-mir-887


GUUUAGUGGUACUAUACCUCAGUUUUAUCAGGUGUUCUUAAAAUCACCUGGAAA


CACUGAGGUUGUGUCUCACUGAAC (SEQ. ID. NO: 180)


 


>hsa-mir-888


GCUGCUGUUGGGAGACCCUGGUCUGCACUCUAUCUGUAUUCUUACUGAAGGGAG


UGCAGGGCAGGGUUUCCCAUACAGAGGGC (SEQ. ID. NO: 181)


 


>hsa-mir-889


GGAAUUGACUUAGCUGGGUAGUGGGGAACCCUUCCAUGAGGAGUAGAACACUCC


UUAUGCAAGAUUCCCUUCUACCUGGCUGGGUUGGAGUC (SEQ. ID. NO: 182)


 


>hsa-mir-890


UCAUUCCUUCAGUGUUGAAACAAUCUCUACUGAACCAGCUUCAAACAAGUUCACU


GGAGUUUGUUUCAAUAUUGCAAGAAUGA (SEQ. ID. NO: 183)


 


>hsa-mir-891


CACAAACUGUGAAGUGCUGUGGAUUUCUUUGUGAAUCACCAUAUCUAAGCUAAU


GUGGUGGUGGUUUACAAAGUAAUUCAUAGUGCUUCACAGGUG (SEQ. ID. NO: 184)


 


>hsa-mir-892


GCGGCUGCGGCGGCGGCGGCGGCGGCGGCGGCGGCUGUUGCUGUUGCUGCUGCUG


CUGCUGCUGCUGUUGCUGCUGCUGCUGCUGCUGCUGC (SEQ. ID. NO: 185)


 


>hsa-mir-893


GAGGGGGAAGACGGGAGGAAAGAAGGGAGUGGUUCCAUCACGCCUCCUCACUCC


UCUCCUCCCGUCUUCUCCUCUC (SEQ. ID. NO: 186)


 


>hsa-mir-894


CUACUGCUGUUGGUGGCAGCUUGGUGGUCGUAUGUGUGACGCCAUUUACUUGAA


CCUUUAGGAGUGACAUCACAUAUACGGCAGCUAAACUGCUACAUGGGACAACAA


UU (SEQ. ID. NO: 187)
















TABLE A2







MicroRNA Sequences








Name
Mature MicroRNA (5′ -> 3′)












hsa-miR-100516
UACUCAAAAAGCUGUCAGUCA (SEQ. ID. NO: 281)



 


hsa-miR-100604
UGCGGGGCUAGGGCUAACAGCA (SEQ. ID. NO: 282)


 


hsa-miR-100610-5p
CAUGCCUUGAGUGUAGGACCGU (SEQ. ID. NO: 283)


 


hsa-miR-100631
UCCGAGCCUGGGUCUCCCUCUU (SEQ. ID. NO: 284)


 


hsa-miR-100701
AAGGUUACUUGUUAGUUCAGG (SEQ. ID. NO: 285)


 


hsa-miR-100723
CGUGGGCCUGAUGUGGUGCUGG (SEQ. ID. NO: 286)


 


hsa-miR-100730
AAACAUUCGCGGUGCACUUCUU (SEQ. ID. NO: 287)


 


hsa-miR-100732
AAGGAUUCUGCUGUCGGUCCC (SEQ. ID. NO: 288)


 


hsa-miR-100754
UGAUAUGUUUGAUAUUGGGUU (SEQ. ID. NO: 289)


 


hsa-miR-100760
GCACUGAGAUGGGAGUGGUGUA (SEQ. ID. NO: 290)


 


hsa-miR-100814
GCAGGAACUUGUGAGUCUCCU (SEQ. ID. NO: 291)


 


hsa-miR-100815
AAUGGCGCCACUAGGGUUGUGU (SEQ. ID. NO: 292)


 


hsa-miR-100818
AGGGGGAAAGUUCUAUAGUCC (SEQ. ID. NO: 293)


 


hsa-miR-100819
UCCAUUACACUACCCUGCCUCU (SEQ. ID. NO: 294)


 


hsa-miR-100824
GGAGAAAUUAUCCUUGGUGUGU (SEQ. ID. NO: 295)


 


hsa-miR-100825-3p
UGUGACAGAUUGAUAACUGAAA (SEQ. ID. NO: 296)


 


hsa-miR-100825-5p
UCGGGGAUCAUCAUGUCACGAGA (SEQ. ID. NO: 297)


 


hsa-miR-100829-3p
UAAUUUUAUGUAUAAGCUAGU (SEQ. ID. NO: 298)


 


hsa-miR-100835-5p
AGGAAGCCCUGGAGGGGCUGGAG (SEQ. ID. NO: 299)


 


hsa-miR-100842
CGAAAACAGCAAUUACCUUUGC (SEQ. ID. NO: 300)


 


hsa-miR-100843-3p
CAACUAGACUGUGAGCUUCUAG (SEQ. ID. NO: 301)


 


hsa-miR-100843-5p
AAGGAGCUUACAAUCUAGCUGGG (SEQ. ID. NO: 302)


 


hsa-miR-100846
CGGCUCUGGGUCUGUGGGGAG (SEQ. ID. NO: 303)


 


hsa-miR-100851
GUGAACGGGCGCCAUCCCGAGG (SEQ. ID. NO: 304)


 


hsa-miR-100852
UCAGCAAACAUUUAUUGUGUGC (SEQ. ID. NO: 305)


 


hsa-miR-100854
CUGCCCUGGCCCGAGGGACCGA (SEQ. ID. NO: 306)


 


hsa-miR-100855-3p
CACGCUCAUGCACACACCCACA (SEQ. ID. NO: 307)


 


hsa-miR-100855-5p
UGAGUGUGUGUGUGUGAGUGUGU (SEQ. ID. NO: 308)


 


hsa-miR-100869-3p
UAUGUCUGCUGACCAUCACCUU (SEQ. ID. NO: 309)


 


hsa-miR-100869-5p
UGGUGGGCCGCAGAACAUGUGC (SEQ. ID. NO: 310)


 


hsa-miR-100871-3p
CGCGGGUGCUUACUGACCCUU (SEQ. ID. NO: 311)


 


hsa-miR-100871-5p
CGGGUCGGAGUUAGCUCAAGCGG (SEQ. ID. NO: 312)


 


hsa-miR-100885
GCGACCCAUACUUGGUUUCAG (SEQ. ID. NO: 313)


 


hsa-miR-100887-3p
CCUGGAAACACUGAGGUUGUGU (SEQ. ID. NO: 314)


 


hsa-miR-100887-5p
UAUACCUCAGUUUUAUCAGGUG (SEQ. ID. NO: 315)


 


hsa-miR-100891-3p
UGGUGGUUUACAAAGUAAUUCA (SEQ. ID. NO: 316)


 


hsa-miR-100891-5p
UGGAUUUCUUUGUGAAUCACCA (SEQ. ID. NO: 317)


 


hsa-miR-101001
ACCAGGAGGCUGAGGCCCCU (SEQ. ID. NO: 318)


 


hsa-miR-146b
UGAGAACUGAAUUCCAUAGGCU (SEQ. ID. NO: 319)


 


hsa-miR-147b
GUGUGCGGAAAUGCUUCUGCUA (SEQ. ID. NO: 320)


 


hsa-miR-181d
AACAUUCAUUGUUGUCGGUGGGU (SEQ. ID. NO: 321)


 


hsa-miR-18b
UAAGGUGCAUCUAGUGCAGUUAG (SEQ. ID. NO: 322)


 


hsa-miR-193b
AACUGGCCCUCAAAGUCCCGCU (SEQ. ID. NO: 323)


 


hsa-miR-200001
UGCAACGAACCUGAGCCACUGA (SEQ. ID. NO: 324)


 


hsa-miR-200002
AUAAUACAUGGUUAACCUCUUU (SEQ. ID. NO: 325)


 


hsa-miR-200003
UACUUGGAAAGGCAUCAGUUG (SEQ. ID. NO: 326)


 


hsa-miR-200004
UGCAACUUACCUGAGUCAUUGA (SEQ. ID. NO: 327)


 


hsa-miR-200007
GUAGAGGAGAUGGCGCAGGG (SEQ. ID. NO: 328)


 


hsa-miR-200008
UACCCAUUGCAUAUCGGAGUU (SEQ. ID. NO: 329)


 


hsa-miR-20b
CAAAGUGCUCAUAGUGCAGGUAG (SEQ. ID. NO: 330)


 


hsa-miR-20b-3p
ACUGUAGUAUGGGCACUUCCAG (SEQ. ID. NO: 331)


 


hsa-miR-216b
AAAUCUCUGCAGGCAAAUGUGA (SEQ. ID. NO: 332)


 


hsa-miR-301b
CAGUGCAAUGAUAUUGUCAAAGCA (SEQ. ID. NO: 333)


 


hsa-miR-329
AACACACCUGGUUAACCUCUUU (SEQ. ID. NO: 334)


 


hsa-miR-33b
GUGCAUUGCUGUUGCAUUGC (SEQ. ID. NO: 335)


 


hsa-miR-374b
AUAUAAUACAACCUGCUAAGUG (SEQ. ID. NO: 336)


 


hsa-miR-375
UUUGUUCGUUCGGCUCGCGUGA (SEQ. ID. NO: 337)


 


hsa-miR-376a
AUCAUAGAGGAAAAUCCACGU (SEQ. ID. NO: 338)


 


hsa-miR-376b
AUCAUAGAGGAAAAUCCAUGUU (SEQ. ID. NO: 339)


 


hsa-miR-376c
AAUCGUACAGGGUCAUCCACUU (SEQ. ID. NO: 340)


 


hsa-miR-376c
AAUCGUACAGGGUCAUCCACUU (SEQ. ID. NO: 341)


 


hsa-miR-377
AUCACACAAAGGCAACUUUUGU (SEQ. ID. NO: 342)


 


hsa-miR-378
ACUGGACUUGGAGUCAGAAGG (SEQ. ID. NO: 343)


 


hsa-miR-379
UGGUAGACUAUGGAACGUAGG (SEQ. ID. NO: 344)


 


hsa-miR-380
UAUGUAAUAUGGUCCACAUCUU (SEQ. ID. NO: 345)


 


hsa-miR-410
AAUAUAACACAGAUGGCCUGU (SEQ. ID. NO: 346)


 


hsa-miR-421-3p
AUCAACAGACAUUAAUUGGGCG (SEQ. ID. NO: 347)


 


hsa-miR-429
UAAUACUGUCUGGUAAAACCGU (SEQ. ID. NO: 348)


 


hsa-miR-431
UGUCUUGCAGGCCGUCAUGCA (SEQ. ID. NO: 349)


 


hsa-miR-432
UCUUGGAGUAGGUCAUUGGGUGG (SEQ. ID. NO: 350)


 


hsa-miR-433
AUCAUGAUGGGCUCCUCGGUGU (SEQ. ID. NO: 351)


 


hsa-miR-449a
UGGCAGUGUAUUGUUAGCUGGU (SEQ. ID. NO: 352)


 


hsa-miR-449b
AGGCAGUGUAUUGUUAGCUGGC (SEQ. ID. NO: 353)


 


hsa-miR-450a
UUUUGCGAUGUGUUCCUAAUAU (SEQ. ID. NO: 354)


 


hsa-miR-451
AAACCGUUACCAUUACUGAGUU (SEQ. ID. NO: 355)


 


hsa-miR-452
AACUGUUUGCAGAGGAAACUGA (SEQ. ID. NO: 356)


 


hsa-miR-453
AGGUUGUCCGUGGUGAGUUCGCA (SEQ. ID. NO: 357)


 


hsa-miR-454
UAGUGCAAUAUUGCUUAUAGGGU (SEQ. ID. NO: 358)


 


hsa-miR-455-5p
UAUGUGCCUUUGGACUACAUCG (SEQ. ID. NO: 359)


 


hsa-miR-484
UCAGGCUCAGUCCCCUCCCGAU (SEQ. ID. NO: 360)


 


hsa-miR-485-3p
GUCAUACACGGCUCUCCUCUCU (SEQ. ID. NO: 361)


 


hsa-miR-485-5p
AGAGGCUGGCCGUGAUGAAUUC (SEQ. ID. NO: 362)


 


hsa-mir-486_os
CGGGGCAGCUCAGUACAGGAU (SEQ. ID. NO: 3603)


 


hsa-miR-487
AAUCAUACAGGGACAUCCAGUU (SEQ. ID. NO: 364)


 


hsa-miR-488
UUGAAAGGCUAUUUCUUGGUCU (SEQ. ID. NO: 365)


 


hsa-miR-490
CCAUGGAUCUCCAGGUGGGU (SEQ. ID. NO: 366)


 


hsa-miR-493
UGAAGGUCUACUGUGUGCCAGG (SEQ. ID. NO: 367)


 


hsa-miR-497
CAGCAGCACACUGUGGUUUGU (SEQ. ID. NO: 368)


 


hsa-miR-502
AAUGCACCUGGGCAAGGAUUCA (SEQ. ID. NO: 369)


 


hsa-miR-503
UAGCAGCGGGAACAGUUCUGCAG (SEQ. ID. NO: 370)


 


hsa-miR-505
CGUCAACACUUGCUGGUUUCCU (SEQ. ID. NO: 371)


 


hsa-miR-509-3p
UGAUUGGUACGUCUGUGGGUAG (SEQ. ID. NO: 372)


 


hsa-miR-514
AUUGACACUUCUGUGAGUAGA (SEQ. ID. NO: 373)


 


hsa-miR-92b
UAUUGCACUCGUCCCGGCCUCC (SEQ. ID. NO: 374)
















TABLE A3







MicroRNA Hairpin Precursor Sequences








Name
Hairpin Precursor (5′ → 3′)












hsa-mir-100516
GGCAGUGCUCUACUCAAAAAGCUGUCAGUCACUUAGAUUACAUGUGACUG




ACACCUCUUUGGGUGAAGGAAGGCUCA (SEQ. ID. NO: 375)


 


hsa-mir-100604
UUGGGCAAGGUGCGGGGCUAGGGCUAACAGCAGUCUUACUGAAGGUUUC



CUGGAAACCACGCACAUGCUGUUGCCACUAACCUCAACCUUACUCGGUC



(SEQ. ID. NO: 376)


 


hsa-mir-100610
UUCUCUCCUCCAUGCCUUGAGUGUAGGACCGUUGGCAUCUUAAUUACCCU



CCCACACCCAAGGCUUGCAAAAAAGCGAG (SEQ. ID. NO: 377)


 


hsa-mir-100631
AGGGGCGGGAGGGGGGUCCCCGGUGCUCGGAUCUCGAGGGUGCUUAUU



GUUCGGUCCGAGCCUGGGUCUCCCUCUUCCCCCCAACC (SEQ. ID. NO:



378)


 


hsa-mir-100701
AACUUGUUAGAAGGUUACUUGUUAGUUCAGGACCUCAUUACUUUCUGCCU



GAACUAUUGCAGUAGCCUCCUAACUGGUUAU (SEQ. ID. NO: 379)


 


hsa-mir-100723
CCGAGCCUCCAGUACCACGUGUCAGGGCCACAUGAGCUGGGCCUCGUGG



GCCUGAUGUGGUGCUGGGGCCUCAGGG (SEQ. ID. NO: 380)


 


hsa-mir-100730
UACUUAAUGAGAAGUUGCCCGUGUUUUUUUCGCUUUAUUUGUGACGAAAC



AUUCGCGGUGCACUUCUUUUUCAGUAUC (SEQ. ID. NO: 381)


 


hsa-mir-100732
ACGUCAGGGAAAGGAUUCUGCUGUCGGUCCCACUCCAAAGUUCACAGAAU



GGGUGGUGGGCACAGAAUCUGGACUCUGCUUGUG (SEQ. ID. NO: 382)


 


hsa-mir-100754
UGCUUCUGUGUGAUAUGUUUGAUAUUGGGUUGUUUAAUUAGGAACCAAC



UAAAUGUCAAACAUAUUCUUACAGCAGCAG (SEQ. ID. NO: 383)


 


hsa-mir-100760
CCUGAGCCUUGCACUGAGAUGGGAGUGGUGUAAGGCUCAGGUAUGCACA



GCUCCCAUCUCAGAACAAGGCUCGGGUG (SEQ. ID. NO: 384)


 


hsa-mir-100814
GUGUGCAUUUGCAGGAACUUGUGAGUCUCCUAUUGAAAAUGAACAGGAGA



CUGAUGAGUUCCCGGGAACACCCACAA (SEQ. ID. NO: 385)


 


hsa-mir-100815
AUGCACUGCACAACCCUAGGAGAGGGUGCCAUUCACAUAGACUAUAAUUG



AAUGGCGCCACUAGGGUUGUGCAGUGCACAA (SEQ. ID. NO: 386)


 


hsa-mir-100818
UAGAGGGAUGAGGGGGAAAGUUCUAUAGUCCUGUAAUUAGAUCUCAGGA



CUAUAGAACUUUCCCCCUCAUCCCUCUGCC (SEQ. ID. NO: 387)


 


hsa-mir-100819
CCGCACUCUCUCCAUUACACUACCCUGCCUCUUCUCCAUGAGAGGCAGCG



GGGUGUAGUGGAUAGAGCACGGGU (SEQ. ID. NO: 388)


 


hsa-mir-100824
UCAUACUUGAGGAGAAAUUAUCCUUGGUGUGUUCGCUUUAUUUAUGAUG



AAUCAUACAAGGACAAUUUCUUUUUGAGUAUCAAA (SEQ. ID. NO: 389)


 


hsa-mir-100825
CUCAGACAUCUCGGGGAUCAUCAUGUCACGAGAUACCAGUGUGCACUUGU



GACAGAUUGAUAACUGAAAGGUCUGGGAG (SEQ. ID. NO: 390)


 


hsa-mir-100829
AGUCAGAAAUGAGCUUAUUCAUAAAAGUGCAGUAUGGUGAAGUCAAUCUG



UAAUUUUAUGUAUAAGCUAGUCUCUGAUUGA (SEQ. ID. NO: 391)


 


hsa-mir-100835
CAGGAAGAGGAGGAAGCCCUGGAGGGGCUGGAGGUGAUGGAUGUUUUCC



UCCGGUUCUCAGGGCUCCACCUCUUUCGGGCC (SEQ. ID. NO: 392)


 


hsa-mir-100842
AGGUGGGUGCAAAGGUAAUUGCAGUUUUUCCCAUUAUUUUAAUUGCGAAA



ACAGCAAUUACCUUUGCACCAACCUGA (SEQ. ID. NO: 393)


 


hsa-mir-100843
AACUGCCCUCAAGGAGCUUACAAUCUAGCUGGGGGUAAAUGACUUGCACA



UGAACACAACUAGACUGUGAGCUUCUAGAGGGCAGGGA (SEQ. ID. NO:



394)


 


hsa-mir-100846
GGCGCGUCGCCCCCCUCAGUCCACCAGAGCCCGGAUACCUCAGAAAUUCG



GCUCUGGGUCUGUGGGGAGCGAAAUGCAAC (SEQ. ID. NO: 395)


 


hsa-mir-100851
GUGCAGAUCCUUGGGAGCCCUGUUAGACUCUGGAUUUUACACUUGGAGU



GAACGGGCGCCAUCCCGAGGCUUUGCACAG (SEQ. ID. NO: 396)


 


hsa-mir-100852
CAUUAGUAGGCCUCAGUAAAUGUUUAUUAGAUGAAUAAAUGAAUGACUCA



UCAGCAAACAUUUAUUGUGUGCCUGCUAAAGU (SEQ. ID. NO: 397)


 


hsa-mir-100854
UUAGCCCUGCGGCCCCACGCACCAGGGUAAGAGAGACUCUCGCUUCCUGC



CCUGGCCCGAGGGACCGACUGGCUGGGC (SEQ. ID. NO: 398)


 


hsa-mir-100855
UGCGGGCGUGUGAGUGUGUGUGUGUGAGUGUGUGUCGCUCCGGGUCCA



CGCUCAUGCACACACCCACACGCCCACACU (SEQ. ID. NO: 399)


 


hsa-mir-100869
UAAGUGGAAAGAUGGUGGGCCGCAGAACAUGUGCUGAGUUCGUGCCAUA



UGUCUGCUGACCAUCACCUUUAGAAGCCCC (SEQ. ID. NO: 400)


 


hsa-mir-100871
CACUCCUACCCGGGUCGGAGUUAGCUCAAGCGGUUACCUCCUCAUGCCGG



ACUUUCUAUCUGUCCAUCUCUGUGCUGGGGUUCGAGACCCGCGGGUGCU



UACUGACCCUUUUAUGCAAUAA (SEQ. ID. NO: 401)


 


hsa-mir-100885
CCUGGCCCAUGAAAUCAAGCGUGGGUGAGACCUGGUGCAGAACGGGAAG



GCGACCCAUACUUGGUUUCAGAGGCUGUGAG (SEQ. ID. NO: 402)


 


hsa-mir-100887
UUAGUGGUACUAUACCUCAGUUUUAUCAGGUGUUCUUAAAAUCACCUGGA



AACACUGAGGUUGUGUCUCACUGAAC (SEQ. ID. NO: 403)


 


hsa-mir-100891
UGAAGUGCUGUGGAUUUCUUUGUGAAUCACCAUAUCUAAGCUAAUGUGG



UGGUGGUUUACAAAGUAAUUCAUAGUGCUUCA (SEQ. ID. NO: 404)


 


hsa-mir-101001
UCUCCUCGAGGGGUCUCUGCCUCUACCCAGGACUCUUUCAUGACCAGGAG



GCUGAGGCCCCUCACAGGCGGC (SEQ. ID. NO: 405)


 


hsa-mir-146b
CACCUGGCACUGAGAACUGAAUUCCAUAGGCUGUGAGCUCUAGCAAUGCC



CUGUGGACUCAGUUCUGGUGCCCGGCAGU (SEQ. ID. NO: 406)


 


hsa-mir-147b
UAUAAAUCUAGUGGAAACAUUUCUGCACAAACUAGAUUCUGGACACCAGU



GUGCGGAAAUGCUUCUGCUACAUUUUUAGG (SEQ. ID. NO: 407)


 


hsa-mir-181d
GGUCACAAUCAACAUUCAUUGUUGUCGGUGGGUUGUGAGGACUGAGGCC



AGACCCACCGGGGGAUGAAUGUCACUGUGGCUGGG (SEQ. ID. NO: 408)


 


hsa-mir-18b
UCUCUUGUGUUAAGGUGCAUCUAGUGCAGUUAGUGAAGCAGCUUAGAAU



CUACUGCCCUAAAUGCCCCUUCUGGCACAGGCUGCC (SEQ. ID. NO: 409)


 


hsa-mir-193b
GUCUCAGAAUCGGGGUUUUGAGGGCGAGAUGAGUUUAUGUUUUAUCCAA



CUGGCCCUCAAAGUCCCGCUUUUGGGGUCA (SEQ. ID. NO: 410)


 


hsa-mir-200001
CCUUAAUCCUUGCAACGAACCUGAGCCACUGAUUCAGUAAAAUACUCAGU



GGCACAUGUUUGUUGUGAGGGUCAAAAGA (SEQ. ID. NO: 411)


 


hsa-mir-200002
AUAUUUGAGGAGAGGUUAUCCGUGUUAUGUUCGCUUCAUUCAUCAUGAAU



AAUACAUGGUUAACCUCUUUUUGAAUAUCA (SEQ. ID. NO: 412)


 


hsa-mir-200003
GGAAGUGCCCUACUUGGAAAGGCAUCAGUUGCUUAGAUUACAUGUAACUA



UUCCCUUUCUGAGUAGAGUAAGUCUUA (SEQ. ID. NO: 413)


 


hsa-mir-200004
CCUUAAUCCUUGCAACUUACCUGAGUCAUUGAUUCAGUAAAACAUUCAAU



GGCACAUGUUUGUUGUUAGGGUCAAAAGA (SEQ. ID. NO: 414)


 


hsa-mir-200007
GCUAGAGAAGGUAGAGGAGAUGGCGCAGGGGACACGGGCAAAGACUUGG



GGGUUCCUGGGACCCUCAGACGUGUGUCCUCUUCUCCCUCCUCCCAGGU



GUAUG (SEQ. ID. NO: 415)


 


hsa-mir-200008
CCUUCUCCCAUACCCAUUGCAUAUCGGAGUUGUGAAUUCUCAAAACACCU



CCUGUGUGCAUGGAUUACAGGAGGGUGA (SEQ. ID. NO: 416)


 


hsa-mir-20b
CUAGUAGUACCAAAGUGCUCAUAGUGCAGGUAGUUUUGGCAUGACUCUAC



UGUAGUAUGGGCACUUCCAGUACUCUUGGA (SEQ. ID. NO: 417)


 


hsa-mir-216b
GCAGACUGGAAAAUCUCUGCAGGCAAAUGUGAUGUCACUGAGGAAAUCAC



ACACUUACCCGUAGAGAUUCUACAGUCUGACA (SEQ. ID. NO: 418)


 


hsa-mir-301b
GCCGCAGGUGCUCUGACGAGGUUGCACUACUGUGCUCUGAGAAGCAGUG



CAAUGAUAUUGUCAAAGCAUCUGGGACCA (SEQ. ID. NO: 419)


 


hsa-mir-329-1
GUACCUGAAGAGAGGUUUUCUGGGUUUCUGUUUCUUUAAUGAGGACGAA



ACACACCUGGUUAACCUCUUUUCCAGUAUCA (SEQ. ID. NO: 420)


 


hsa-mir-329-2
GUACCUGAAGAGAGGUUUUCUGGGUUUCUGUUUCUUUAUUGAGGACGAA



ACACACCUGGUUAACCUCUUUUCCAGUAUCA (SEQ. ID. NO: 421)


 


hsa-mir-33b
CGGCCCCGCGGUGCAUUGCUGUUGCAUUGCACGUGUGUGAGGCGGGUGC



AGUGCCUCGGCAGUGCAGCCCGGAGCCGGCC (SEQ. ID. NO: 422)


 


hsa-mir-374b
ACUCGGAUGGAUAUAAUACAACCUGCUAAGUGUCCUAGCACUUAGCAGGU



UGUAUUAUCAUUGUCCGUGUCU (SEQ. ID. NO: 423)


 


hsa-mir-375
CUCCCGCCCCGCGACGAGCCCCUCGCACAAACCGGACCUGAGCGUUUUGU



UCGUUCGGCUCGCGUGAGGCAGGGGCG (SEQ. ID. NO: 424)


 


hsa-mir-376a-1
UAUUUAAAAGGUAGAUUCUCCUUCUAUGAGUACAUUAUUUAUGAUUAAUC



AUAGAGGAAAAUCCACGUUUUCAGUAUC (SEQ. ID. NO: 425)


 


hsa-mir-376a-2
UAUUUAAAAGGUAGAUUUUCCUUCUAUGGUUACGUGUUUGAUGGUUAAUC



AUAGAGGAAAAUCCACGUUUUCAGUAUC (SEQ. ID. NO: 426)


 


hsa-mir-376b
GUAUUUAAAACGUGGAUAUUCCUUCUAUGUUUACGUGAUUCCUGGUUAAU



CAUAGAGGAAAAUCCAUGUUUUCAGUAUCA (SEQ. ID. NO: 427)


 


hsa-mir-376c
UAUUUAAAAGGUGGAUAUUCCUUCUAUGUUUAUGUUAUUUAUGGUUAAAC



AUAGAGGAAAUUCCACGUUUUCAGUAUC (SEQ. ID. NO: 428)


 


hsa-mir-376c
UAUUUAAAAGGUGGAUAUUCCUUCUAUGUUUAUGUUAUUUAUGGUUAAAC



AUAGAGGAAAUUCCACGUUUUCAGUAUC (SEQ. ID. NO: 429)


 


hsa-mir-377
ACCCUUGAGCAGAGGUUGCCCUUGGUGAAUUCGCUUUAUUUAUGUUGAA



UCACACAAAGGCAACUUUUGUUUGAGUAUCA (SEQ. ID. NO: 430)


 


hsa-mir-378
CACCCAGGGCUCCUGACUCCAGGUCCUGUGUGUUACCUAGAAAUAGCACU



GGACUUGGAGUCAGAAGGCCUGAGUGGA (SEQ. ID. NO: 431)


 


hsa-mir-379
CCUGAAGAGAUGGUAGACUAUGGAACGUAGGCGUUAUGAUUUCUGACCUA



UGUAACAUGGUCCACUAACUCUCAGUAUC (SEQ. ID. NO: 432)


 


hsa-mir-380
ACCUGAAAAGAUGGUUGACCAUAGAACAUGCGCUAUCUCUGUGUCGUAUG



UAAUAUGGUCCACAUCUUCUCAAUAUCA (SEQ. ID. NO: 433)


 


hsa-mir-410
ACCUGAGAAGAGGUUGUCUGUGAUGAGUUCGCUUUUAUUAAUGACGAAUA



UAACACAGAUGGCCUGUUUUCAGUACC (SEQ. ID. NO: 434)


 


hsa-mir-421
CAUUGUAGGCCUCAUUAAAUGUUUGUUGAAUGAAAAAAUGAAUCAUCAAC



AGACAUUAAUUGGGCGCCUGCUCUGU (SEQ. ID. NO: 435)


 


hsa-mir-429
GCCGAUGGGCGUCUUACCAGACAUGGUUAGACCUGGCCCUCUGUCUAAUA



CUGUCUGGUAAAACCGUCCAUCCGCUG (SEQ. ID. NO: 436)


 


hsa-mir-431
UCCUGCGAGGUGUCUUGCAGGCCGUCAUGCAGGCCACACUGACGGUAAC



GUUGCAGGUCGUCUUGCAGGGCUUCUCGCAAGACG (SEQ. ID. NO: 437)


 


hsa-mir-432
CUCCUCCAGGUCUUGGAGUAGGUCAUUGGGUGGAUCCUCUAUUUCCUUA



CGUGGGCCACUGGAUGGCUCCUCCAUGUCUUGGAGUAGAU (SEQ. ID.



NO: 438)


 


hsa-mir-433
CGGGGAGAAGUACGGUGAGCCUGUCAUUAUUCAGAGAGGCUAGAUCCUC



UGUGUUGAGAAGGAUCAUGAUGGGCUCCUCGGUGUUCUCCAGGUA (SEQ.



ID. NO: 439)


 


hsa-mir-449a
UGUGAUGAGCUGGCAGUGUAUUGUUAGCUGGUUGAAUAUGUGAAUGGCA



UCGGCUAACAUGCAACUGCUGUCUUAUUGCAUA (SEQ. ID. NO: 440)


 


hsa-mir-449b
UGAAUCAGGUAGGCAGUGUAUUGUUAGCUGGCUGCUUGGGUCAAGUCAG



CAGCCACAACUACCCUGCCACUUGCUUCUGGA (SEQ. ID. NO: 441)


 


hsa-mir-450a-1
ACUAAACUGUUUUUGCGAUGUGUUCCUAAUAUGCACUAUAAAUAUAUUGG



GAACAUUUUGCAUGUAUAGUUUUGUAU (SEQ. ID. NO: 442)


 


hsa-mir-450a-2
GCUAAACUAUUUUUGCGAUGUGUUCCUAAUAUGUAAUAUAAAUGUAUUGG



GGACAUUUUGCAUUCAUAGUUUUGUAU (SEQ. ID. NO: 443)


 


hsa-mir-451
AAUGGCAAGGAAACCGUUACCAUUACUGAGUUUAGUAAUGGUAAUGGUUC



UCUUGCUAUACC (SEQ. ID. NO: 444)


 


hsa-mir-452
AAGCACUUACAACUGUUUGCAGAGGAAACUGAGACUUUGUAACUAUGUCU



CAGUCUCAUCUGCAAAGAAGUAAGUGCUUUGCC (SEQ. ID. NO: 445)


 


hsa-mir-453
AGAAGAUGCAGGAAUGCUGCGAGCAGUGCCACCUCAUGGUACUCGGAGG



GAGGUUGUCCGUGGUGAGUUCGCAUUAUUUAA (SEQ. ID. NO: 446)


 


hsa-mir-454
AUCCUAGAACCCUAUCAAUAUUGUCUCUGCUGUGUAAAUAGUUCUGAGUA



GUGCAAUAUUGCUUAUAGGGUUUUGGUGUUU (SEQ. ID. NO: 447)


 


hsa-mir-455
GGCGUGAGGGUAUGUGCCUUUGGACUACAUCGUGGAAGCCAGCACCAUG



CAGUCCAUGGGCAUAUACACUUGCCUCAAG (SEQ. ID. NO: 448)


 


hsa-mir-484
CUGGGAACCCCGGGGGGGGCGGGGCCUCGCGGCCCUGCAGCCUCGUCAG



GCUCAGUCCCCUCCCGAUAAACCCCUAA (SEQ. ID. NO: 449)


 


hsa-mir-485
GUACUUGGAGAGAGGCUGGCCGUGAUGAAUUCGAUUCAUCAAAGCGAGU



CAUACACGGCUCUCCUCUCUUUUAGUGUCA (SEQ. ID. NO: 450)


 


hsa-mir-486_os
CCCUGGGGCAUCCUGUACUGAGCUGCCCCGAGGCCCUUCAUGCUGCCCAG



CUCGGGGCAGCUCAGUACAGGAUACUCGGGGUGG (SEQ. ID. NO: 451)


 


hsa-mir-487
UACUUGAAGAGUGGUUAUCCCUGCUGUGUUCGCUUAAUUUAUGACGAAUC



AUACAGGGACAUCCAGUUUUUCAGUAUC (SEQ. ID. NO: 452)


 


hsa-mir-488
AAUCAUCUCUCCCAGAUAAUGGCACUCUCAAACAAGUUUCCAAAUUGUUU



GAAAGGCUAUUUCUUGGUCAGAUGACUCU (SEQ. ID. NO: 453)


 


hsa-mir-490
UUGUUCGACACCAUGGAUCUCCAGGUGGGUCAAGUUUAGAGAUGCACCAA



CCUGGAGGACUCCAUGCUGUUGAGCUGUU (SEQ. ID. NO: 454)


 


hsa-mir-493
CUCCAGGGCUUUGUACAUGGUAGGCUUUCAUUCAUUCGUUUGCACAUUCG



GUGAAGGUCUACUGUGUGCCAGGCCCUGUGCCA (SEQ. ID. NO: 455)


 


hsa-mir-497
GCUCCCGCCCCAGCAGCACACUGUGGUUUGUACGGCACUGUGGCCACGUC



CAAACCACACUGUGGUGUUAGAGCGAGGGUGGGGGAG (SEQ. ID. NO:



456)


 


hsa-mir-502
CCCCUCUCUAAUCCUUGCUAUCUGGGUGCUAGUGCUGGCUCAAUGCAAUG



CACCUGGGCAAGGAUUCAGAGAGGGGGA (SEQ. ID. NO: 457)


 


hsa-mir-503
AGCCGUGCCCUAGCAGCGGGAACAGUUCUGCAGUGAGCGAUCGGUGCUC



UGGGGUAUUGUUUCCGCUGCCAGGGUAAGUCUGG (SEQ. ID. NO: 458)


 


hsa-mir-505
ACCCAGUGGGGGAGCCAGGAAGUAUUGAUGUUUCUGCCAGUUUAGCGUC



AACACUUGCUGGUUUCCUCUCUGGAGCA (SEQ. ID. NO: 459)


 


hsa-mir-509-1
GUGGUACCCUACUGCAGACAGUGGCAAUCAUGUAUAAUUAAAAAUGAUUG



GUACGUCUGUGGGUAGAGUACUGCAU (SEQ. ID. NO: 460)


 


hsa-mir-509-2
GUGGUACCCUACUGCAGACGUGGCAAUCAUGUAUAAUUAAAAAUGAUUGG



UACGUCUGUGGGUAGAGUACUGCAU (SEQ. ID. NO: 461)


 


hsa-mir-509-3
GUGGUACCCUACUGCAGACAGUGGCAAUCAUGUAUAAUUAAAAAUGAUUG



GUACGUCUGUGGGUAGAGUACUGCAU (SEQ. ID. NO: 462)


 


hsa-mir-514-1
CUGUGGUACCCUACUCUGGAGAGUGACAAUCAUGUAUAAUUAAAUUUGAU



UGACACUUCUGUGAGUAGAGUAACGCAUGA (SEQ. ID. NO: 463)


 


hsa-mir-514-2
CUGUGGUACCCUACUCUGGAGAGUGACAAUCAUGUAUAACUAAAUUUGAU



UGACACUUCUGUGAGUAGAGUAACGCAUGA (SEQ. ID. NO: 464)


 


hsa-mir-514-3
CUGUGGUACCCUACUCUGGAGAGUGACAAUCAUGUAUAACUAAAUUUGAU



UGACACUUCUGUGAGUAGAGUAACGCAUGA (SEQ. ID. NO: 465)


 


hsa-mir-92b
GGCGGGCGGGAGGGACGGGACGCGGUGCAGUGUUGUUUUUUCCCCCGCC



AAUAUUGCACUCGUCCCGGCCUCCGGCCCCCCCG (SEQ. ID. NO: 466)
















TABLE A4







MicroRNA Sequences










Name
Mature MicroRNA (5′ to 3′)







hsa-miR-100516
UACUCAAAAAGCUGUCAGUCA




(SEQ. ID. NO: 467)



 



hsa-miR-100701
AAGGUUACUUGUUAGUUCAGG




(SEQ. ID. NO: 468)



 



hsa-miR-100760
GCACUGAGAUGGGAGUGGUGUA




(SEQ. ID. NO: 469)



 



hsa-miR-100885
GCGACCCAUACUUGGUUUCAG




(SEQ. ID. NO: 470)



 



hsa-miR-100887-3p
CCUGGAAACACUGAGGUUGUGU




(SEQ. ID. NO: 471)



 



hsa-miR-100887-5p
UAUACCUCAGUUUUAUCAGGUG




(SEQ. ID. NO: 472)



 



hsa-miR-100891-3p
UGGUGGUUUACAAAGUAAUUCA




(SEQ. ID. NO: 473)



 



hsa-miR-100891-5p
UGGAUUUCUUUGUGAAUCACCA




(SEQ. ID. NO: 474)



 



hsa-miR-200001
UGCAACGAACCUGAGCCACUGA




(SEQ. ID. NO: 475)



 



hsa-miR-200002
AUAAUACAUGGUUAACCUCUUU




(SEQ. ID. NO: 476)



 



hsa-miR-200003
UACUUGGAAAGGCAUCAGUUG




(SEQ. ID. NO: 477)



 



hsa-miR-200004
UGCAACUUACCUGAGUCAUUGA




(SEQ. ID. NO: 478)



 



hsa-miR-200007
GUAGAGGAGAUGGCGCAGGG




(SEQ. ID. NO: 479)



 



hsa-miR-200008
UACCCAUUGCAUAUCGGAGUU




(SEQ. ID. NO: 480)



 



hsa-mir-486_os
CGGGGCAGCUCAGUACAGGAU




(SEQ. ID. NO: 481)

















TABLE A5







MicroRNA Hairpin Precursor Sequences








Name
Hairpin Precursor (5′ → 3′)












hsa-miR-
GGCAGUGCUCUACUCAAAAAGCUGUCAGUCACUUAGA



100516
UUACAUGUGACUGACACCUCUUUGGGUGAAGGAAGGCUCA



(SEQ. ID. NO: 482)


 


hsa-miR-
AACUUGUUAGAAGGUUACUUGUUAGUUCAGGACCUCAUU


100701
ACUUUCUGCCUGAACUAUUGCAGUAGCCUCCUAACUGGUUAU



(SEQ. ID. NO: 483)


 


hsa-miR-
CCUGAGCCUUGCACUGAGAUGGGAGUGGUGUAAGGCUCAGG


100760
UAUGCACAGCUCCCAUCUCAGAACAAGGCUCGGGUG (SEQ. ID.



NO: 484)


 


hsa-miR-
CCUGGCCCAUGAAAUCAAGCGUGGGUGAGACCUGGUGCAG


100885
AACGGGAAGGCGACCCAUACUUGGUUUCAGAGGCUGUGAG



(SEQ. ID. NO: 485)


 


hsa-miR-
UUAGUGGUACUAUACCUCAGUUUUAUCAGGUGUUCUUAAA


100887-3p
AUCACCUGGAAACACUGAGGUUGUGUCUCACUGAAC (SEQ. ID.



NO: 486)


 


hsa-miR-
UUAGUGGUACUAUACCUCAGUUUUAUCAGGUGUUCUUAAA


100887-5p
AUCACCUGGAAACACUGAGGUUGUGUCUCACUGAAC (SEQ. ID.



NO: 487)


 


hsa-miR-
UGAAGUGCUGUGGAUUUCUUUGUGAAUCACCAUAUCUAAGC


100891-3p
UAAUGUGGUGGUGGUUUACAAAGUAAUUCAUAGUGCUUCA



(SEQ. ID. NO: 488)


 


hsa-miR-
UGAAGUGCUGUGGAUUUCUUUGUGAAUCACCAUAUCUAAGC


100891-5p
UAAUGUGGUGGUGGUUUACAAAGUAAUUCAUAGUGCUUCA



(SEQ. ID. NO: 489)


 


hsa-miR-
CCUUAAUCCUUGCAACGAACCUGAGCCACUGAUUCAGUAAAA


200001
UACUCAGUGGCACAUGUUUGUUGUGAGGGUCAAAAGA (SEQ. ID. NO: 490)


 


hsa-miR-
AUAUUUGAGGAGAGGUUAUCCGUGUUAUGUUCGCUUCAUUCA


200002
UCAUGAAUAAUACAUGGUUAACCUCUUUUUGAAUAUCA (SEQ.



ID. NO: 491)


 


hsa-miR-
GGAAGUGCCCUACUUGGAAAGGCAUCAGUUGCUUAGAUUACAU


200003
GUAACUAUUCCCUUUCUGAGUAGAGUAAGUCUUA (SEQ. ID. NO:



492)


 


hsa-miR-
CCUUAAUCCUUGCAACUUACCUGAGUCAUUGAUUCAGUAAAAC


200004
AUUCAAUGGCACAUGUUUGUUGUUAGGGUCAAAAGA (SEQ. ID. NO: 493)


 


hsa-miR-
GCUAGAGAAGGUAGAGGAGAUGGCGCAGGGGACACGGGCAAAG


200007
ACUUGGGGGUUCCUGGGACCCUCAGACGUGUGUCCUCUUCUCCC



UCCUCCCAGGUGUAUG (SEQ. ID. NO: 494)


 


hsa-miR-
CCUUCUCCCAUACCCAUUGCAUAUCGGAGUUGUGAAUUCUC


200008
AAAACACCUCCUGUGUGCAUGGAUUACAGGAGGGUGA (SEQ. ID. NO: 495)


 


hsa-mir-
CCCUGGGGCAUCCUGUACUGAGCUGCCCCGAGGCCCUUCAU


486_os
GCUGCCCAGCUCGGGGCAGCUCAGUACAGGAUACUCGGGGUGG



(SEQ. ID. NO: 496)
















TABLE A6







MicroRNA Sequences








name
MicroRNA (5′ → 3′)












hsa-mir-18b-3p
CUGCCCUAAAUGCCCCUUCUGGC (SEQ. ID. NO: 497)



 


hsa-miR-618
UUAAUAUGUACUGACAAAGCGU (SEQ. ID. NO: 498)


 


hsa-miR-619
UUUCCGGCUCGCGUGGGUGUGU (SEQ. ID. NO: 499)


 


hsa-miR-620
AUGUUGGGAGCGGGCAGGUUGG (SEQ. ID. NO: 500)


 


hsa-miR-723-5p
AGUACCACGUGUCAGGGCCACAUGA (SEQ. ID. NO: 501)


 


hsa-mir-816
UUGGGGAAACGGCCGCUGAGUGA (SEQ. ID. NO: 502)


 


hsa-mir-817
CUGUAUGCCCUCACCGCUCAGC (SEQ. ID. NO: 503)


 


hsa-mir-821-1
GCGGCGGCGGCGGAGGCU (SEQ. ID. NO: 504)


 


hsa-mir-821-2/3
GCGGCGGCGGCGGAGGCU (SEQ. ID. NO: 505)


 


hsa-mir-828-3p
UCUAGUAAGAGUGGCAGUCGA (SEQ. ID. NO: 506)


 


hsa-mir-828-5p
AUGCUGACAUAUUUACUAGAGG (SEQ. ID. NO: 507)


 


hsa-mir-831-1
UGGGGCGGAGCUUCCGGAGGCC (SEQ. ID. NO: 508)


 


hsa-mir-831-2
UGGGGCGGAGCUUCCGGAGGCC (SEQ. ID. NO: 509)


 


hsa-mir-831-3/-4/-5
UGGGGCGGAGCUUCCGGAGGCC (SEQ. ID. NO: 510)


 


hsa-mir-840-3p
ACUCGGCGUGGCGUCGGUCGUGG (SEQ. ID. NO: 511)


 


hsa-mir-840-5p
UCGACCGGACCUCGACCGGCUC (SEQ. ID. NO: 512)


 


hsa-mir-845-1
AAAGCAUGCUCCAGUGGCGC (SEQ. ID. NO: 513)


 


hsa-mir-845-2
AAAGCAUGCUCCAGUGGCGC (SEQ. ID. NO: 514)


 


hsa-mir-847
CAGAGAGGACCACUAUGGCGGG (SEQ. ID. NO: 515)


 


hsa-mir-848
AUUGCCAUCCCCUAUGGACCAG (SEQ. ID. NO: 516)


 


hsa-mir-849
UGUCUACUACUGGAGACACUGG (SEQ. ID. NO: 517)


 


hsa-mir-850
UUAGGGCCCUGGCUCCAUCUCC (SEQ. ID. NO: 518)


 


hsa-mir-853
UGGGAUCUCCGGGGUCUUGGUU (SEQ. ID. NO: 519)


 


hsa-mir-857
AAGGCAGGGCCCCCGCUCCCCGG (SEQ. ID. NO: 520)


 


hsa-mir-864
AAAAGCUGAGUUGAGAGG (SEQ. ID. NO: 521)


 


hsa-mir-151
UCGAGGAGCUCACAGUCUAGA (SEQ. ID. NO: 522)
















TABLE A7







MicroRNA Hairpin Precursor Sequences.








name
Hairpin Precursor (5′ → 3′)












>hsa-mir-18b-3p
CUUGUGUUAAGGUGCAUCUAGUGCAGUUAGUGAAGCAGCUUAGA




AUCUACUGCCCUAAAUGCCCCUUCUGGCACAGG (SEQ. ID. NO: 523)


 


>hsa-miR-618
UUAUUGUGAAAUAUGUCAUUAAUAUGUACUGACAAAGCGUAUCUG



UGUAAUAAAUAUGCUUUUUGUCAGUACAUGUUAAUGGUAUAUUUC



AUAACAA (SEQ. ID. NO: 524)


 


>hsa-miR-619
GCGGCUGCUGGACCCACCCGGCCGGGAAUAGUGCUCCUGGUUGUU



UCCGGCUCGCGUGGGUGUGUCGGCGGCGGG (SEQ. ID. NO: 525)


 


>hsa-miR-620
CGCCCCCACGUGGCCCCGCCCCCUGAGGCCGGCGCUGCCGCCAUGU



UGGGAGCGGGCAGGUUGGGAGCG (SEQ. ID. NO: 526)


 


>hsa-miR-723-5p
GCCACCUUCCGAGCCUCCAGUACCACGUGUCAGGGCCACAUGAGCUG



GGCCUCGUGGGCCUGAUGUGGUGCUGGGGCCUCAGGGGUCUG (SEQ.



ID. NO: 527)


 


>hsa-mir-816
GGGUUUGGGGAAACGGCCGCUGAGUGAGGCGUCGGCUGUGUUUCUC



ACCGCGGUCUUUUCCUCCCACUC (SEQ. ID. NO: 528)


 


>hsa-mir-817
CUUGGUGACGCUGUAUGCCCUCACCGCUCAGCCCCUGGGGCUGGCUU



GGCAGACAGUACAGCAUCCAGGGGAGUCAAGGGCAUGGGGCGAGACC



AGA (SEQ. ID. NO: 529)


 


>hsa-mir-821-1
GCGGCGGCGGCGGAGGCUGCUGCUGGGGCGGCUGCUGCUGGGGCGG



CUGCGGCGGCGGCUGCUGCGGGGGCUGCUGCUGCUGUUGC (SEQ. ID.



NO: 530)


 


>hsa-mir-821-2/3
GCGGCUGCGGCGGCGGCGGAGGCUGCGGCGGCGACCGUGGCAGAGGC



GGUGGCGGAGGCCUCCGUGGCGGAGGCGGAAGC (SEQ. ID. NO: 531)


 


>hsa-mir-828-3p
CUUCCUCAUGCUGACAUAUUUACUAGAGGGUAAAAUUAAUAACCUUCUA



GUAAGAGUGGCAGUCGAAGGGAAG (SEQ. ID. NO: 532)


 


>hsa-mir-828-5p
CUUCCUCAUGCUGACAUAUUUACUAGAGGGUAAAAUUAAUAACCUUCUA



GUAAGAGUGGCAGUCGAAGGGAAG (SEQ. ID. NO: 533)


 


>hsa-mir-831-1
GCUCCGCCCCACGUCGCAUGCGCCCCGGGAACGCGUGGGGCGGAGC



UUCCGGAGGCCCCGCUCUGCUGCCGACCCUGUGGAGCGGAGGGUGA



AGCCUCCGGAUGCCAGUCCCUCAUCGCUGGCCUGGUCGCGCUGUGG



CGAAGGGGGCGGAGC (SEQ. ID. NO: 534)


 


>hsa-mir-831-2
GCUCCGCCCCACGUCGCAUGCGCCCCGGGAACGCGUGGGGCGGAGC



UUCCGGAGGCCCCGCCCUGCUGCCGACCCUGUGGAGCGGAGGGUGA



AGCCUCCGGAUGCCAGUCCCUCAUCGCUGGCCCGGUCGCGCUGUGG



CGAAGGGGGCGGAGC (SEQ. ID. NO: 535)


 


>hsa-mir-831-3/-4/-5
CGCUCCGCCCCACGUCGCAUGCGCCCCGGGAAAGCGUGGGGCGGAG



CUUCCGGAGGCCCCGCCCUGCUGCCGACCCUGUGGAGCGGAGGGUG



AAGCCUCCGGAUGCCAGUCCCUCAUCGCUGGCCCGGUCGCGCUGUG



GCGAAGGGGGCGGAGC (SEQ. ID. NO: 536)


 


>hsa-mir-840-3p
UUCAUCAAGACCCAGCUGAGUCACUGUCACUGCCUACCAAUCUCGAC



CGGACCUCGACCGGCUCGUCUGUGUUGCCAAUCGACUCGGCGUGGC



GUCGGUCGUGGUAGAUAGGCGGUCAUGCAUACGAAUUUUCAGCUCU



UGUUCUGGUGAC (SEQ. ID. NO: 537)


 


>hsa-mir-840-5p
UUCAUCAAGACCCAGCUGAGUCACUGUCACUGCCUACCAAUCUCGAC



CGGACCUCGACCGGCUCGUCUGUGUUGCCAAUCGACUCGGCGUGGC



GUCGGUCGUGGUAGAUAGGCGGUCAUGCAUACGAAUUUUCAGCUCU



UGUUCUGGUGAC (SEQ. ID. NO: 538)


 


>hsa-mir-845-1
CGCGAGGCCGGGGUCGAGCGCUUCAGUAGCUCAUGGCUCUGUAGAG



UGCGCAUGGCCAAGCAAAGGAAAGCAUGCUCCAGUGGCGCA (SEQ. ID.



NO: 539)


 


>hsa-mir-845-2
AGUAACCACUUAGUGUGUAUUGACUUGUCAGAAUUUUCAGAAUUUAA



AGCAUGCUCCAGUGGCGCA (SEQ. ID. NO: 540)


 


>hsa-mir-847
UUACUGUGUCAUUGUUGCUGUCAUUGCUACUGAGGAGUACUGACCAG



AAUCAUCUGCAACUCUUAGUUGGCAGAGAGGACCACUAUGGCGGGUAG



(SEQ. ID. NO: 541)


 


>hsa-mir-848
UGGGCCAGAUUGCCAUCCCCUAUGGACCAGAAGCCAAGGAUCUCUCUA



GUGAUGGUCAGAGGGCCCAAAUGGCAGGGAUACCCA (SEQ. ID. NO:



542)


 


>hsa-mir-849
GCUUCUGUCUACUACUGGAGACACUGGUAGUAUAAAACCCAGAGUCUC



CAGUAAUGGACGGGAGC (SEQ. ID. NO: 543)


 


>hsa-mir-850
CUGGGUUAGGGCCCUGGCUCCAUCUCCUUUAGGAAAACCUUCUGUGGG



GAGUGGGGCUUCGACCCUAACCCAG (SEQ. ID. NO: 544)


 


>hsa-mir-853
CCUGGGCUCUGACCUGAGACCUCUGGGUUCUGAGCUGUGAUGUUGCUC



UCGAGCUGGGAUCUCCGGGGUCUUGGUUCAGGG (SEQ. ID. NO: 545)


 


>hsa-mir-857
GGGCCCGGCCCCAGGAGCGGGGCCUGGGCAGCCCCGUGUGUUGAGGAA



GGAAGGCAGGGCCCCCGCUCCCCGGGCCU (SEQ. ID. NO: 546)


 


>hsa-mir-864
CCUUCUCUUCUCAGUUCUUCCCCAAGUUAGGAAAAGCUGAGUUGAGAGGG



(SEQ. ID. NO: 547)


 


>hsa-mir-151
GUCUCUCUUCAGGGCUCCCGAGACACAGAAACAGACACCUGCCCUCGAG



GAGCUCACAGUCUAGAC (SEQ. ID. NO: 548)
















TABLE A8







MicroRNA Sequence and Hairpin Precursor Sequence











Mature MicroRNA




Name
(5′ → 3′)
Hairpin Precursor Sequence





hsa-miR-544
AUUCUGCAU
CACCUAGGGAUCUUGUUAAAAAGCAGAUUCUGAU




UUUUAGCAA
UCAGGGACCAAGAUUCUGCAUUUUUAGCAAGUUC



GUUC (SEQ.
UCAAGUGAUG (SEQ. ID. NO: 550)



ID. NO: 549)









In this specification, a base refers to any one of the nucleotide bases normally found in naturally occurring DNA or RNA. The bases can be purines or pyrimidines. Examples of purine bases include adenine (A) and guanine (G). Examples of pyrimidine bases include thymine (T), cytosine (C) and uracil (U). The adenine can be replaced with 2,6-diaminopurine.
Sequences of nucleic acid molecules disclosed in this specification are shown having uracil bases. Uracil bases occur in RNA molecules. The invention also includes DNA molecules. The sequence of bases of the DNA molecule is the same as the RNA molecule, except that in the DNA molecule, the uracil bases are replaced with thymine bases.
Each base in the sequence can form a Watson-Crick base pair with a complementary base. Watson-Crick base pairs as used herein refer to the hydrogen bonding interaction between, for example, the following bases: adenine and thymine (A-T); adenine and uracil (A-U); and cytosine and guanine (C-G).
Equivalents refer to molecules wherein up to thirty percent of the contiguous bases in, for example, SEQ. ID. NOS:1-94 are wobble bases, and/or up to ten percent, and preferably up to five percent of the contiguous bases are non-complementary.
As used herein, wobble bases refer to either: 1) substitution of a cytosine with a uracil, or 2) the substitution of an adenine with a guanine, in the sequence of the molecule. These wobble base substitutions are generally referred to as UG or GU wobbles. Table B shows the number of contiguous bases and the maximum number of wobble bases in the molecule.







TABLE B





Number of contiguous Bases and Maximum Number of Wobble Bases

















No. of Contiguous Bases

















10
11
12
13
14
15
16
17
18





Max. No. of
3
3
3
3
4
4
4
5
5


Wobble Base


Pairs












No. of Contiguous



Bases















19
20
21
22
23







Max. No. of
5
6
6
6
6



Wobble Base



Pairs










The term “non-complementary” as used herein refers to additions, deletions, mismatches or combinations thereof. Additions refer to the insertion in the contiguous sequence of any base described above. Deletions refer to the removal of any moiety present in the contiguous sequence. Mismatches refer to the substitution of one of the bases in the contiguous sequence with a different base.
The additions, deletions or mismatches can occur anywhere in the contiguous sequence, for example, at either end of the contiguous sequence or within the contiguous sequence of the molecule. Typically, the additions, deletions or mismatches occur at the end of the contiguous sequence if the contiguous sequence is relatively short, such as, for example, from about ten to about fifteen bases in length. If the contiguous sequence is relatively long, such as, for example, a minimum of sixteen contiguous sequences, the additions, deletions, or mismatches may occur anywhere in the contiguous sequence.
For example, none or one of the contiguous bases may be additions, deletions, or mismatches when the number of contiguous bases is ten to nineteen; and none, or one or two additions, deletions, or mismatches are permissible when the number of contiguous bases is twenty or more.
In addition to the at least ten contiguous nucleotides of the microRNA, the isolated DNA or RNA molecule may also have one or more additional nucleotides. There is no upper limit to the additional number of nucleotides. Typically, no more than about 500 nucleotides, and preferably no more than about 300 nucleotides are added to the at least ten contiguous bases of a microRNA.
Any nucleotide can be added. The additional nucleotides can comprise any base described above. Thus, for example, the additional nucleotides may be any one or more of A, G, C, T, or U.
In one embodiment, the microRNA is part of a hairpin precursor sequence or fragment thereof. For example, suitable hairpin precursor sequences are shown in Table A1 as SEQ ID NOs:95-187. Further hairpin precursor sequences are shown in the following: Table A3 as SEQ. ID. NOs: 375-466; Table A5 as SEQ. ID. NOs: 482-496; Table A7 as SEQ. ID. NOs: 523-548; and Table A8 as SEQ. ID. NO: 550.
The fragment can be any fragment of the hairpin precursor sequence containing at least ten, preferably at least fifteen, more preferably at least twenty nucleotides at the 5′ end and/or nucleotides at the 3′ end. Preferably the sequence of nucleotides is in the hairpin precursor in which the microRNA is present.
The microRNA or hairpin precursor can be inserted into a vector, such as, for example, a recombinant vector. Typically, to construct a recombinant vector containing a microRNA, the hairpin precursor sequence which contains the microRNA sequence is incorporated into the vector. See for example, Chen et al. Science 2004, 303:83-86.
The recombinant vector may be any recombinant vector, such as a plasmid, a cosmid or a phage. Recombinant vectors generally have an origin of replication. The vector may be, for example, a viral vector, such as an adenovirus vector or an adeno-associated virus (AAV) vector. See for example: Ledley 1996, Pharmaceutical Research 13:1595-1614 and Verma et al. Nature 1997, 387:239-242.
The vector may further include a selectable marker. Suitable selectable markers include a drug resistance marker, such as tetracycline or gentamycin, or a detectable gene marker, such as β-galactosidase or luciferase.
In a preferred embodiment, the isolated DNA or RNA molecule consists of any one of the microRNA sequences or a hairpin precursor sequence shown in SEQ ID NOs:1-187.
In another preferred embodiment, the isolated DNA or RNA molecule consists of any one of the microRNA sequences or a hairpin precursor sequence shown in SEQ ID NOs:281-466.
In a further preferred embodiment, the isolated DNA or RNA molecule consists of any one of the microRNA sequences or a hairpin precursor sequence shown in SEQ ID NOs:467-496.
In yet a further preferred embodiment, the isolated DNA or RNA molecule consists of any one of the microRNA sequences or a hairpin precursor sequence shown in SEQ ID NOs:497-548.
In yet a further preferred embodiment, the isolated DNA or RNA molecule consists of any one of the microRNA sequences or a hairpin precursor sequence shown in SEQ ID NOs:549-550.
In this specification, “isolated” means that the molecule is essentially free of other nucleic acids. Essentially free from other nucleic acids means that the molecule is at least about 90%, preferably at least about 95%, and more preferably at least about 98% free of other nucleic acids.
Preferably, the molecule is essentially pure, which means that the molecules are free not only of other nucleic acids, but also of other materials used in the synthesis and isolation of the molecule. Materials used in synthesis include, for example, enzymes. Materials used in isolation include, for example, gels, such as SDS-PAGE. The molecule is at least about 90% free, preferably at least about 95% free and, more preferably at least about 98% free of such materials.
The sequence of bases in a microRNA or hairpin precursor is highly conserved. Due to the high conservation, the sequence can be from a cell of any mammal. Examples of mammals include pet animals, such as dogs and cats, farm animals, such as cows, horses and sheeps, laboratory animals, such as rats, mice and rabbits, and primates; such as monkeys and humans. Preferably, the mammal is human or mouse.
Modified Single Stranded microRNA Molecules
In another embodiment, the invention relates to a modified single stranded microRNA molecule. The modified single stranded microRNA molecule can be any of the microRNA molecules, hairpin precursor molecules, or equivalents thereof described above, except that the modified molecule comprises at least one modified moiety (i.e., at least one moiety is not an unmodified deoxyribonucleotide moiety or an unmodified ribonucleotide moiety). In this embodiment, the modified microRNA molecule comprises a minimum number of ten moieties, preferably a minimum of thirteen, more preferably a minimum of fifteen, even more preferably a minimum of eighteen, and most preferably a minimum of twenty-one moieties.
The modified microRNA molecules preferably comprise a maximum number of fifty moieties, more preferably a maximum of forty, even more preferably a maximum of thirty, most preferably a maximum of twenty-five, and optimally a maximum of twenty-three moieties. A suitable range of minimum and maximum numbers of moieties may be obtained by combining any of the above minima with any of the above maxima.
Each modified moiety comprises a base bonded to a backbone unit. The backbone unit may be any molecular unit that is able to stably bind to a base and to form an oligomeric chain. In this specification, the backbone units of a modified moiety do not include the backbone units commonly found in naturally occurring DNA or RNA molecules.
Such modified microRNA molecules have increased nuclease resistance. Therefore, the nuclease resistance of the molecule is increased compared to a sequence containing only unmodified ribonucleotide moieties, unmodified deoxyribonucleotide moieties or both. Such modified moieties are well known in the art, and were reviewed, for example, by Kurreck, Eur. J. Biochem. 270, 1628-1644 (2003).
The nuclease resisted can be an exonuclease, an endonuclease, or both. The exonuclease can be a 3′→45′ exonuclease or a 5′→3′ exonuclease. Examples of 3′→5′ human exonuclease include PNPT1, Werner syndrome helicase, RRP40, RRP41, RRP42, RRP45, and RRP46. Examples of 5′→3′ exonuclease include XRN2, and FEN1. Examples of endonucleases include Dicer, Drosha, RNase4, Ribonuclease P, Ribonuclease H1, DHP1, ERCC-1 and OGG1. Examples of nucleases which function as both an exonuclease and an endonuclease include APE1 and EXO1.
A modified moiety can occur at any position in the microRNA molecule. For example, to protect microRNA molecules against 3′→5′ exonucleases, the molecules can have at least one modified moiety at the 3′ end of the molecule and preferably at least two modified moieties at the 3′ end. If it is desirable to protect the molecule against 5′→3′ exonuclease, the microRNA molecules can have at least one modified moiety and preferably at least two modified moieties at the 5′ end of the molecule. The microRNA molecules can also have at least one and preferably at least two modified moieties between the 5′ and 3′ end of the molecule to increase resistance of the molecule to endonucleases. Preferably, at least about 10%, more preferably at least about 25%, even more preferably at least about 50%, and further more preferably at least about 75%, and most preferably at least about 95% of the moieties are modified. In one embodiment, all of the moieties are modified (e.g., nuclease resistant).
In one example of a modified microRNA molecule, the molecule comprises at least one modified deoxyribonucleotide moiety. Suitable modified deoxyribonucleotide moieties are known in the art. Such modified deoxyribonucleotide moieties comprise, for example, phosphorothioate deoxyribose groups as the backbone unit. See structure 1 in FIG. 1. A modified microRNA molecule comprising phosphorothioate deoxyribonucleotide moieties is generally referred to as phosphorothioate (PS) DNA. See, for example, Eckstein, Antisense Nucleic Acids Drug Dev. 10, 117-121 (2000).
Another suitable example of a modified deoxyribonucleotide moiety is an N′3-N′5 phosphoroamidate deoxyribonucleotide moiety, which comprises an N′3-N′5 phosphoroamidate deoxyribose group as the backbone unit. See structure 2 in FIG. 1. An oligonucleotide molecule comprising phosphoroamidate deoxyribonucleotide moieties is generally referred to as phosphoroamidate (NP) DNA. See, for example, Gryaznov et al., J. Am. Chem. Soc. 116, 3143-3144 (1994).
In another example of a modified microRNA molecule, the molecule comprises at least one modified ribonucleotide moiety. A suitable example of a modified ribonucleotide moiety is a ribonucleotide moiety that is substituted at the 2′ position. The substituents at the 2′ position may, for example, be a C1 to C4 alkyl group. The C1 to C4 alkyl group may be saturated or unsaturated, and unbranched or branched. Some examples of C1 to C4 alkyl groups include ethyl, isopropyl, and allyl. The preferred C1 to C4 alkyl group is methyl. See structure 3 in FIG. 1. An oligoribonucleotide molecule comprising ribonucleotide moieties substituted at the 2′ position with a C1 to C4 alkyl group is generally referred to as a 2′-O—(C1-C4 alkyl) RNA, e.g., 2′-O-methyl RNA (OMe RNA).
Another suitable example of a substituent at the 2′ position of a modified ribonucleotide moiety is a C1 to C4 alkoxy-C1 to C4 alkyl group. The C1 to C4 alkoxy (alkyloxy) and C1 to C4 alkyl group may comprise any of the alkyl groups described above. The preferred C1 to C4 alkoxy-C1 to C4 alkyl group is methoxyethyl. See structure 4 in FIG. 1. An oligonucleotide molecule comprising more than one ribonucleotide moiety that is substituted at the 2′ position with a C1 to C4 alkoxy-C1 to C4 alkyl group is referred to as a 2′-O—(C1 to C4 alkoxy-C1 to C4 alkyl) RNA, e.g., 2′-O-methoxyethyl RNA (MOE RNA).
Another suitable example of a modified ribonucleotide moiety is a ribonucleotide that has a methylene bridge between the 2′-oxygen atom and the 4′-carbon atom. See structure 5 in FIG. 1. An oligoribonucleotide molecule comprising ribonucleotide moieties that has a methylene bridge between the 2′-oxygen atom and the 4′-carbon atom is generally referred to as locked nucleic acid (LNA). See, for example, Kurreck et al., Nucleic Acids Res. 30, 1911-1918 (2002); Elayadi et al., Curr. Opinion Invest. Drugs 2, 558-561 (2001); Ørum et al., Curr. Opinion Mol. Ther. 3, 239-243 (2001); Koshkin et al., Tetrahedron 54, 3607-3630 (1998); Obika et al., Tetrahedron Lett. 39, 5401-5404 (1998). Locked nucleic acids are commercially available from Proligo (Paris, France and Boulder, Colo., USA).
Another suitable example of a modified ribonucleotide moiety is a ribonucleotide that is substituted at the 2′ position with fluoro group. Such 2′-fluororibonucleotide moieties are known in the art. Molecules comprising 2′-fluororibonucleotide moieties are generally referred to herein as 2′-fluororibo nucleic acids (FANA). See structure 7 in FIG. 1. Damha et al., J. Am. Chem. Soc. 120, 12976-12977 (1998).
In another example of a modified microRNA molecule, the molecule comprises at least one modified moiety comprising a base bonded to an amino acid residue as the backbone unit. Modified moieties that have at least one base bonded to an amino acid residue will be referred to herein as peptide nucleic acid (PNA) moieties. Such moieties are nuclease resistance, and are known in the art. Molecules having PNA moieties are generally referred to as peptide nucleic acids. See structure 6 in FIG. 1. Nielson, Methods Enzymol. 313, 156-164 (1999); Elayadi, et al, id.; Braasch et al., Biochemistry 41, 4503-4509 (2002), Nielsen et al., Science 254, 1497-1500 (1991).
The amino acids can be any amino acid, including natural or non-natural amino acids. Naturally occurring amino acids include, for example, the twenty most common amino acids normally found in proteins, i.e., alanine (Ala), arginine (Arg), asparagine (Asn), aspartic acid (Asp), cysteine (Cys), glutamine (Glu), glutamic acid (Glu), glycine (Gly), histidine (His), isoleucine (Ileu), leucine (Leu), lysine (Lys), methionine (Met), phenylalanine (Phe), proline (Pro), serine (Ser), threonine (Thr), tryptophan, (Trp), tyrosine (Tyr), and valine (Val).
The non-natural amino acids may, for example, comprise alkyl, aryl, or alkylaryl groups. Some examples of alkyl amino acids include α-aminobutyric acid, β-aminobutyric acid, γ-aminobutyric acid, δ-aminovaleric acid, and ε-aminocaproic acid. Some examples of aryl amino acids include ortho-, meta, and para-aminobenzoic acid. Some examples of alkylaryl amino acids include ortho-, meta-, and para-aminophenylacetic acid, and γ-phenyl-β-aminobutyric acid.
Non-naturally occurring amino acids also include derivatives of naturally occurring amino acids. The derivative of a naturally occurring amino acid may, for example, include the addition or one or more chemical groups to the naturally occurring amino acid.
For example, one or more chemical groups can be added to one or more of the 2′, 3′, 4′, 5′, or 6′ position of the aromatic ring of a phenylalanine or tyrosine residue, or the 4′, 5′, 6′, or 7′ position of the benzo ring of a tryptophan residue. The group can be any chemical group that can be added to an aromatic ring. Some examples of such groups include hydroxyl, C1-C4 alkoxy, amino, methylamino, dimethylamino, nitro, halo (i.e., fluoro, chloro, bromo, or iodo), or branched or unbranched C1-C4 alkyl, such as methyl, ethyl, n-propyl, isopropyl, butyl, isobutyl, or t-butyl.
Other examples of non-naturally occurring amino acids which are derivatives of naturally occurring amino acids include norvaline (Nva), norleucine (Nle), and hydroxyproline (Hyp).
The amino acids can be identical or different from one another. Bases are attached to the amino acid unit by molecular linkages. Examples of linkages are methylene carbonyl, ethylene carbonyl and ethyl linkages. (Nielsen et al., Peptide Nucleic Acids Protocols and Applications, Horizon Scientific Press, pages 1-19; Nielsen et al., Science 254: 1497-1500.) One example of an amino acid residue of a PNA moiety is N-(2-aminoethyl)-glycine.
Further examples of PNA moieties include cyclohexyl PNA, retro-inverso PNA, phosphone PNA, propionyl PNA and aminoproline PNA moieties. For a description of these PNA moieties, see FIG. 5 of Nielsen et al., Peptide Nucleic Acids-Protocols and Applications, Horizon Scientific Press, pages 1-19. FIG. 5 on page 7 of Nielsen et al. is hereby incorporated by reference.
PNA can be chemically synthesized by methods known in the art, e.g. by modified Fmoc or tBoc peptide synthesis protocols. The PNA has many desirable properties, including high melting temperatures (Tm), high base-pairing specificity with nucleic acid and an uncharged molecular backbone. Additionally, the PNA does not confer RNase H sensitivity on the target RNA, and generally has good metabolic stability.
Peptide nucleic acids are also commercially available from Applied Biosystems (Foster City, Calif., USA).
In another example of a modified microRNA molecule, the molecule comprises at least one morpholino phosphoroamidate nucleotide moiety. Molecules comprising morpholino phosphoroamidate nucleotide moieties are generally referred to as morpholino (MF) nucleic acids. See structure 8 in FIG. 1. Heasman, Dev. Biol. 243, 209-214 (2002). Morpholino oligonucleotides are commercially available from Gene Tools LLC (Corvallis, Oreg., USA).
In a further example of a modified microRNA molecule, the molecule comprises at least one cyclohexene nucleotide moiety. Molecules comprising cyclohexene nucleotide moieties are generally referred to as cyclohexene nucleic acids (CeNA). See structure 10 in FIG. 1. Wang et al., J. Am. Chem. Soc. 122, 8595-8602 (2000), Verbeure et al., Nucleic Acids Res. 29, 4941-4947 (2001).
In a final example of a modified microRNA molecule, the molecule comprises at least one tricyclo nucleotide moiety. Molecules comprising tricyclo nucleotide moieties are generally referred to as tricyclo nucleic acids (tcDNA). See structure 9 in FIG. 1. Steffens et al., J. Am. Chem. Soc. 119, 11548-11549 (1997), Renneberg et al., J. Am. Chem. Soc. 124, 5993-6002 (2002).
The molecule can be a chimeric modified microRNA molecule. Chimeric molecules containing a mixture of any of the moieties mentioned above are also known, and may be made by methods known, in the art. See, for example, references cited above, and Wang et al, Proc. Natl. Acad. Sci. USA 96, 13989-13994 (1999), Liang et al., Eur. J. Biochem. 269, 5753-5758 (2002), Lok et al., Biochemistry 41, 3457-3467 (2002), and Damha et al., J. Am. Chem. Soc. 120, 12976-12977 (2002).
The modified microRNA molecules of the invention comprise at least ten, preferably at least thirteen, more preferably at least fifteen, and even more preferably at least twenty contiguous bases having any of the contiguous base sequences of a naturally occurring microRNA molecule shown in SEQ ID NOs:1-94, SEQ. ID. NOs: 281-374, SEQ. ID NOs:467-481, SEQ. ID. NOs:497-522, or SEQ. ID. NO:549; except that the modified molecule comprises at least one modified moiety. In a preferred embodiment, the modified microRNA molecules comprise the entire sequence of any of the microRNA molecule shown in SEQ ID NOs:1-94, SEQ. ID. NOs: 281-374, SEQ. ID. NOs:467-481, SEQ. ID. NOs:497-522, or SEQ. ID. NO:549.
Any number of additional moieties, up to a maximum of forty moieties, having any base sequence can be added to the moieties comprising the contiguous base sequence, as long as the total number of moieties in the molecule does not exceed fifty. The additional moieties can be added to the 5′ end, the 3′ end, or to both ends of the contiguous sequence. The additional moieties can include a sequence of bases at the 5′ end and/or a sequence of bases at the 3′ end present in the hairpin precursor from which the microRNA is present or any fragment thereof. The additional moieties in the molecule, if any, can be any modified or unmodified moiety described above.
The modified microRNA molecules include equivalents thereof. Equivalents include wobble bases and non-complementary bases as described above.
Further, no more than fifty percent, and preferably no more than thirty percent, of the contiguous moieties contain deoxyribonucleotide backbone units. For example, Table C and D show maximum numbers of deoxyribonucleotide backbone units for 19-23 contiguous bases.
In another embodiment, in addition to the wobble base pairs and non-complementary bases described above, the moiety corresponding to position 11 in a naturally occurring microRNA sequence can be an addition, deletion or mismatch.
The modified microRNA molecule is preferably isolated, more preferably purified, as defined above.







TABLE C





Fifty Percent of the Contiguous Moieties containing


Deoxyribonucleotide Backbone Units

















No. of Contiguous Bases

















10
11
12
13
14
15
16
17
18





Max. No. of
5
5
6
6
7
7
8
8
9


Deoxyribonucleotide


Backbone Units












No. of



Contiguous Bases















19
20
21
22
23







Max. No. of
9
10
10
11
11



Deoxyribonucleotide



Backbone Units

















TABLE D





Thirty Percent of the Contiguous Moieties Containing


Deoxyribonucleotide Backbone Units

















No. of Contiguous Bases

















10
11
12
13
14
15
16
17
18





Max. No. of
3
3
3
3
4
4
4
5
5


Deoxyribonucleotide


Backbone Units












No. of



Contiguous Bases















19
20
21
22
23







Max. No. of
5
6
6
6
6



Deoxyribonucleotide



Backbone Units










In yet another embodiment, caps can be attached to one end, to both ends, and/or between the ends of the molecule in order to increase resistance to nucleases of the modified microRNA molecules or isolated DNA or RNA molecules of the present invention described above. Increasing resistance to, for example, exonucleases and/or endonucleases is desirable. Any cap known to those in the art for increasing nuclease resistance can be employed.
Examples of such caps include inverted nucleotide caps and chemical caps. Inverted nucleotide caps can be attached at the 5′ and/or 3′ end. Chemical caps can be attached to one end, both ends, and/or between the ends of the molecule.
An inverted nucleotide cap refers to a 3′→5′ sequence of nucleic acids attached to the modified microRNA molecule or DNA or RNA molecules at the 5′ and/or the 3′ end. There is no limit to the maximum number of nucleotides in the inverted cap just as long as it does not interfere with binding of the microRNA molecule or isolated DNA or RNA molecule to its target mRNA. Any nucleotide can be used in the inverted nucleotide cap. Usually, the nucleotide cap is less than about forty nucleotides in length, preferably less than about thirty nucleotides in length, more preferably less than about twenty nucleotides in length, and even more preferably less than about ten nucleotides in length. Typically, the inverted nucleotide cap is one nucleotide in length. The nucleotide for the inverted cap is generally thymine, but can be any nucleotide such as adenine, guanine, uracil, or cytosine.
A chemical cap refers to any chemical group known to those in the art for increasing nuclease resistance of nucleic acids. Examples of such chemical caps include hydroxyalkyl groups (alkyl hydroxides) or aminoalkyl groups (alkyl amines). Hydroxyalkyl groups are sometimes referred to as alkyl glycoyl groups (e.g., ethylene glycol). Aminoalkyl groups are sometimes referred to as amino linkers.
The alkyl chain in the hydroxyalkyl group or aminoalkyl groups can be a straight chain or branched chain. The minimum number of carbon atoms present in the alkyl chain is one, preferably at least two, and more preferably at least about three carbon atoms.
The maximum number of carbon atoms present in the alkyl chain is about eighteen, preferably about sixteen, and more preferably about twelve. Typical alkyl groups include methyl, ethyl, and propyl. The alkyl groups can be further substituted with one or more hydroxyl and/or amino groups.
Some examples of amino linkers are shown in Table E. The amino linkers listed in Table E are commercially available from TriLink Biotechnologies, San Diego, Calif.
Isolated MicroRNP
In another aspect, the invention provides an isolated microRNP comprising any of the isolated DNA or RNA molecules described above or modified microRNA molecules described above. The isolated DNA or RNA molecules or modified microRNA molecules described above in the microRNP can be bound to a protein.
Examples of such proteins include those proteins belonging to the Ago family. Examples of proteins of the Ago family include Ago 1, 2, 3, and 4. Typically, the Ago 2 protein and microRNA complex guides target mRNA cleavage in RNAi, while Ago 1, 3 and 4 represses translation of target mRNAs.
Anti-MicroRNA Molecules
In another aspect, the invention provides an anti-microRNA molecule. The anti-microRNA molecule may be any of the isolated DNA or RNA molecules described above or modified microRNA molecules described above, except that the sequence of bases of the anti-microRNA molecule is complementary to the sequence of bases in an isolated DNA or RNA molecule or modified microRNA molecule.
Examples of sequences of anti-microRNA molecules are shown in Tables F, F1, F2, F3 and F4.







TABLE E





Amino Linkers from TriLink Biotechnologies

















2′-Deoxycytidine-5-C6 Amino Linker (3′ Terminus)



2′-Deoxycytidine-5-C6 Amino Linker (5′ or Internal)



3′ C3 Amino Linker



3′ C6 Amino Linker



3′ C7 Amino Linker



5′ C12 Amino Linker



5′ C3 Amino Linker



5′ C6 Amino Linker



C7 Internal Amino Linker



Thymidine-5-C2 Amino Linker (5′ or Internal)



Thymidine-5-C6 Amino Linker (3′ Terminus)



Thymidine-5-C6 Amino Linker (Internal)

















TABLE F







Anti-microRNA Sequences for microRNAs in Table A








MicroRNA
Anti-microRNA Sequence (5′ → 3′)












miR-18b-5p
CUAACUGCACUAGAUGCACCUUA (SEQ. ID. NO: 188)



 


miR-20b-3p
CUGGAAGUGCCCAUACUACAGU (SEQ. ID. NO: 189)


 


miR-20b-5p
CUACCUGCACUAUGAGCACUUUG (SEQ. ID. NO: 190)


 


miR-301b
UGCUUUGACAAUAUCAUUGCACUG (SEQ. ID. NO: 191)


 


miR-329
AAAGAGGUUAACCAGGUGUGUU (SEQ. ID. NO: 192)


 


miR-374b
CACUUAGCAGGUUGUAUUAUAU (SEQ. ID. NO: 193)


 


miR-421
CGCCCAAUUAAUGUCUGUUGAU (SEQ. ID. NO: 194)


 


miR-500
ACCCUAUAAGCAAUAUUGCACUA (SEQ. ID. NO: 195)


 


miR-504
GCAAUGCAACAGCAAUGCAC (SEQ. ID. NO: 196)


 


miR-604
UGCUGUUAGCCCUAGCCCCGCA (SEQ. ID. NO: 197)


 


miR-610
ACGGUCCUACACUCAAGGCAUG (SEQ. ID. NO: 198)


 


miR-618
ACGCUUUGUCAGUACAUAUUAA (SEQ. ID. NO: 199)


 


miR-619
ACACACCCACGCGAGCCGGAAA (SEQ. ID. NO: 200)


 


miR-620
CCAACCUGCCCGCUCCCAACAU (SEQ. ID. NO: 201)


 


miR-631
AAGAGGGAGACCCAGGCUCGGA (SEQ. ID. NO: 202)


 


miR-720a
ACCAGCUAACAAUACACUGCCA (SEQ. ID. NO: 203)


 


miR-720b
GCCAGCUAACAAUACACUGCCU (SEQ. ID. NO: 204)


 


miR-723-3p
CCAGCACCACAUCAGGCCCACG (SEQ. ID. NO: 205)


 


miR-723-5p
UGUGGCCCUGACACGUGGUACU (SEQ. ID. NO: 206)


 


miR-730
AAGAAGUGCACCGCGAAUGUUU (SEQ. ID. NO: 207)


 


miR-732
GGGACCGACAGCAGAAUCCUUU (SEQ. ID. NO: 208)


 


miR-734
ACGGUUUUACCAGACAGUAUUA (SEQ. ID. NO: 209)


 


miR-755
UCACAUUUGCCUGCAGAGAUUU (SEQ. ID. NO: 210)


 


miR-800a
AAGUGGAUGACCCUGUACGAUU (SEQ. ID. NO: 211)


 


miR-800b
AACUGGAUGUCCCUGUAUGAUU (SEQ. ID. NO: 212)


 


miR-803
CGAUGUAGUCCAAAGGCACAUA (SEQ. ID. NO: 213)


 


miR-805
AUAUUAGGAACACAUCGCAAAA (SEQ. ID. NO: 214)


 


miR-806
ACUCAGUAAUGGUAACGGUUU (SEQ. ID. NO: 215)


 


miR-809
ACACCGAGGAGCCCAUCAUGAU (SEQ. ID. NO: 216)


 


miR-810
CUGCAUGACGGCCUGCAAGACA (SEQ. ID. NO: 217)


 


miR-811
GUCUCAGUUUCCUCUGCAAACA (SEQ. ID. NO: 218)


 


miR-812
GCGAACUCACCACGGACAACCU (SEQ. ID. NO: 219)


 


miR-814
GGAGACUCACAAGUUCCUGC (SEQ. ID. NO: 220)


 


miR-815
GCACAACCCUAGUGGCGCCAUU (SEQ. ID. NO: 221)


 


miR-816
CACUCAGCGGCCGUUUCCCCAA (SEQ. ID. NO: 222)


 


miR-817
GCUGAGCGGUGAGGGCAUACAG (SEQ. ID. NO: 223)


 


miR-818
AGGACUAUAGAACUUUCCCCCU (SEQ. ID. NO: 224)


 


miR-819
AGAGGCAGGGUAGUGUAAUGGA (SEQ. ID. NO: 225)


 


miR-821
CAGCAGCCUCCGCCGCCGCCGC (SEQ. ID. NO: 226)


 


miR-822
UAGCAGAAGCAUUUCCGCACAC (SEQ. ID. NO: 227)


 


miR-824
ACACACCAAGGAUAAUUUCUCC (SEQ. ID. NO: 228)


 


miR-825-3p
UUCAGUUAUCAAUCUGUCACAA (SEQ. ID. NO: 229)


 


miR-825-5p
CUCGUGACAUGAUGAUCCCCGA (SEQ. ID. NO: 230)


 


miR-826
CUCUACUCACAGAAGUGUCAAU (SEQ. ID. NO: 231)


 


miR-828-3p
UUCGACUGCCACUCUUACUAGA (SEQ. ID. NO: 232)


 


miR-828-5p
CCUCUAGUAAAUAUGUCAGCAU (SEQ. ID. NO: 233)


 


miR-829-5p
CUGCACUUUUAUGAAUAAGCUC (SEQ. ID. NO: 234)


 


miR-829-3p
GACUAGCUUAUACAUAAAAUUA (SEQ. ID. NO: 235)


 


miR-831
GGCCUCCGGAAGCUCCGCCCCA (SEQ. ID. NO: 236)


 


miR-832
UGACCCACCUGGAGAUCCAUGG (SEQ. ID. NO: 237)


 


miR-834
CCUGGCACACAGUAGACCUUCA (SEQ. ID. NO: 238)


 


miR-835-5p
UCCAGCCCCUCCAGGGCUUCCU (SEQ. ID. NO: 239)


 


miR-835-3p
AGGUGGAGCCCUGAGAACCGGA (SEQ. ID. NO: 240)


 


miR-837
UGAGGGGCCUCAGCCUCCUGGU (SEQ. ID. NO: 241)


 


miR-838
AUCGGGAGGGGACUGAGCCUGA (SEQ. ID. NO: 242)


 


miR-839-5p
UCGGGGCAGCUCAGUACAGGA (SEQ. ID. NO: 243)


 


miR-839-3p
AUCCUGUACUGAGCUGCCCCG (SEQ. ID. NO: 244)


 


miR-840-3p
CCACGACCGACGCCACGCCGAG (SEQ. ID. NO: 245)


 


miR-840-5p
AGCCGGUCGAGGUCCGGUCGA (SEQ. ID. NO: 246)


 


miR-841
GACCAAGAAAUAGCCUUUCAAA (SEQ. ID. NO: 247)


 


miR-842
GCAAAGGUAAUUGCUGUUUUCG (SEQ. ID. NO: 248)


 


miR-843
CUAGAAGCUCACAGUCUAGUUG (SEQ. ID. NO: 249)


 


miR-845
UGCGCCACUGGAGCAUGCUUU (SEQ. ID. NO: 250)


 


miR-846
GCUCCCCACAGACCCAGAGCCG (SEQ. ID. NO: 251)


 


miR-847
CCCGCCAUAGUGGUCCUCUCUG (SEQ. ID. NO: 252)


 


miR-848
CUGGUCCAUAGGGGAUGGCAAU (SEQ. ID. NO: 253)


 


miR-849
CCAGUGUCUCCAGUAGUAGACA (SEQ. ID. NO: 254)


 


miR-850
GGAGAUGGAGCCAGGGCCCUAA (SEQ. ID. NO: 255)


 


miR-851
CCUCGGGAUGGCGCCCGUUCAC (SEQ. ID. NO: 255)


 


miR-852
GCACACAAUAAAUGUUUGCUGA (SEQ. ID. NO: 256)


 


miR-853
AACCAAGACCCCGGAGAUCCCA (SEQ. ID. NO: 257)


 


miR-854
UCGGUCCCUCGGGCCAGGGCAG (SEQ. ID. NO: 258)


 


miR-855-3p
UGUGGGUGUGUGCAUGAGCGUG (SEQ. ID. NO: 259)


 


miR-855-5p
CACACUCACACACACACACUCA (SEQ. ID. NO: 260)


 


miR-857
CGGGGAGCGGGGGCCCUGCCUU (SEQ. ID. NO: 261)


 


miR-864
CCCUCUCAACUCAGCUUUU (SEQ. ID. NO: 262)


 


miR-867
GUCUAGACUGUGAGCUCCUCGA (SEQ. ID. NO: 263)


 


miR-869
GCACAUGUUCUGCGGCCCACCA (SEQ. ID. NO: 264)


 


miR-871-3p
CAGCACAGAGAUGGACAGAUAG (SEQ. ID. NO: 265)


 


miR-871-5p
CCGCUUGAGCUAACUCCGACCCG (SEQ. ID. NO: 266)


 


miR-92b
GGAGGCCGGGACGAGUGCAAUA (SEQ. ID. NO: 267)


 


miR-896
GCUGCCGUAUAUGUGAUGUCAC (SEQ. ID. NO: 268)


 


miR-883
GAGGUUUCCCGUGUAUGUUUCA (SEQ. ID. NO: 269)


 


miR-884
GAACUUGCUAAAAAUGCAGAAU (SEQ. ID. NO: 270)


 


miR-885
ACUGAAACCAAGUAUGGGUCGC (SEQ. ID. NO: 271)


 


miR-886
AGCACAGACUUGCUGUGAUGUU (SEQ. ID. NO: 272)


 


miR-887
CACCUGAUAAAACUGAGGUAUA (SEQ. ID. NO: 273)


 


miR-888
ACACAACCUCAGUGUUUCCAGG (SEQ. ID. NO: 274)


 


miR-889
GAUAGAGUGCAGACCAGGGUCU (SEQ. ID. NO: 275)


 


miR-890
CCUCAUGGAAGGGUUCCCCACU (SEQ. ID. NO: 276)


 


miR-891
UCAGUAGAGAUUGUUUCAACAC (SEQ. ID. NO: 277)


 


miR-892
GGUGAUUCACAAAGAAAUCCAU (SEQ. ID. NO: 278)


 


miR-893
ACAGCCGCCGCCGCCGCCGCCG (SEQ. ID. NO: 279)


 


miR-894
UUCCCUUCUUUCCUCCCGUCUU (SEQ. ID. NO: 280)
















TABLE F1







Anti-microRNA sequences for microRNAs in Table A2








MicroRNA
Anti-microRNA Sequence (5′ → 3′)












hsa-miR-100516
UGACUGACAGCUUUUUGAGUA (SEQ. ID. NO: 551)



 


hsa-miR-100604
UGCUGUUAGCCCUAGCCCCGCA (SEQ. ID. NO: 552)


 


hsa-miR-100610-
ACGGUCCUACACUCAAGGCAUG (SEQ. ID. NO: 553)


5p


 


hsa-miR-100631
AAGAGGGAGACCCAGGCUCGGA (SEQ. ID. NO: 554)


 


hsa-miR-100701
CCUGAACUAACAAGUAACCUU (SEQ. ID. NO: 555)


 


hsa-miR-100723
CCAGCACCACAUCAGGCCCACG (SEQ. ID. NO: 556)


 


hsa-miR-100730
AAGAAGUGCACCGCGAAUGUUU (SEQ. ID. NO: 557)


 


hsa-miR-100732
GGGACCGACAGCAGAAUCCUU (SEQ. ID. NO: 558)


 


hsa-miR-100754
AACCCAAUAUCAAACAUAUCA (SEQ. ID. NO: 559)


 


hsa-miR-100760
UACACCACUCCCAUCUCAGUGC (SEQ. ID. NO: 560)


 


hsa-miR-100814
AGGAGACUCACAAGUUCCUGC (SEQ. ID. NO: 561)


 


hsa-miR-100815
ACACAACCCUAGUGGCGCCAUU (SEQ. ID. NO: 562)


 


hsa-miR-100818
GGACUAUAGAACUUUCCCCCU (SEQ. ID. NO: 563)


 


hsa-miR-100819
AGAGGCAGGGUAGUGUAAUGGA (SEQ. ID. NO: 564)


 


hsa-miR-100824
ACACACCAAGGAUAAUUUCUCC (SEQ. ID. NO: 565)


 


hsa-miR-100825-
UUUCAGUUAUCAAUCUGUCACA (SEQ. ID. NO: 566)


3p


 


hsa-miR-100825-
UCUCGUGACAUGAUGAUCCCCGA (SEQ. ID. NO: 567)


5p


 


hsa-miR-100829-
ACUAGCUUAUACAUAAAAUUA (SEQ. ID. NO: 568)


3p


 


hsa-miR-100835-
CUCCAGCCCCUCCAGGGCUUCCU (SEQ. ID. NO: 569)


5p


 


hsa-miR-100842
GCAAAGGUAAUUGCUGUUUUCG (SEQ. ID. NO: 570)


 


hsa-miR-100843-
CUAGAAGCUCACAGUCUAGUUG (SEQ. ID. NO: 571)


3p


 


hsa-miR-100843-
CCCAGCUAGAUUGUAAGCUCCUU (SEQ. ID. NO: 572)


5p


 


hsa-miR-100846
CUCCCCACAGACCCAGAGCCG (SEQ. ID. NO: 573)


 


hsa-miR-100851
CCUCGGGAUGGCGCCCGUUCAC (SEQ. ID. NO: 574)


 


hsa-miR-100852
GCACACAAUAAAUGUUUGCUGA (SEQ. ID. NO: 575)


 


hsa-miR-100854
UCGGUCCCUCGGGCCAGGGCAG (SEQ. ID. NO: 576)


 


hsa-miR-100855-
UGUGGGUGUGUGCAUGAGCGUG (SEQ. ID. NO: 577)


3p


 


hsa-miR-100855-
ACACACUCACACACACACACUCA (SEQ. ID. NO: 578)


5p


 


hsa-miR-100869-
AAGGUGAUGGUCAGCAGACAUA (SEQ. ID. NO: 579)


3p


 


hsa-miR-100869-
GCACAUGUUCUGCGGCCCACCA (SEQ. ID. NO: 580)


5p


 


hsa-miR-100871-
AAGGGUCAGUAAGCACCCGCG (SEQ. ID. NO: 581)


3p


 


hsa-miR-100871-
CCGCUUGAGCUAACUCCGACCCG (SEQ. ID. NO: 582)


5p


 


hsa-miR-100885
CUGAAACCAAGUAUGGGUCGC (SEQ. ID. NO: 583)


 


hsa-miR-100887-
ACACAACCUCAGUGUUUCCAGG (SEQ. ID. NO: 584)


3p


 


hsa-miR-100887-
CACCUGAUAAAACUGAGGUAUA (SEQ. ID. NO: 585)


5p


 


hsa-miR-100891-
UGAAUUACUUUGUAAACCACCA (SEQ. ID. NO: 586)


3p


 


hsa-miR-100891-
UGGUGAUUCACAAAGAAAUCCA (SEQ. ID. NO: 587)


5p


 


hsa-miR-101001
AGGGGCCUCAGCCUCCUGGU (SEQ. ID. NO: 588)


 


hsa-miR-146b
AGCCUAUGGAAUUCAGUUCUCA (SEQ. ID. NO: 589)


 


hsa-miR-147b
UAGCAGAAGCAUUUCCGCACAC (SEQ. ID. NO: 590)


 


hsa-miR-181d
ACCCACCGACAACAAUGAAUGUU (SEQ. ID. NO: 591)


 


hsa-miR-18b
CUAACUGCACUAGAUGCACCUUA (SEQ. ID. NO: 592)


 


hsa-miR-193b
AGCGGGACUUUGAGGGCCAGUU (SEQ. ID. NO: 593)


 


hsa-miR-200001
UCAGUGGCUCAGGUUCGUUGCA (SEQ. ID. NO: 594)


 


hsa-miR-200002
AAAGAGGUUAACCAUGUAUUAU (SEQ. ID. NO: 595)


 


hsa-miR-200003
CAACUGAUGCCUUUCCAAGUA (SEQ. ID. NO: 596)


 


hsa-miR-200004
UCAAUGACUCAGGUAAGUUGCA (SEQ. ID. NO: 597)


 


hsa-miR-200007
CCCUGCGCCAUCUCCUCUAC (SEQ. ID. NO: 598)


 


hsa-miR-200008
AACUCCGAUAUGCAAUGGGUA (SEQ. ID. NO: 599)


 


hsa-miR-20b
CUACCUGCACUAUGAGCACUUUG (SEQ. ID. NO: 600)


 


hsa-miR-20b-3p
CUGGAAGUGCCCAUACUACAGU (SEQ. ID. NO: 601)


 


hsa-miR-216b
UCACAUUUGCCUGCAGAGAUUU (SEQ. ID. NO: 602)


 


hsa-miR-301b
UGCUUUGACAAUAUCAUUGCACUG (SEQ. ID. NO: 603)


 


hsa-miR-329
AAAGAGGUUAACCAGGUGUGUU (SEQ. ID. NO: 604)


 


hsa-miR-33b
GCAAUGCAACAGCAAUGCAC (SEQ. ID. NO: 605)


 


hsa-miR-374b
CACUUAGCAGGUUGUAUUAUAU (SEQ. ID. NO: 606)


 


hsa-miR-375
UCACGCGAGCCGAACGAACAAA (SEQ. ID. NO: 607)


 


hsa-miR-376a
ACGUGGAUUUUCCUCUAUGAU (SEQ. ID. NO: 608)


 


hsa-miR-376b
AACAUGGAUUUUCCUCUAUGAU (SEQ. ID. NO: 609)


 


hsa-miR-376c
AAGUGGAUGACCCUGUACGAUU (SEQ. ID. NO: 610)


 


hsa-miR-376c
AAGUGGAUGACCCUGUACGAUU (SEQ. ID. NO: 611)


 


hsa-miR-377
ACAAAAGUUGCCUUUGUGUGAU (SEQ. ID. NO: 612)


 


hsa-miR-378
CCUUCUGACUCCAAGUCCAGU (SEQ. ID. NO: 613)


 


hsa-miR-379
CCUACGUUCCAUAGUCUACCA (SEQ. ID. NO: 614)


 


hsa-miR-380
AAGAUGUGGACCAUAUUACAUA (SEQ. ID. NO: 615)


 


hsa-miR-410
ACAGGCCAUCUGUGUUAUAUU (SEQ. ID. NO: 616)


 


hsa-miR-421-3p
CGCCCAAUUAAUGUCUGUUGAU (SEQ. ID. NO: 617)


 


hsa-miR-429
ACGGUUUUACCAGACAGUAUUA (SEQ. ID. NO: 618)


 


hsa-miR-431
UGCAUGACGGCCUGCAAGACA (SEQ. ID. NO: 619)


 


hsa-miR-432
CCACCCAAUGACCUACUCCAAGA (SEQ. ID. NO: 620)


 


hsa-miR-433
ACACCGAGGAGCCCAUCAUGAU (SEQ. ID. NO: 621)


 


hsa-miR-449a
ACCAGCUAACAAUACACUGCCA (SEQ. ID. NO: 622)


 


hsa-miR-449b
GCCAGCUAACAAUACACUGCCU (SEQ. ID. NO: 623)


 


hsa-miR-450a
AUAUUAGGAACACAUCGCAAAA (SEQ. ID. NO: 624)


 


hsa-miR-451
AACUCAGUAAUGGUAACGGUUU (SEQ. ID. NO: 625)


 


hsa-miR-452
UCAGUUUCCUCUGCAAACAGUU (SEQ. ID. NO: 626)


 


hsa-miR-453
UGCGAACUCACCACGGACAACCU (SEQ. ID. NO: 627)


 


hsa-miR-454
ACCCUAUAAGCAAUAUUGCACUA (SEQ. ID. NO: 628)


 


hsa-miR-455-5p
CGAUGUAGUCCAAAGGCACAUA (SEQ. ID. NO: 629)


 


hsa-miR-484
AUCGGGAGGGGACUGAGCCUGA (SEQ. ID. NO: 630)


 


hsa-miR-485-3p
AGAGAGGAGAGCCGUGUAUGAC (SEQ. ID. NO: 631)


 


hsa-miR-485-5p
GAAUUCAUCACGGCCAGCCUCU (SEQ. ID. NO: 632)


 


hsa-mir-486_os
AUCCUGUACUGAGCUGCCCCG (SEQ. ID. NO: 633)


 


hsa-miR-487
AACUGGAUGUCCCUGUAUGAUU (SEQ. ID. NO: 634)


 


hsa-miR-488
AGACCAAGAAAUAGCCUUUCAA (SEQ. ID. NO: 635)


 


hsa-miR-490
ACCCACCUGGAGAUCCAUGG (SEQ. ID. NO: 636)


 


hsa-miR-493
CCUGGCACACAGUAGACCUUCA (SEQ. ID. NO: 637)


 


hsa-miR-497
ACAAACCACAGUGUGCUGCUG (SEQ. ID. NO: 638)


 


hsa-miR-502
UGAAUCCUUGCCCAGGUGCAUU (SEQ. ID. NO: 639)


 


hsa-miR-503
CUGCAGAACUGUUCCCGCUGCUA (SEQ. ID. NO: 640)


 


hsa-miR-505
AGGAAACCAGCAAGUGUUGACG (SEQ. ID. NO: 641)


 


hsa-miR-509-3p
CUACCCACAGACGUACCAAUCA (SEQ. ID. NO: 642)


 


hsa-miR-514
UCUACUCACAGAAGUGUCAAU (SEQ. ID. NO: 643)


 


hsa-miR-92b
GAGGCCGGGACGAGUGCAAUA (SEQ. ID. NO: 644)
















TABLE F2







Anti-microRNA sequences for microRNAs in Table A4








MicroRNA
Anti-microRNA Sequence (5′ → 3′)





hsa-miR-100516
UGACUGACAGCUUUUUGAGUA



(SEQ. ID. NO: 645)


 


hsa-miR-100701
CCUGAACUAACAAGUAACCUU



(SEQ. ID. NO: 646)


 


hsa-miR-100760
UACACCACUCCCAUCUCAGUGC



(SEQ. ID. NO: 647)


 


hsa-miR-100885
CUGAAACCAAGUAUGGGUCGC



(SEQ. ID. NO: 648)


 


hsa-miR-100887-3p
ACACAACCUCAGUGUUUCCAGG



(SEQ. ID. NO: 649)


 


hsa-miR-100887-5p
CACCUGAUAAAACUGAGGUAUA



(SEQ. ID. NO: 650)


 


hsa-miR-100891-3p
UGAAUUACUUUGUAAACCACCA



(SEQ. ID. NO: 651)


 


hsa-miR-100891-5p
UGGUGAUUCACAAAGAAAUCCA



(SEQ. ID. NO: 652)


 


hsa-miR-200001
UCAGUGGCUCAGGUUCGUUGCA



(SEQ. ID. NO: 653)


 


hsa-miR-200002
AAAGAGGUUAACCAUGUAUUAU



(SEQ. ID. NO: 654)


 


hsa-miR-200003
CAACUGAUGCCUUUCCAAGUA



(SEQ. ID. NO: 655)


 


hsa-miR-200004
UCAAUGACUCAGGUAAGUUGCA



(SEQ. ID. NO: 656)


 


hsa-miR-200007
CCCUGCGCCAUCUCCUCUAC



(SEQ. ID. NO: 657)


 


hsa-miR-200008
AACUCCGAUAUGCAAUGGGUA



(SEQ. ID. NO: 658)


 


hsa-mir-486_os
UCCUGUACUGAGCUGCCCCG



(SEQ. ID. NO: 659)
















TABLE F3







Anti-microRNA sequences for microRNAs in Table A6








MicroRNA
Anti-microRNA Sequence (5′ → 3′)












hsa-mir-18b-3p
GCCAGAAGGGGCAUUUAGGGCAG (SEQ. ID. NO: 660)



 


hsa-miR-618
ACGCUUUGUCAGUACAUAUUAA (SEQ. ID. NO: 661)


 


hsa-miR-619
ACACACCCACGCGAGCCGGAAA (SEQ. ID. NO: 662)


 


hsa-miR-620
CCAACCUGCCCGCUCCCAACAU (SEQ. ID. NO: 663)


 


hsa-miR-723-5p
UCAUGUGGCCCUGACACGUGGUACU (SEQ. ID. NO: 664)


 


hsa-mir-816
UCACUCAGCGGCCGUUUCCCCAA (SEQ. ID. NO: 665)


 


hsa-mir-817
GCUGAGCGGUGAGGGCAUACAG (SEQ. ID. NO: 666)


 


hsa-mir-821-1
AGCCUCCGCCGCCGCCGC (SEQ. ID. NO: 667)


 


hsa-mir-821-2/3
AGCCUCCGCCGCCGCCGC (SEQ. ID. NO: 668)


 


hsa-mir-828-3p
UCGACUGCCACUCUUACUAGA (SEQ. ID. NO: 669)


 


hsa-mir-828-5p
CCUCUAGUAAAUAUGUCAGCAU (SEQ. ID. NO: 670)


 


hsa-mir-831-1
GGCCUCCGGAAGCUCCGCCCCA (SEQ. ID. NO: 671)


 


hsa-mir-831-2
GGCCUCCGGAAGCUCCGCCCCA (SEQ. ID. NO: 672)


 


hsa-mir-831-3/-
GGCCUCCGGAAGCUCCGCCCCA (SEQ. ID. NO: 673)


4/-5


 


hsa-mir-840-3p
CCACGACCGACGCCACGCCGAGU (SEQ. ID. NO: 674)


 


hsa-mir-840-5p
GAGCCGGUCGAGGUCCGGUCGA (SEQ. ID. NO: 675)


 


hsa-mir-845-1
GCGCCACUGGAGCAUGCUUU (SEQ. ID. NO: 676)


 


hsa-mir-845-2
GCGCCACUGGAGCAUGCUUU (SEQ. ID. NO: 677)


 


hsa-mir-847
CCCGCCAUAGUGGUCCUCUCUG (SEQ. ID. NO: 678)


 


hsa-mir-848
CUGGUCCAUAGGGGAUGGCAAU (SEQ. ID. NO: 679)


 


hsa-mir-849
CCAGUGUCUCCAGUAGUAGACA (SEQ. ID. NO: 680)


 


hsa-mir-850
GGAGAUGGAGCCAGGGCCCUAA (SEQ. ID. NO: 681)


 


hsa-mir-853
AACCAAGACCCCGGAGAUCCCA (SEQ. ID. NO: 682)


 


hsa-mir-857
CCGGGGAGCGGGGGCCCUGCCUU (SEQ. ID. NO: 683)


 


hsa-mir-864
CCUCUCAACUCAGCUUUU (SEQ. ID. NO: 684)


 


hsa-mir-151
CUAGACUGUGAGCUCCUCGA (SEQ. ID. NO: 685)
















TABLE F4







Anti-microRNA sequences for microRNA in Table A8










MicroRNA
Anti-microRNA Sequence (5′ → 3′)







hsa-miR-544
AUUCUGCAUUUUUAGCAAGUUC




(SEQ. ID. NO: 686)










The anti-microRNA molecule can be modified as described above for modified microRNA molecules. In one embodiment, the contiguous moieties in the anti-microRNA molecule are complementary to the corresponding microRNA molecule. The degree of complementarity of the anti-microRNA molecules are subject to the same restrictions described above for modified microRNA molecules, including the restriction relating to wobble base pairs, as well as those relating to additions, deletions and mismatches.
In a preferable embodiment, if the anti-microRNA molecule comprises only unmodified moieties, then the anti-microRNA molecule comprises at least one base, in the at least ten contiguous bases, which is non-complementary to the microRNA and/or comprises a chemical cap.
In another preferable embodiment, if the at least ten contiguous bases in an anti-microRNA molecule is perfectly (i.e., 100%) complementary to a microRNA molecule, then the anti-microRNA molecule contains at least one modified moiety in the at least ten contiguous bases and/or comprises a chemical cap.
In yet another embodiment, the moiety in the anti-microRNA molecule at the position corresponding to position 11 of a naturally occurring microRNA is non-complementary. The moiety in the anti-microRNA molecule corresponding to position 11 of a naturally occurring microRNA can be rendered non-complementary by the introduction of an addition, deletion or mismatch, as described above.
Utility
The microRNA molecules and anti-microRNA molecules of the present invention have numerous in vitro, ex vivo, and in vivo applications.
For example, the microRNA molecules and/or anti-microRNA molecules of the present invention can be introduced into a cell to study the function of the microRNA, and microRNA molecules in general.
In one embodiment, a microRNA in a cell is inhibited with a suitable anti-microRNA molecule. Alternatively, the activity of a microRNA molecule in a cell can be enhanced by introducing into the cell one or more additional microRNA molecules. The function of the microRNA can be inferred by observing changes associated with inhibition and/or enhanced activity of the microRNA in the cell.
In one aspect of the invention, the invention relates to a method for inhibiting microRNP activity in a cell. The method for inhibiting microRNP activity in a cell comprises introducing into the cell a single-stranded anti-microRNA molecule of the invention. The microRNP comprises a microRNA molecule. Any anti-microRNA molecule can be used in the method for inhibiting microRNP activity in a cell, as long as the anti-microRNA molecule is complementary, subject to the restrictions described above, to the microRNA present in the microRNP.
The anti-microRNA molecules of the present invention are capable of inhibiting microRNP activity by binding to the microRNA in the microRNP in a host cell. MicroRNP activity refers to the cleavage or the repression of translation of a target sequence. The target sequence may be any sequence which is partially or perfectly complementary to the sequence of bases in a microRNA.
For example, the microRNA molecules and anti-microRNA molecules of the present invention may be used as a modulator of the expression of genes which are at least partially complementary to the anti-microRNA molecules or microRNA. For instance, if a particular microRNA is beneficial for the survival of a cell, an appropriate isolated microRNA of the present invention may be introduced into the cell to promote survival. Alternatively, if a particular microRNA is harmful (e.g., induces apoptosis, induces cancer, etc.), an appropriate anti-microRNA molecule can be introduced into the cell in order to inhibit the activity of the microRNA and reduce the harm.
The microRNA molecules and/or anti-microRNA molecules can be introduced into a cell by any method known to those skilled in the art. For example, the microRNA molecules and/or anti-microRNA molecules can be injected directly into a cell, such as by microinjection. Alternatively, the molecules can be contacted with a cell, preferably aided by a delivery system.
Useful delivery systems include, for example, liposomes and charged lipids, Liposomes typically encapsulate oligonucleotide molecules within their aqueous center. Charged lipids generally form lipid-oligonucleotide molecule complexes as a result of opposing charges.
These liposomes-oligonucleotide molecule complexes or lipid-oligonucleotide molecule complexes are usually internalized in cells by endocytosis. The liposomes or charged lipids generally comprise helper lipids which disrupt the endosomal membrane and release the oligonucleotide molecules.
Other methods for introducing a microRNA molecule or an anti-microRNA into a cell include use of delivery vehicles, such as dendrimers, biodegradable polymers, polymers of amino acids, polymers of sugars, and oligonucleotide-binding nanoparticles. In addition, pluoronic gel as a depot reservoir can be used to deliver the anti-microRNA oligonucleotide molecules over a prolonged period. The above methods are described in, for example, Hughes et al., Drug Discovery Today 6, 303-315 (2001); Liang et al. Eur. J. Biochem. 269 5753-5758 (2002); and Becker et al., In Antisense Technology in the Central Nervous System (Leslie, R. A., Hunter, A. J. & Robertson, H. A., eds), pp. 147-157, Oxford University Press.
Targeting of a microRNA molecule or an anti-microRNA molecule to a particular cell can be performed by any method known to those skilled in the art. For example, the microRNA molecule or anti-microRNA molecule can be conjugated to an antibody or ligand specifically recognized by receptors on the cell.
The molecules can be administered to a mammal by any method known to those skilled in the art. Some examples of suitable modes of administration include oral and systemic administration. Systemic administration can be enteral or parenteral. Liquid or solid (e.g., tablets, gelatin capsules) formulations can be employed.
Parenteral administration of the molecules include, for example intravenous, intramuscular, and subcutaneous injections. For instance, a molecule may be administered to a mammal by sustained release, as is known in the art. Sustained release administration is a method of drug delivery to achieve a certain level of the drug over a particular period of time.
Other routes of administration include oral, topical, intrabronchial, or intranasal administration. For oral administration, liquid or solid formulations may be used. Some examples of formulations suitable for oral administration include tablets, gelatin capsules, pills, troches, elixirs, suspensions, syrups, and wafers. Intrabronchial administration can include an inhaler spray. For intranasal administration, administration of a molecule of the present invention can be accomplished by a nebulizer or liquid mist.
The molecules of the present invention can be in a suitable pharmaceutical carrier. In this specification, a pharmaceutical carrier is considered to be synonymous with a vehicle or an excipient as is understood by practitioners in the art. Examples of carriers include starch, milk, sugar, certain types of clay, gelatin, stearic acid or salts thereof, magnesium or calcium stearate, talc, vegetable fats or oils, gums and glycols.
The pharmaceutical carrier may also comprise one or more of the following: a stabilizer, a surfactant, preferably a nonionic surfactant, and optionally a salt and/or a buffering agent.
The stabilizer may, for example, be an amino acid, such as for instance, glycine; or an oligosaccharide, such as for example, sucrose, tetralose, lactose or a dextran. Alternatively, the stabilizer may be a sugar alcohol, such as for instance, mannitol; or a combination thereof. Preferably the stabilizer or combination of stabilizers constitutes from about 0.1% to about 10% weight for weight of the molecules.
The surfactant is preferably a nonionic surfactant, such as a polysorbate. Some examples of suitable surfactants include Tween 20, Tween 80; a polyethylene glycol or a polyoxyethylene polyoxypropylene glycol, such as Pluronic F-68 at from about 0.001% (w/v) to about 10% (w/v).
The salt or buffering agent may be any salt or buffering agent, such as for example sodium chloride, or sodium/potassium phosphate, respectively. Preferably, the buffering agent maintains the pH of the molecules of the present invention in the range of about 5.5 to about 7.5. The salt and/or buffering agent is also useful to maintain the osmolality at a level suitable for administration to a mammal. Preferably the salt or buffering agent is present at a roughly isotonic concentration of about 150 mM to about 300 mM.
The pharmaceutical carrier may additionally contain one or more conventional additives. Some examples of such additives include a solubilizer such as, for example, glycerol; an antioxidant such as for example, benzalkonium chloride (a mixture of quaternary ammonium compounds, known as “quart”), benzyl alcohol, chloretone or chlorobutanol; anaesthetic agent such as for example a morphine derivative; or an isotonic agent etc., such as described above. As a further precaution against oxidation or other spoilage, the molecules may be stored under nitrogen gas in vials sealed with impermeable stoppers.
Another in vitro application of the microRNA molecules and/or anti-microRNA molecules of the present invention is their use as diagnostic tools. For this purpose, the microRNA molecules and/or anti-microRNA molecules can be labeled.
The molecules of the present invention can be labeled in accordance with any method known in the art. For example, methods for labeling oligonucleotides have been described, for example, by Leary et al., 1983. Proc. Natl. Acad. Sci. USA 80:4045; Renz and Kurz 1984. Nucl. Acids Res. 12:3435; Richardson and Gumport 1983. Nucl. Acids Res. 11:6167; Smith et al. 1985. Nucl. Acids Res. 13:2399; Meinkoth and Wahl, Anal. 1984. Biochem. 138:267; and Ausubel, F. M. et al. (Eds.) Current Protocols in Molecular Biology, John Wiley & Sons, Inc., New York, 1999, each of which is incorporated herein by reference.
The label may be radioactive. Some examples of useful radioactive labels include 32P, 125I, 131I, 35S, 14C, and 3H. Use of radioactive labels have been described in U.K. 2,034,323, U.S. Pat. No. 4,358,535, and U.S. Pat. No. 4,302,204.
Some examples of non-radioactive labels include enzymes and chromophores. Useful enzymatic labels include enzymes that cause a detectable change in a substrate. Some useful enzymes and their substrates include, for example, horseradish peroxidase (pyrogallol and o-phenylenediamine), beta-galactosidase (fluorescein beta-D-galactopyranoside), and alkaline phosphatase (5-bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium). The use of enzymatic labels have been described in U.K. 2,019,404, EP 63,879, in Ausubel, F. M. et al. (Eds.), Rotman 1961. Proc. Natl. Acad. Sci. USA 47:1981-1991, and by Current Protocols in Molecular Biology, John Wiley & Sons, Inc., New York (1999).
Useful chromophores include, for example, fluorescent, chemiluminescent, and bioluminescent molecules, as well as dyes. Some specific chromophores useful in the present invention include, for example, fluorescein, rhodamine, Cy3, Cy5, Texas red, phycoerythrin, umbelliferone, luminol.
The labels may be conjugated to the molecules of the present invention by methods that are well known in the art. The labels may be directly attached through a functional group on the molecule. The probe either contains or can be caused to contain such a functional group. Some examples of suitable functional groups include, for example, amino, carboxyl, sulfhydryl, maleimide, isocyanate, isothiocyanate.
Alternatively, labels such as enzymes and chromophoric molecules may be conjugated to the molecules by means of coupling agents, such as dialdehydes, carbodiimides, dimaleimides, and the like. The label may also be conjugated to the molecule by means of a ligand attached to the molecule by a method described above and a receptor for that ligand attached to the label. Any of the known ligand-receptor combinations is suitable. Some suitable ligand-receptor pairs include, for example, biotin-avidin or -streptavidin, and antibody-antigen. The biotin-avidin combination is preferred.
Some microRNAs are expressed in specific tissues or cells. The expression of the microRNAs of the present invention in various tissues is shown below in Table G and Table G1. Table G and Table G1 show the relative cloning frequency in percent relative to total number of identified microRNAs for each given library. In Table G and Table G1, the expression of a given microRNA continues across several pages.
The expression of a microRNA is considered to be specifically enriched in a tissue- or cell type if its expression is more than about three-fold, preferably more than about four-fold, and more preferably more than about five-fold more than its expression in other tissue- or cell-types. For example, microRNA hsa-mir-20b is expressed in the B-cell derived lymphoma BL41 (0.05% expression); in the embryonal derived cell line/tumor NT2/D1 (0.37% expression) NCCIT (0.72% expression), and Hek (0.13% expression); small cell adreno-carcinoma cell line SW13 (without and with yellow fever virus infection; 2.01% and 2.93% expression, respectively); and ductile breast carcinoma HCC38 (0.09% expression). The expression of microRNA hsa-mir-20b is considered to be enriched in small cell adreno-carcinoma cell line SW13 since its expression is about three-fold more than that of its expression in other tissue- and cell-types.
Thus, for instance, anti-microRNA molecules of the present invention can be used as a probe to identify a particular tissue- or cell type.
In addition, the microRNA molecules and/or anti-microRNA molecules of the present invention can be used in microarrays for microRNA expression analysis. For example, the anti-microRNA molecules of the present invention can be labeled in a microarray. Samples containing microRNAs can be added and the hybridization detected. Such microarrays may be used in, for example, diagnostic assays to survey microRNA expression in clinical samples of cancer patients and contribute to the diagnosis and staging for risk evaluation for certain cancer types.







TABLE G





Relative Cloning Frequency in % Relative to Total Number


of Identified MicroRNA for Each Given Library.

















Adult brain












miRNA
cerebellum
frontalcortex
midbrain







hsa-mir-20b
—
—
—



hsa-mir-301b
—
—
—



hsa-mir-302b
—
—
—



hsa-mir-302c
—
—
—



hsa-mir-302d
—
—
—



hsa-mir-329
—
—
0.07



hsa-mir-367
—
—
—



hsa-mir-368
0.13
0.26
—



hsa-mir-369
—
—
—



hsa-mir-374a
—
0.07
0.07



hsa-mir-374b
—
—
0.07



hsa-mir-410
—
—
0.07



hsa-mir-421
—
—
—



hsa-mir-423
—
—
0.07



hsa-mir-425
—
0.20
0.40



hsa-mir-500
0.13
—
0.07



hsa-mir-502
—
—
—



hsa-mir-504
—
—
—



hsa-mir-519
—
—
—



hsa-mir-604
0.13
0.26
0.61



hsa-mir-610
—
—
—



hsa-mir-615
—
—
—



hsa-mir-618
—
—
—



hsa-mir-619
—
—
—



hsa-mir-620
—
—
—



hsa-mir-631
—
—
—



hsa-mir-720a
—
—
—



hsa-mir-720b
—
—
—



hsa-mir-800a
—
0.07
0.07



hsa-mir-800b
—
—
0.07



hsa-mir-803
—
—
—



hsa-mir-805
—
—
—



hsa-mir-451
0.13
0.53
0.88



hsa-mir-433
—
—
0.07



hsa-mir-431
—
0.13
—



hsa-mir-452
—
—
—



hsa-mir-453
—
—
—



hsa-mir-813
—
—
0.07



hsa-mir-814
—
—
—



hsa-mir-815
—
0.07
0.13



hsa-mir-816
—
—
—



hsa-mir-817
—
—
—



hsa-mir-818
—
—
—



hsa-mir-819
0.13
0.20
—



hsa-mir-821
—
—
—



hsa-mir-822
—
—
—



hsa-mir-823
0.13
—
—



hsa-mir-824
—
0.07
0.07



hsa-mir-825
—
—
—



hsa-mir-826
—
—
—



hsa-mir-827
—
—
—



hsa-mir-828
—
0.13
0.07



hsa-mir-829
—
—
—



hsa-mir-831
—
—
—



hsa-mir-832
—
—
—



hsa-mir-834
—
—
—



hsa-mir-835
—
—
—



hsa-mir-837
—
—
—



hsa-mir-838
—
—
—













Neuroblastoma












Medulloblastoma
BE(2)-
SH-
SH-SY5Y_retinoic


miRNA
DAOY
M17
SY5Y
acid





hsa-mir-20b
—
—
—
—


hsa-mir-301b
—
0.62
0.32
0.74


hsa-mir-302b
—
—
—
—


hsa-mir-302c
—
—
—
—


hsa-mir-302d
—
—
—
—


hsa-mir-329
—
—
—
—


hsa-mir-367
—
—
—
—


hsa-mir-368
0.90
0.31
0.16
—


hsa-mir-369
—
—
—
—


hsa-mir-374a
—
—
0.08
0.54


hsa-mir-374b
—
—
0.89
—


hsa-mir-410
—
0.31
—
—


hsa-mir-421
—
—
—
—


hsa-mir-423
0.90
—
1.13
0.40


hsa-mir-425
0.23
0.16
0.81
2.02


hsa-mir-500
—
0.16
—
—


hsa-mir-502
0.23
0.93
—
—


hsa-mir-504
—
—
—
—


hsa-mir-519
—
—
—
—


hsa-mir-604
—
—
1.62
0.94


hsa-mir-610
—
—
—
—


hsa-mir-615
0.11
—
—
—


hsa-mir-618
—
—
—
—


hsa-mir-619
—
—
—
—


hsa-mir-620
—
—
—
—


hsa-mir-631
—
—
—
—


hsa-mir-720a
—
—
—
—


hsa-mir-720b
—
—
—
—


hsa-mir-800a
—
—
—
—


hsa-mir-800b
—
0.31
—
—


hsa-mir-803
—
—
—
—


hsa-mir-805
—
0.16
—
—


hsa-mir-451
—
—
—
—


hsa-mir-433
—
—
—
—


hsa-mir-431
—
0.47
—
—


hsa-mir-452
—
—
—
—


hsa-mir-453
—
0.16
—
—


hsa-mir-813
0.23
0.16
—
—


hsa-mir-814
—
0.31
0.32
0.67


hsa-mir-815
—
—
0.48
0.40


hsa-mir-816
—
—
—
—


hsa-mir-817
—
—
—
0.13


hsa-mir-818
—
—
—
—


hsa-mir-819
—
—
—
—


hsa-mir-821
—
—
—
—


hsa-mir-822
0.23
—
—
—


hsa-mir-823
—
—
—
—


hsa-mir-824
—
—
—
—


hsa-mir-825
—
—
—
—


hsa-mir-826
—
—
—
—


hsa-mir-827
—
—
—
—


hsa-mir-828
—
—
—
—


hsa-mir-829
—
—
—
—


hsa-mir-831
—
—
—
—


hsa-mir-832
—
0.62
0.32
0.40


hsa-mir-834
—
0.93
—
—


hsa-mir-835
—
—
0.32
—


hsa-mir-837
—
0.16
—
—


hsa-mir-838
—
—
—
—


















He-






pa-






to-





Hepatocellular
blas-



Skin
Liver
carcinoma
toma












mIRNA
fibroblasts_CMV
liver
Huh7.5
Huh7.5_HCV
PLC





hsa-mir-20b
—
—
—
—
—


hsa-mir-301b
—
—
—
—
—


hsa-mir-302b
—
—
—
—
—


hsa-mir-302c
—
—
—
—
—


hsa-mir-302d
—
—
—
—
—


hsa-mir-329
—
—
—
—
—


hsa-mir-367
—
—
—
—
—


hsa-mir-368
0.60
—
—
—
—


hsa-mir-369
0.40
—
—
—
—


hsa-mir-374a
0.40
—
0.52
3.33
0.94


hsa-mir-374b
—
—
—
—
1.96


hsa-mir-410
—
—
—
—
—


hsa-mir-421
—
—
0.26
—
0.29


hsa-mir-423
—
—
0.26
—
0.22


hsa-mir-425
—
0.07
—
—
1.81


hsa-mir-500
0.20
—
—
—
0.07


hsa-mir-502
0.20
0.07
—
—
—


hsa-mir-504
—
—
—
—
0.44


hsa-mir-519
0.20
0.07
—
—
—


hsa-mir-604
0.60
—
0.52
—
0.22


hsa-mir-610
0.20
—
—
1.67
—


hsa-mir-615
—
—
—
—
—


hsa-mir-618
—
—
—
—
—


hsa-mir-619
—
—
—
—
—


hsa-mir-620
—
—
—
—
—


hsa-mir-631
—
—
—
—
—


hsa-mir-720a
—
—
—
—
—


hsa-mir-720b
—
—
—
—
—


hsa-mir-800a
—
—
—
—
—


hsa-mir-800b
—
—
—
—
—


hsa-mir-803
—
—
—
—
—


hsa-mir-805
—
—
—
—
0.07


hsa-mir-451
—
0.50
—
—
—


hsa-mir-433
—
—
—
—
—


hsa-mir-431
—
—
—
—
—


hsa-mir-452
—
—
—
—
—


hsa-mir-453
—
—
—
—
—


hsa-mir-813
0.20
—
—
—
—


hsa-mir-814
—
—
—
—
—


hsa-mir-815
—
—
—
—
—


hsa-mir-816
—
—
—
—
0.07


hsa-mir-817
—
0.07
—
—
—


hsa-mir-818
—
—
—
—
—


hsa-mir-819
—
0.07
—
—
—


hsa-mir-821
—
—
—
—
—


hsa-mir-822
0.40
—
—
—
—


hsa-mir-823
—
0.07
—
—
0.07


hsa-mir-824
—
—
—
—
—


hsa-mir-825
—
—
—
—
0.07


hsa-mir-826
—
—
—
—
—


hsa-mir-827
—
—
—
—
—


hsa-mir-828
—
—
—
—
—


hsa-mir-829
—
—
—
—
—


hsa-mir-831
—
—
—
—
—


hsa-mir-832
—
—
—
—
—


hsa-mir-834
0.20
—
—
—
—


hsa-mir-835
—
—
—
—
—


hsa-mir-837
—
—
—
—
—


hsa-mir-838
—
—
—
—
—













Activated




B-cells
B-cell derived lymphomas













mIRNA
primary B cells
BL41
BL41/95
LY3
U266
BCBL1





hsa-mir-20b
—
0.05
—
—
—
—


hsa-mir-301b
—
0.20
—
—
—
0.73


hsa-mir-302b
—
—
—
—
—
—


hsa-mir-302c
—
—
—
—
—
—


hsa-mir-302d
—
—
—
—
—
—


hsa-mir-329
—
—
—
—
—
—


hsa-mir-367
—
—
—
—
—
—


hsa-mir-368
—
—
—
—
—
—


hsa-mir-369
—
—
—
—
—
—


hsa-mir-374a
—
0.10
—
—
—
0.25


hsa-mir-374b
—
0.10
—
—
0.41
0.25


hsa-mir-410
—
—
—
—
—
—


hsa-mir-421
—
—
—
—
—
0.25


hsa-mir-423
—
0.29
—
—
—
—


hsa-mir-425
2.50
0.10
0.29
0.99
0.82
0.48


hsa-mir-500
—
0.49
0.15
—
0.41
—


hsa-mir-502
—
—
—
—
—
—


hsa-mir-504
—
—
—
—
—
0.49


hsa-mir-519
—
—
0.15
—
—
—


hsa-mir-604
—
—
—
—
—
—


hsa-mir-610
—
0.10
—
—
—
—


hsa-mir-615
—
—
—
—
—
—


hsa-mir-618
—
—
—
—
—
—


hsa-mir-619
—
—
—
—
—
—


hsa-mir-620
—
—
—
—
—
—


hsa-mir-631
—
—
—
—
—
—


hsa-mir-720a
—
—
—
—
—
0.25


hsa-mir-720b
—
—
—
—
—
—


hsa-mir-800a
—
—
—
—
—
—


hsa-mir-800b
—
—
—
—
—
—


hsa-mir-803
—
—
—
—
—
—


hsa-mir-805
—
—
—
—
—
—


hsa-mir-451
—
—
—
—
—
—


hsa-mir-433
—
—
—
—
—
—


hsa-mir-431
—
—
—
—
—
—


hsa-mir-452
—
—
—
—
—
—


hsa-mir-453
—
—
—
—
—
—


hsa-mir-813
—
—
—
—
—
—


hsa-mir-814
—
—
—
—
—
—


hsa-mir-815
—
0.10
—
—
—
—


hsa-mir-816
—
—
—
—
—
—


hsa-mir-817
—
—
—
—
—
—


hsa-mir-818
—
0.20
—
—
—
—


hsa-mir-819
—
—
—
—
—
—


hsa-mir-821
—
—
0.29
—
—
—


hsa-mir-822
—
—
—
—
—
—


hsa-mir-823
—
—
—
—
—
0.25


hsa-mir-824
—
—
—
—
—
—


hsa-mir-825
—
—
—
—
—
—


hsa-mir-826
—
—
—
—
—
—


hsa-mir-827
—
—
—
—
—
—


hsa-mir-828
—
—
—
—
—
—


hsa-mir-829
—
—
—
0.50
—
—


hsa-mir-831
—
—
—
—
—
—


hsa-mir-832
—
—
—
—
—
—


hsa-mir-834
—
—
—
—
—
—


hsa-mir-835
—
—
—
—
—
—


hsa-mir-837
—
—
—
—
—
—


hsa-mir-838
—
—
0.15
—
—
—













Spleen
Endocrine organs













mIRNA
spleen
pituitary
SW13
SW13-YFV
ovary
testis





hsa-mir-20b
—
—
2.01
2.93
—
—


hsa-mir-301b
—
—
0.13
0.61
—
—


hsa-mir-302b
—
—
—
—
—
—


hsa-mir-302c
—
—
—
—
—
—


hsa-mir-302d
—
—
—
—
—
—


hsa-mir-329
—
0.06
—
—
—
—


hsa-mir-367
—
—
—
—
—
—


hsa-mir-368
0.18
0.62
—
—
0.30
0.30


hsa-mir-369
—
0.12
—
—
—
—


hsa-mir-374a
—
0.12
0.07
—
0.08
—


hsa-mir-374b
—
0.06
0.20
—
0.08
—


hsa-mir-410
—
0.43
—
—
—
—


hsa-mir-421
—
—
—
—
—
—


hsa-mir-423
0.92
—
—
0.24
0.38
0.07


hsa-mir-425
0.18
0.06
0.40
0.61
0.08
0.15


hsa-mir-500
—
0.06
—
0.24
—
—


hsa-mir-502
—
0.06
—
0.12
—
0.74


hsa-mir-504
—
—
0.13
0.12
—
—


hsa-mir-519
0.18
—
—
—
0.15
—


hsa-mir-604
0.18
0.06
—
—
0.23
0.15


hsa-mir-610
—
—
0.13
0.12
0.15
0.07


hsa-mir-615
—
—
—
0.24
—
—


hsa-mir-618
—
—
—
0.24
—
—


hsa-mir-619
—
0.06
—
0.24
—
—


hsa-mir-620
—
—
—
—
—
—


hsa-mir-631
—
—
—
—
—
—


hsa-mir-720a
—
—
—
—
—
0.30


hsa-mir-720b
—
—
0.13
—
—
—


hsa-mir-800a
—
0.18
—
—
—
—


hsa-mir-800b
—
—
—
—
—
—


hsa-mir-803
—
—
—
—
—
—


hsa-mir-805
—
—
—
—
—
—


hsa-mir-451
0.18
1.29
—
—
0.75
0.07


hsa-mir-433
—
0.06
—
—
—
—


hsa-mir-431
—
—
—
—
—
—


hsa-mir-452
—
—
—
—
—
—


hsa-mir-453
—
—
—
—
—
—


hsa-mir-813
—
0.06
—
—
—
—


hsa-mir-814
—
—
—
—
—
—


hsa-mir-815
—
0.06
—
—
—
—


hsa-mir-816
—
0.06
0.13
0.12
—
—


hsa-mir-817
—
—
—
—
—
—


hsa-mir-818
—
—
—
—
—
—


hsa-mir-819
—
—
—
—
—
—


hsa-mir-821
—
—
—
—
—
—


hsa-mir-822
—
—
—
—
—
—


hsa-mir-823
0.18
—
—
—
—
—


hsa-mir-824
—
—
—
—
—
—


hsa-mir-825
—
0.31
—
—
—
—


hsa-mir-826
—
0.12
—
—
0.15
0.59


hsa-mir-827
—
0.08
—
—
—
0.44


hsa-mir-828
—
—
—
0.12
—
—


hsa-mir-829
—
—
—
0.24
—
—


hsa-mir-831
—
—
0.13
0.12
—
—


hsa-mir-832
—
—
—
—
—
—


hsa-mir-834
—
—
—
—
—
—


hsa-mir-835
—
—
0.27
—
—
—


hsa-mir-837
—
0.06
—
—
—
0.07


hsa-mir-838
—
—
—
—
—
—














Embryonal derived





cell lines/tumors
Cervic















Saos-


carcinoma
Epididymis


mIRNA
NT2/D1
2
NCCIT
Hek
HeLa S3
epididymis





hsa-mir-20b
0.37
—
0.72
0.13
—
—


hsa-mir-301b
—
—
—
—
—
—


hsa-mir-302b
3.90
—
15.22 
—
—
—


hsa-mir-302c
9.06
—
5.07
—
—
—


hsa-mir-302d
1.50
—
4.35
—
—
—


hsa-mir-329
—
—
—
—
—
—


hsa-mir-367
9.71
—
10.14 
—
—
—


hsa-mir-368
—
—
—
—
—
—


hsa-mir-369
—
—
—
—
—
—


hsa-mir-374a
1.35
—
—
0.25
0.32
0.16


hsa-mir-374b
0.49
—
1.45
0.25
0.16
—


hsa-mir-410
—
—
—
—
—
—


hsa-mir-421
—
—
—
—
0.16
0.08


hsa-mir-423
—
1.69
0.72
—
0.32
—


hsa-mir-425
0.12
—
—
0.76
0.16
—


hsa-mir-500
0.12
—
—
0.25
—
—


hsa-mir-502
—
—
—
0.25
0.48
—


hsa-mir-504
—
—
—
0.51
0.16
—


hsa-mir-519
—
—
—
0.25
0.16
—


hsa-mir-604
0.12
—
—
0.25
—
—


hsa-mir-610
0.12
—
—
0.25
—
0.24


hsa-mir-615
—
—
—
—
—
—


hsa-mir-618
—
—
—
—
—
—


hsa-mir-619
—
—
—
—
—
—


hsa-mir-620
—
—
—
—
—
—


hsa-mir-631
—
—
—
—
—
—


hsa-mir-720a
—
—
—
—
—
0.08


hsa-mir-720b
—
—
—
—
—
—


hsa-mir-800a
—
—
—
—
—
—


hsa-mir-800b
—
—
—
—
—
—


hsa-mir-803
0.25
—
—
0.25
—
—


hsa-mir-805
—
—
—
—
—
—


hsa-mir-451
—
—
—
—
—
0.40


hsa-mir-433
—
—
—
—
—
—


hsa-mir-431
—
—
—
—
—
—


hsa-mir-452
—
—
—
—
—
—


hsa-mir-453
—
—
—
—
—
—


hsa-mir-813
—
—
—
—
—
—


hsa-mir-814
0.12
—
—
—
—
—


hsa-mir-815
0.12
—
—
0.51
—
—


hsa-mir-816
—
—
—
0.25
—
—


hsa-mir-817
—
—
—
—
—
—


hsa-mir-818
—
—
0.72
—
0.16
—


hsa-mir-819
—
—
—
—
—
—


hsa-mir-821
—
—
—
—
—
—


hsa-mir-822
—
—
—
—
—
—


hsa-mir-823
—
—
—
—
—
—


hsa-mir-824
—
—
—
—
—
—


hsa-mir-825
—
—
—
0.25
—
—


hsa-mir-826
—
—
—
—
—
—


hsa-mir-827
—
—
—
—
—
—


hsa-mir-828
—
—
—
—
—
—


hsa-mir-829
—
—
—
—
0.16
—


hsa-mir-831
—
—
—
—
—
—


hsa-mir-832
—
—
—
—
—
—


hsa-mir-834
—
—
—
—
—
0.08


hsa-mir-835
—
—
—
—
—
—


hsa-mir-837
0.12
—
—
—
—
—


hsa-mir-838
—
—
—
—
0.16
—












Breast carcinoma













mIRNA
MCF10A
MCF7
HCC38
SkBr3
BT474
T47





hsa-mir-20b
—
—
0.09
—
—
—


hsa-mir-301b
—
—
—
—
—
0.60


hsa-mir-302b
—
—
—
—
—
—


hsa-mir-302c
—
—
—
—
—
—


hsa-mir-302d
—
—
—
—
—
—


hsa-mir-329
—
—
—
—
—
—


hsa-mir-367
—
—
—
—
—
—


hsa-mir-368
—
0.25
—
—
—
—


hsa-mir-369
—
—
—
—
—
—


hsa-mir-374a
—
—
0.09
0.47
—
0.09


hsa-mir-374b
—
—
0.19
—
0.05
0.43


hsa-mir-410
—
—
—
—
—
—


hsa-mir-421
—
0.13
—
—
—
0.09


hsa-mir-423
0.19
0.25
0.47
0.12
0.42
0.51


hsa-mir-425
—
0.38
0.75
0.93
1.50
2.22


hsa-mir-500
—
—
0.19
—
0.98
0.34


hsa-mir-502
—
0.50
—
—
—
—


hsa-mir-504
0.09
0.13
0.09
0.23
0.61
0.09


hsa-mir-519
0.09
0.13
—
0.23
0.05
0.17


hsa-mir-604
0.19
—
0.19
—
0.19
0.17


hsa-mir-610
—
—
—
—
—
—


hsa-mir-615
—
—
—
—
—
—


hsa-mir-618
—
—
—
—
—
—


hsa-mir-619
—
—
—
—
—
—


hsa-mir-620
—
0.25
—
—
—
—


hsa-mir-631
—
0.25
—
—
—
—


hsa-mir-720a
—
—
—
—
—
—


hsa-mir-720b
—
—
—
—
—
—


hsa-mir-800a
—
—
—
—
—
—


hsa-mir-800b
—
—
—
—
—
—


hsa-mir-803
—
—
—
—
—
—


hsa-mir-805
—
—
—
—
—
—


hsa-mir-451
—
—
—
—
—
—


hsa-mir-433
—
—
—
—
—
—


hsa-mir-431
—
—
—
—
—
—


hsa-mir-452
—
—
—
0.12
0.05
—


hsa-mir-453
—
—
—
—
—
—


hsa-mir-813
—
—
—
—
—
—


hsa-mir-814
—
—
—
—
—
—


hsa-mir-815
—
0.13
0.09
—
0.05
—


hsa-mir-816
0.09
0.13
—
—
—
—


hsa-mir-817
—
—
—
—
—
—


hsa-mir-818
—
—
—
—
0.05
—


hsa-mir-819
—
—
—
—
—
—


hsa-mir-821
—
—
—
—
—
—


hsa-mir-822
—
—
—
—
—
—


hsa-mir-823
—
—
—
—
—
—


hsa-mir-824
—
—
—
—
—
—


hsa-mir-825
—
—
—
—
—
—


hsa-mir-826
—
—
—
—
—
—


hsa-mir-827
—
—
—
—
—
—


hsa-mir-828
—
—
—
—
—
—


hsa-mir-829
—
—
0.09
—
0.05
0.09


hsa-mir-831
—
—
—
—
—
—


hsa-mir-832
—
—
—
—
—
—


hsa-mir-834
—
0.13
—
—
—
—


hsa-mir-835
—
—
—
—
0.05
—


hsa-mir-837
—
—
—
—
—
—


hsa-mir-838
—
—
—
—
—
0.09












Adult brain












mIRNA
cerebellum
frontalcortex
midbrain







hsa-mir-839
—
—
0.07



hsa-mir-841
0.51
—
—



hsa-mir-842
—
—
—



hsa-mir-843
—
0.07
—



hsa-mir-845
—
—
—



hsa-mir-846
—
—
0.07



hsa-mir-847
—
—
—



hsa-mir-848
—
—
—



hsa-mir-849
—
—
—



hsa-mir-850
0.13
—
—



hsa-mir-851
—
—
—



hsa-mir-852
—
—
—



hsa-mir-853
—
—
—



hsa-mir-854
0.26
—
—



hsa-mir-855
—
0.13
—



hsa-mir-857
—
—
—



hsa-mir-864
—
—
—



hsa-mir-867
—
—
0.07



hsa-mir-869
—
—
0.07



hsa-mir-871
—
—
—



hsa-mir-883
—
—
—



hsa-mir-884
—
—
—



hsa-mir-885
—
—
—



hsa-mir-886
—
—
—



hsa-mir-887
—
—
—



hsa-mir-888
—
—
—



hsa-mir-889
—
—
—



hsa-mir-890
—
—
—



hsa-mir-891
—
—
—



hsa-mir-892
—
—
—



hsa-mir-893
—
—
—



hsa-mir-894
—
—
—



hsa-mir-92b
—
0.07
0.07













Neuroblastoma












Medulloblastoma
BE(2)-
SH-
SH-SY5Y_retinoic


mIRNA
DAOY
M17
SY5Y
acid





hsa-mir-839
—
—
—
—


hsa-mir-841
—
—
0.65
0.40


hsa-mir-842
—
0.16
0.16
—


hsa-mir-843
0.45
0.93
2.10
2.02


hsa-mir-845
0.23
—
0.32
—


hsa-mir-846
—
—
—
0.13


hsa-mir-847
—
—
—
—


hsa-mir-848
—
—
—
—


hsa-mir-849
—
—
—
—


hsa-mir-850
—
—
—
—


hsa-mir-851
—
—
—
0.13


hsa-mir-852
—
—
—
—


hsa-mir-853
—
—
0.32
0.13


hsa-mir-854
—
0.16
—
—


hsa-mir-855
—
—
—
—


hsa-mir-857
—
—
0.32
0.27


hsa-mir-864
—
—
—
—


hsa-mir-867
—
—
—
—


hsa-mir-869
—
0.16
—
—


hsa-mir-871
0.23
—
—
—


hsa-mir-883
—
—
—
—


hsa-mir-884
—
0.16
—
—


hsa-mir-885
—
—
—
—


hsa-mir-886
—
—
—
—


hsa-mir-887
—
—
—
—


hsa-mir-888
—
—
—
—


hsa-mir-889
—
—
—
—


hsa-mir-890
—
—
—
—


hsa-mir-891
—
—
—
0.13


hsa-mir-892
—
—
—
—


hsa-mir-893
—
—
—
—


hsa-mir-894
—
—
—
—


hsa-mir-92b
—
—
—
—


















He-






pa-






to-





Hepatocellular
blas-



Skin
Liver
carcinoma
toma












mIRNA
fibroblasts_CMV
liver
Huh7.5
Huh7.5_HCV
PLC





hsa-mir-839
—
0.07
—
—
—


hsa-mir-841
—
—
—
—
—


hsa-mir-842
—
—
—
—
—


hsa-mir-843
0.20
—
—
—
—


hsa-mir-845
—
—
—
—
—


hsa-mir-846
—
—
—
—
—


hsa-mir-847
—
—
—
—
—


hsa-mir-848
0.40
—
—
—
—


hsa-mir-849
—
—
—
—
—


hsa-mir-850
0.20
—
—
—
—


hsa-mir-851
—
—
—
—
—


hsa-mir-852
—
—
—
—
0.29


hsa-mir-853
—
—
—
—
0.07


hsa-mir-854
—
0.07
—
—
—


hsa-mir-855
—
—
0.26
—
—


hsa-mir-857
—
—
—
—
—


hsa-mir-864
—
—
—
—
—


hsa-mir-867
—
—
0.13
—
—


hsa-mir-869
—
—
—
—
—


hsa-mir-871
0.40
—
0.26
—
—


hsa-mir-883
—
—
—
—
—


hsa-mir-884
—
—
—
—
—


hsa-mir-885
—
—
—
—
—


hsa-mir-886
—
—
—
—
—


hsa-mir-887
—
—
—
—
—


hsa-mir-888
—
—
—
—
—


hsa-mir-889
—
—
—
—
—


hsa-mir-890
—
—
—
—
—


hsa-mir-891
—
—
—
—
—


hsa-mir-892
0.20
—
—
—
—


hsa-mir-893
—
—
—
—
—


hsa-mir-894
—
—
—
—
—


hsa-mir-92b
—
—
—
—
0.04













Activated




B-cells
B-cell derived lymphomas













mIRNA
primary B cells
BL41
BL41/95
LY3
U266
BCBL1





hsa-mir-839
—
—
—
—
—
—


hsa-mir-841
—
—
—
—
—
—


hsa-mir-842
—
—
—
—
—
—


hsa-mir-843
—
—
—
—
—
—


hsa-mir-845
—
—
—
—
—
—


hsa-mir-846
—
—
—
—
—
—


hsa-mir-847
—
—
—
—
—
—


hsa-mir-848
—
—
—
—
—
—


hsa-mir-849
—
—
—
—
—
—


hsa-mir-850
—
—
—
—
—
—


hsa-mir-851
—
—
—
—
—
—


hsa-mir-852
—
—
—
—
—
—


hsa-mir-853
—
—
—
—
—
—


hsa-mir-854
—
—
—
—
—
—


hsa-mir-855
—
—
—
—
—
—


hsa-mir-857
—
—
—
—
—
—


hsa-mir-864
—
—
—
—
—
—


hsa-mir-867
—
—
—
—
—
—


hsa-mir-869
—
—
—
—
—
—


hsa-mir-871
—
—
—
—
—
1.45


hsa-mir-883
—
—
—
—
—
—


hsa-mir-884
—
—
—
—
—
—


hsa-mir-885
—
—
—
—
—
—


hsa-mir-886
—
—
—
—
—
—


hsa-mir-887
—
—
—
—
—
—


hsa-mir-888
—
—
—
—
—
—


hsa-mir-889
—
—
—
—
0.41
—


hsa-mir-890
—
—
—
—
—
—


hsa-mir-891
—
—
—
—
—
—


hsa-mir-892
—
—
—
—
—
—


hsa-mir-893
—
—
—
—
—
—


hsa-mir-894
—
—
—
—
—
—


hsa-mir-92b
—
—
—
0.50
—
0.49













Spleen
Endocrine organs













mIRNA
spleen
pituitary
SW13
SW13-YFV
ovary
testis





hsa-mir-839
0.18
—
—
—
—
—


hsa-mir-841
—
—
—
—
—
—


hsa-mir-842
—
—
—
—
—
—


hsa-mir-843
—
0.06
—
—
0.45
—


hsa-mir-845
—
—
—
0.12
—
—


hsa-mir-846
—
—
—
—
—
—


hsa-mir-847
—
—
—
—
—
—


hsa-mir-848
—
—
—
—
—
—


hsa-mir-849
—
—
—
—
—
—


hsa-mir-850
—
—
—
—
—
—


hsa-mir-851
—
—
—
—
—
—


hsa-mir-852
—
—
—
—
—
—


hsa-mir-853
0.18
—
—
—
—
—


hsa-mir-854
—
—
—
—
0.08
—


hsa-mir-855
0.18
0.12
—
—
0.53
0.52


hsa-mir-857
—
—
0.13
—
—
—


hsa-mir-864
—
—
—
—
—
—


hsa-mir-867
0.09
—
0.13
0.18
—
0.07


hsa-mir-869
—
—
—
—
—
—


hsa-mir-871
—
—
0.13
—
—
—


hsa-mir-883
—
0.06
—
—
—
—


hsa-mir-884
—
—
—
—
—
—


hsa-mir-885
—
—
0.13
0.24
—
—


hsa-mir-886
—
—
—
—
—
—


hsa-mir-887
—
—
—
0.24
—
—


hsa-mir-888
—
—
—
—
—
0.07


hsa-mir-889
—
—
—
—
—
—


hsa-mir-890
—
—
—
—
—
—


hsa-mir-891
—
—
—
—
—
—


hsa-mir-892
—
—
—
—
—
—


hsa-mir-893
0.18
—
—
—
—
—


hsa-mir-894
—
—
—
—
—
—


hsa-mir-92b
0.55
0.06
0.13
0.12
—
—














Embryonal derived





cell lines/tumors
Cervic















Saos-


carcinoma
Epididymis


mIRNA
NT2/D1
2
NCCIT
Hek
HeLa S3
epididymis





hsa-mir-839
—
1.69
—
—
—
—


hsa-mir-841
0.12
—
—
—
—
—


hsa-mir-842
0.12
—
—
—
—
—


hsa-mir-843
1.97
—
—
0.25
—
—


hsa-mir-845
0.12
—
—
—
—
—


hsa-mir-846
—
—
—
—
—
—


hsa-mir-847
—
—
—
—
—
—


hsa-mir-848
—
—
—
—
—
—


hsa-mir-849
—
—
—
—
—
—


hsa-mir-850
—
—
—
—
—
—


hsa-mir-851
0.12
—
—
—
—
—


hsa-mir-852
0.37
—
—
—
—
—


hsa-mir-853
—
—
—
—
—
—


hsa-mir-854
—
—
—
—
—
—


hsa-mir-855
—
—
—
—
0.32
0.16


hsa-mir-857
0.12
—
—
—
—
—


hsa-mir-864
0.25
—
—
—
—
—


hsa-mir-867
—
—
—
—
—
—


hsa-mir-869
—
—
—
—
—
—


hsa-mir-871
—
—
0.72
—
0.32
—


hsa-mir-883
—
—
—
—
—
—


hsa-mir-884
—
—
—
—
—
—


hsa-mir-885
—
—
—
—
—
—


hsa-mir-886
—
—
—
—
—
—


hsa-mir-887
—
—
—
—
—
—


hsa-mir-888
—
—
—
—
—
—


hsa-mir-889
—
—
—
—
—
—


hsa-mir-890
—
—
—
—
—
—


hsa-mir-891
—
—
—
—
—
—


hsa-mir-892
—
—
—
—
—
—


hsa-mir-893
—
—
—
—
—
—


hsa-mir-894
—
—
—
—
—
—


hsa-mir-92b
0.37
—
—
—
0.16
—












Breast carcinoma













mIRNA
MCF10A
MCF7
HCC38
SkBr3
BT474
T47





hsa-mir-839
—
—
—
—
—
—


hsa-mir-841
—
—
—
—
—
—


hsa-mir-842
—
—
—
—
—
—


hsa-mir-843
—
0.13
—
—
0.23
—


hsa-mir-845
—
—
—
—
—
—


hsa-mir-846
—
—
—
—
—
—


hsa-mir-847
—
—
—
0.23
—
—


hsa-mir-848
—
—
—
—
—
—


hsa-mir-849
—
—
—
0.23
—
—


hsa-mir-850
—
—
—
—
—
—


hsa-mir-851
—
—
—
—
—
—


hsa-mir-852
—
—
—
0.12
—
—


hsa-mir-853
—
0.13
—
—
—
—


hsa-mir-854
—
—
—
—
—
—


hsa-mir-855
—
—
0.19
—
—
—


hsa-mir-857
—
—
—
—
—
—


hsa-mir-864
—
—
—
—
—
—


hsa-mir-867
—
—
—
—
—
0.04


hsa-mir-869
—
—
—
—
—
—


hsa-mir-871
—
—
0.09
—
—
—


hsa-mir-883
—
—
—
—
—
—


hsa-mir-884
—
—
—
—
—
—


hsa-mir-885
—
—
—
—
—
—


hsa-mir-886
—
—
—
—
0.05
—


hsa-mir-887
—
—
—
—
—
—


hsa-mir-888
—
—
—
—
—
—


hsa-mir-889
—
—
—
—
—
—


hsa-mir-890
—
—
—
—
0.05
—


hsa-mir-891
—
—
—
—
—
—


hsa-mir-892
—
—
—
—
—
—


hsa-mir-893
—
—
—
—
—
—


hsa-mir-894
—
—
—
—
—
0.09


hsa-mir-92b
—
0.63
—
0.12
—
—





The “—” in the table indicates 0%.













TABLE G1





Relative Cloning Frequency in % Relative to Total Number of Identified MicroRNA


for Each Given Library.

















Adult brain













miRNA
hsa_cerebellum
hsa_frontaicartex
hsa_midbrain
hsa_hippocampus






hsa-miR-100516
—
—
—
—



hsa-miR-100516
—
—
—
—



hsa-miR-100604
0.13
0.26
0.60
0.09



hsa-miR-100610-5p
—
—
—
—



hsa-miR-100631
—
—
—
—



hsa-miR-100732
—
—
—
—



hsa-miR-100814
—
—
—
—



hsa-miR-100815
—
0.07
0.13
0.09



hsa-miR-100818
—
—
—
—



hsa-miR-100819
0.13
0.20
—
—



hsa-miR-100824
—
0.07
0.07
—



hsa-miR-100825-3p
—
—
—
—



hsa-miR-100825-5p
—
—
—
—



hsa-miR-100829-3p
—
—
—
—



hsa-miR-100835-5p
—
—
—
—



hsa-miR-100842
—
—
—
—



hsa-miR-100843-3p
—
0.07
—
0.26



hsa-miR-100843-5p
—
0.07
—
0.26



hsa-miR-100846
—
—
0.07
—



hsa-miR-100851
—
—
—
—



hsa-miR-100852
—
—
—
—



hsa-miR-100854
0.25
—
—
0.09



hsa-miR-100855-3p
—
0.13
—
0.09



hsa-miR-100855-5p
—
0.13
—
0.09



hsa-miR-100869-3p
—
—
—
—



hsa-miR-100869-5p
—
—
—
—



hsa-miR-100871-3p
—
—
—
—



hsa-miR-100871-5p
—
—
—
—



hsa-miR-100885
—
—
—
—



hsa-miR-100885
—
—
—
—



hsa-miR-100887-3p
—
—
—
—



hsa-miR-100887-3p
—
—
—
—



hsa-miR-100887-5p
—
—
—
—



hsa-miR-100887-5p
—
—
—
—



hsa-miR-100891-3p
—
—
—
—



hsa-miR-100891-3p
—
—
—
—



hsa-miR-100891-5p
—
—
—
—



hsa-miR-100891-5p
—
—
—
—



hsa-miR-101001
—
—
—
—



hsa-miR-146b
—
—
—
—



hsa-miR-147b
—
—
—
—



hsa-miR-181d
—
0.03
—
—



hsa-miR-18b
—
—
—
—



hsa-mir-18b-3p
—
—
—
—



hsa-miR-193b
—
—
—
—



hsa-miR-20b
—
—
—
—



hsa-miR-20b-3p
—
—
—
—



hsa-miR-218b
—
—
—
—



hsa-miR-301b
—
—
—
—



hsa-miR-329
—
—
0.07
—



hsa-miR-33b
—
—
—
0.09



hsa-miR-374b
—
—
0.07
0.26



hsa-miR-375
—
—
—
—



hsa-miR-376a
—
—
—
—



hsa-miR-376b
—
—
—
—



hsa-miR-376c
—
0.07
0.07
—



hsa-miR-376c
—
0.07
0.07
—



hsa-miR-377
—
0.07
—
0.26



hsa-miR-378
—
—
0.07
—



hsa-miR-379
—
0.13
0.27
0.43



hsa-miR-380
—
—
—
—



hsa-miR-410
—
—
0.07
—



hsa-miR-421-3p
—
—
—
0.09



hsa-miR-429
—
—
—
—



hsa-miR-431
—
0.13
—
—



hsa-miR-432
—
—
0.07
—



hsa-miR-433
—
—
0.07
—



hsa-miR-449a
—
—
—
—



hsa-miR-449b
—
—
—
—



hsa-miR-450a
—
—
—
—



hsa-miR-451
0.13
0.52
0.67
—



hsa-miR-452
—
—
—
—



hsa-miR-453
—
—
—
—



hsa-miR-454
0.13
—
0.07
—



hsa-miR-455-5p
—
—
—
—



hsa-miR-484
—
—
—
—



hsa-miR-485-3p
—
—
—
0.09



hsa-miR-485-5p
—
—
—
0.09



hsa-mir-486_0s
—
—
—
—



hsa-miR-487
—
—
0.07
—



hsa-miR-488
0.51
—
—
0.69



hsa-miR-490
—
—
—
—



hsa-miR-493
—
—
—
—



hsa-miR-497
—
—
—
—



hsa-miR-502
—
—
—
—



hsa-miR-503
—
—
—
—



hsa-miR-505
0.13
—
—
—



hsa-miR-509-3p
—
—
—
—



hsa-miR-514
—
—
—
—



hsa-miR-544
—
—
—
—



hsa-miR-618
—
—
—
—



hsa-miR-619
—
—
—
—



hsa-miR-620
—
—
—
—



hsa-mir-816
—
—
—
—



hsa-mir-817
—
—
—
—



hsa-mir-828-3p
—
0.13
—
—



hsa-mir-828-5p
—
—
0.07
—



hsa-mir-831-1
—
—
—
—



hsa-mir-840-3p
—
—
—
—



hsa-mir-840-5p
—
—
0.13
—



hsa-mir-847
—
—
—
—



hsa-mir-848
—
—
—
—



hsa-mir-849
—
—
—
—



hsa-mir-850
0.13
—
—
—



hsa-mir-853
—
—
—
—



hsa-mir-857
—
—
—
—



hsa-miR-92b
—
0.07
0.07
—














Medultoblastoma
Glioblastoma
Neuroblastoma














miRNA
hsa_DAOY
hsa_SNB19
BE(2)-ML7
hsa_5H-SY5Y
5H-SY5Y_retinoic acid






hsa-miR-100516
0.23
—
—
—
—



hsa-miR-100516
0.23
—
—
—
—



hsa-miR-100604
—
—
—
1.61
0.94



hsa-miR-100610-5p
—
—
—
—
—



hsa-miR-100631
—
—
—
—
—



hsa-miR-100732
—
—
—
—
—



hsa-miR-100814
—
—
0.30
0.32
0.67



hsa-miR-100815
—
0.20
—
0.48
0.40



hsa-miR-100818
—
—
—
—
—



hsa-miR-100819
—
—
—
—
—



hsa-miR-100824
—
—
—
—
—



hsa-miR-100825-3p
—
—
—
—
—



hsa-miR-100825-5p
—
—
—
—
—



hsa-miR-100829-3p
—
—
—
—
—



hsa-miR-100835-5p
—
—
—
—
—



hsa-miR-100842
—
—
0.15
0.16
—



hsa-miR-100843-3p
0.46
0.20
0.76
1.61
1.89



hsa-miR-100843-5p
0.46
0.20
0.76
1.61
1.89



hsa-miR-100846
—
—
—
—
0.13



hsa-miR-100851
—
—
—
—
0.13



hsa-miR-100852
—
0.20
—
—
—



hsa-miR-100854
—
—
0.15
—
—



hsa-miR-100855-3p
—
—
—
—
—



hsa-miR-100855-5p
—
—
—
—
—



hsa-miR-100859-3p
—
—
0.15
—
—



hsa-miR-100859-5p
—
—
0.15
—
—



hsa-miR-100871-3p
0.23
0.20
—
—
—



hsa-miR-100871-5p
0.23
0.20
—
—
—



hsa-miR-100885
—
—
—
—
—



hsa-miR-100885
—
—
—
—
—



hsa-miR-100887-3p
—
—
—
—
—



hsa-miR-100887-3p
—
—
—
—
—



hsa-miR-100887-5p
—
—
—
—
—



hsa-miR-100887-5p
—
—
—
—
—



hsa-miR-100891-3p
—
—
—
—
—



hsa-miR-100891-3p
—
—
—
—
—



hsa-miR-100891-5p
—
—
—
—
—



hsa-miR-100891-5p
—
—
—
—
—



hsa-miR-101001
—
—
0.15
—
—



hsa-miR-146b
0.11
—
—
—
—



hsa-miR-147b
0.23
—
—
—
—



hsa-miR-181d
—
—
—
—
0.13



hsa-miR-18b
0.11
—
—
—
—



hsa-mir-18b-3p
0.11
—
—
—
—



hsa-miR-193b
—
—
—
—
—



hsa-miR-20b
—
—
—
—
—



hsa-miR-20b-3p
—
—
—
—
—



hsa-miR-216b
—
—
—
—
—



hsa-miR-301b
—
—
0.61
0.32
0.74



hsa-miR-329
—
—
—
—
—



hsa-miR-33b
—
0.40
—
—
—



hsa-miR-374b
—
0.60
—
0.88
—



hsa-miR-375
—
—
0.15
0.16
—



hsa-miR-376a
—
—
—
—
—



hsa-miR-376b
—
—
0.30
—
—



hsa-miR-376c
—
—
—
—
—



hsa-miR-376c
—
—
—
—
—



hsa-miR-377
—
—
1.98
—
—



hsa-miR-378
—
—
—
—
—



hsa-miR-379
—
—
4.57
—
—



hsa-miR-380
—
—
—
—
—



hsa-miR-410
—
—
0.30
—
—



hsa-miR-421-3p
—
—
—
—
—



hsa-miR-429
—
—
—
—
—



hsa-miR-431
—
—
0.46
—
—



hsa-miR-432
0.23
—
0.15
—
—



hsa-miR-433
—
—
—
—
—



hsa-miR-449a
—
—
—
—
—



hsa-miR-449b
—
—
—
—
—



hsa-miR-450a
—
—
0.15
—
—



hsa-miR-451
—
—
—
—
—



hsa-miR-452
—
—
—
—
—



hsa-miR-453
—
—
0.15
—
—



hsa-miR-454
—
—
0.15
—
—



hsa-miR-455-5p
—
—
—
—
—



hsa-miR-484
—
—
—
—
—



hsa-miR-485-3p
—
—
—
—
—



hsa-miR-485-5p
—
—
—
—
—



hsa-mir-486_0s
—
—
—
—
—



hsa-miR-487
—
—
0.30
—
—



hsa-miR-488
—
—
—
0.64
0.40



hsa-miR-490
—
—
0.61
0.32
0.40



hsa-miR-493
—
—
0.91
—
—



hsa-miR-497
—
—
—
—
—



hsa-miR-502
—
—
—
—
—



hsa-miR-503
0.23
—
0.91
—
—



hsa-miR-505
—
—
—
—
—



hsa-miR-509-3p
—
—
—
—
—



hsa-miR-514
—
—
—
—
—



hsa-miR-544
—
—
0.15
—
—



hsa-miR-618
—
—
—
—
—



hsa-miR-619
—
—
—
—
—



hsa-miR-620
—
—
—
—
—



hsa-mir-816
—
—
—
—
—



hsa-mir-817
—
—
—
—
0.13



hsa-mir-828-3p
—
—
—
—
—



hsa-mir-828-5p
—
—
—
—
—



hsa-mir-831-1
—
—
—
—
—



hsa-mir-840-3p
—
—
—
0.32
0.40



hsa-mir-840-5p
0.23
0.40
0.15
0.96
0.54



hsa-mir-847
—
—
—
—
—



hsa-mir-848
—
—
—
—
—



hsa-mir-849
—
—
—
—
—



hsa-mir-850
—
—
—
—
—



hsa-mir-853
—
—
—
0.32
—



hsa-mir-857
—
—
—
0.32
0.27



hsa-miR-92b
—
—
—
—
—















Skin
Liver
Hepatocellular carcinoma
Hepatoblastoma














miRNA
ribroblasts_CMV
hsa_liver
Huh7_HCV
Huh7_Mock
hsa_PLC
hsa_HepG2
hsa_HepG2_2215





hsa-miR-100516
—
—
—
—
—
—
—


hsa-miR-100516
—
—
—
—
—
—
—


hsa-miR-100604
0.60
—
—
0.52
0.22
0.07
—


hsa-miR-100610-5p
—
—
1.67
—
—
—
0.06


hsa-miR-100631
—
—
—
—
—
—
—


hsa-miR-100732
—
—
—
—
—
—
—


hsa-miR-100814
—
—
—
—
—
—
—


hsa-miR-100815
—
—
—
—
—
0.15
—


hsa-miR-100818
—
—
—
—
—
0.07
—


hsa-miR-100819
—
0.07
—
—
—
—
—


hsa-miR-100824
—
—
—
—
—
—
—


hsa-miR-100825-3p
—
—
—
—
—
—
—


hsa-miR-100825-5p
—
—
—
—
—
—
—


hsa-miR-100829-3p
—
—
—
—
—
—
—


hsa-miR-100835-5p
—
—
—
—
—
—
—


hsa-miR-100842
—
—
—
—
—
0.07
—


hsa-miR-100843-3p
0.20
—
—
—
—
—
—


hsa-miR-100843-5p
0.20
—
—
—
—
—
—


hsa-miR-100846
—
—
—
—
—
—
—


hsa-miR-100851
—
—
—
—
—
—
—


hsa-miR-100852
—
—
—
—
0.29
—
0.06


hsa-miR-100854
—
0.07
—
—
—
—
—


hsa-miR-100855-3p
—
—
—
—
—
0.15
0.13


hsa-miR-100855-5p
—
—
—
—
—
0.15
0.13


hsa-miR-100869-3p
—
—
—
—
—
—
—


hsa-miR-100869-5p
—
—
—
—
—
—
—


hsa-miR-100871-3p
—
—
—
0.26
—
—
—


hsa-miR-100871-5p
—
—
—
0.26
—
—
—


hsa-miR-100885
—
—
—
—
—
—
—


hsa-miR-100885
—
—
—
—
—
—
—


hsa-miR-100887-3p
—
—
—
—
—
—
—


hsa-miR-100887-3p
—
—
—
—
—
—
—


hsa-miR-100887-5p
—
—
—
—
—
—
—


hsa-miR-100887-5p
—
—
—
—
—
—
—


hsa-miR-100891-3p
—
—
—
—
—
—
—


hsa-miR-100891-3p
—
—
—
—
—
—
—


hsa-miR-100891-5p
—
—
—
—
—
—
—


hsa-miR-100891-5p
—
—
—
—
—
—
—


hsa-miR-101001
—
—
—
—
—
—
—


hsa-miR-146b
—
—
—
—
—
—
—


hsa-miR-147b
0.40
—
—
—
—
—
—


hsa-miR-181d
—
—
—
—
—
—
—


hsa-miR-18b
—
—
—
—
—
0.11
0.03


hsa-mir-18b-3p
—
—
—
—
—
0.11
0.03


hsa-miR-193b
0.20
0.07
—
0.26
0.07
0.07
0.06


hsa-miR-20b
—
—
—
—
—
—
—


hsa-miR-20b-3p
—
—
—
—
—
—
—


hsa-miR-216b
—
—
—
—
—
—
—


hsa-miR-301b
—
—
—
—
—
0.26
0.39


hsa-miR-329
—
—
—
—
—
—
—


hsa-miR-33b
—
—
—
—
0.43
0.15
—


hsa-miR-374b
—
—
—
—
1.72
0.97
0.71


hsa-miR-375
—
—
—
—
—
—
—


hsa-miR-376a
0.20
—
—
—
—
—
—


hsa-miR-376b
—
—
—
—
—
—
—


hsa-miR-376c
—
—
—
—
—
—
—


hsa-miR-376c
—
—
—
—
—
—
—


hsa-miR-377
—
0.07
—
—
—
—
—


hsa-miR-378
—
0.07
—
0.26
—
0.07
0.06


hsa-miR-379
1.00
—
—
—
—
—
—


hsa-miR-380
—
—
—
—
—
—
—


hsa-miR-410
—
—
—
—
—
—
—


hsa-miR-421-3p
—
—
—
0.26
0.29
—
—


hsa-miR-429
—
—
—
—
—
—
0.13


hsa-miR-431
—
—
—
—
—
—
—


hsa-miR-432
0.20
—
—
—
—
—
—


hsa-miR-433
—
—
—
—
—
—
—


hsa-miR-449a
—
—
—
—
—
—
—


hsa-miR-449b
—
—
—
—
—
—
—


hsa-miR-450a
—
—
—
—
0.07
—
—


hsa-miR-451
—
0.57
—
—
—
—
—


hsa-miR-452
—
—
—
—
—
0.07
0.06


hsa-miR-453
—
—
—
—
—
—
—


hsa-miR-454
0.20
—
—
—
0.07
0.07
—


hsa-miR-455-5p
—
—
—
—
—
0.60
0.26


hsa-miR-484
—
—
—
—
—
0.07
0.06


hsa-miR-485-3p
—
—
—
—
—
—
—


hsa-miR-485-5p
—
—
—
—
—
—
—


hsa-mir-486_os
—
—
—
—
—
—
—


hsa-miR-487
—
—
—
—
—
—
—


hsa-miR-488
—
—
—
—
—
—
—


hsa-miR-490
—
—
—
—
—
—
—


hsa-miR-493
0.20
—
—
—
—
—
—


hsa-miR-497
—
—
—
—
—
—
0.06


hsa-miR-502
—
—
—
—
—
—
—


hsa-miR-503
0.20
—
—
—
—
—
—


hsa-miR-505
—
0.07
—
—
0.07
0.07
0.06


hsa-miR-509-3p
—
—
—
—
—
—
—


hsa-miR-514
—
—
—
—
—
—
—


hsa-miR-544
—
—
—
—
—
—
—


hsa-miR-518
—
—
—
—
—
—
—


hsa-miR-619
—
—
—
—
—
—
—


hsa-miR-620
—
—
—
—
—
—
—


hsa-mir-816
—
—
—
—
0.07
—
—


hsa-mir-817
—
0.07
—
—
—
—
—


hsa-mir-828-3p
—
—
—
—
—
—
—


hsa-mir-828-5p
—
—
—
—
—
—
—


hsa-mir-831-1
—
—
—
—
—
—
—


hsa-mir-840-3p
—
—
—
—
0.07
—
—


hsa-mir-840-5p
—
—
—
0.26
0.22
0.37
0.71


hsa-mir-847
—
—
—
—
—
—
—


hsa-mir-848
0.40
—
—
—
—
—
—


hsa-mir-849
—
—
—
—
—
—
—


hsa-mir-850
0.20
—
—
—
—
—
—


hsa-mir-853
—
—
—
—
—
—
—


hsa-mir-857
—
—
—
—
—
—
—


hsa-miR-92b
—
—
—
—
0.04
—
—












precursor B-ALL














Heart
Spleen
T-cells
B-cells

hsa_B-















miRNA
hsa_heart
hsa_spleen
hsa_CD4
hsa_CD8
hsa_CD19
hsa_B-ALL2_d0
hsa_B-ALL3_d0
ALL4_d0





hsa-miR-100516
—
—
—
—
—
—
—
—


hsa-miR-100516
—
—
—
—
—
—
—
—


hsa-miR-100604
—
0.18
—
0.16
—
—
—
0.10


hsa-miR-100610-5p
—
—
—
—
—
—
—
—


hsa-miR-100631
—
—
—
—
—
—
—
—


hsa-miR-100732
—
—
—
—
—
—
—
—


hsa-miR-100814
—
—
—
—
—
—
—
—


hsa-miR-100815
—
—
0.14
—
—
0.15
0.12
—


hsa-miR-100818
—
—
—
—
—
—
—
—


hsa-miR-100819
—
—
—
—
—
—
—
—


hsa-miR-100824
—
—
—
—
—
—
—
—


hsa-miR-100825-3p
—
—
—
—
—
—
—
—


hsa-miR-100825-5p
—
—
—
—
—
—
—
—


hsa-miR-100829-3p
—
—
—
—
—
—
—
—


hsa-miR-100835-5p
—
—
—
0.16
—
—
—
—


hsa-miR-100842
—
—
0.14
0.16
—
—
—
0.10


hsa-miR-100843-3p
—
—
—
—
—
—
0.12
0.10


hsa-miR-100843-5p
—
—
—
—
—
—
0.12
0.10


hsa-miR-100846
—
—
—
—
—
—
—
—


hsa-miR-100851
—
—
—
—
—
—
—
—


hsa-miR-100852
—
—
—
—
—
—
—
—


hsa-miR-100854
—
—
—
0.16
—
—
—
—


hsa-miR-100855-3p
—
0.18
—
—
—
—
—
—


hsa-miR-100855-5p
—
0.18
—
—
—
—
—
—


hsa-miR-100869-3p
—
—
—
—
—
—
—
—


hsa-miR-100869-5p
—
—
—
—
—
—
—
—


hsa-miR-100871-3p
—
—
—
—
—
—
—
—


hsa-miR-100871-5p
—
—
—
—
—
—
—
—


hsa-miR-100885
—
—
—
—
—
—
—
—


hsa-miR-100885
—
—
—
—
—
—
—
—


hsa-miR-100887-3p
—
—
—
—
—
—
—
—


hsa-miR-100887-3p
—
—
—
—
—
—
—
—


hsa-miR-100887-5p
—
—
—
—
—
—
—
—


hsa-miR-100887-5p
—
—
—
—
—
—
—
—


hsa-miR-100891-3p
—
—
—
—
—
—
—
—


hsa-miR-100891-3p
—
—
—
—
—
—
—
—


hsa-miR-100891-5p
—
—
—
—
—
—
—
—


hsa-miR-100891-5p
—
—
—
—
—
—
—
—


hsa-miR-101001
—
—
—
—
—
—
—
—


hsa-miR-146b
—
—
0.21
—
—
—
—
0.10


hsa-miR-147b
—
—
—
—
—
—
—
—


hsa-miR-181d
—
—
—
—
—
—
—
—


hsa-miR-18b
—
—
—
—
—
—
—
0.10


hsa-mir-18b-3p
—
—
—
—
—
—
—
0.10


hsa-miR-193b
—
0.18
—
—
—
—
—
—


hsa-miR-20b
—
—
—
—
—
—
—
0.10


hsa-miR-20b-3p
—
—
—
—
—
—
—
0.10


hsa-miR-216b
—
—
—
—
—
—
—
0.05


hsa-miR-301b
—
—
—
—
—
—
—
—


hsa-miR-329
—
—
—
—
—
—
—
—


hsa-miR-33b
—
—
—
—
—
—
—
—


hsa-miR-374b
—
—
—
0.48
—
0.45
—
0.10


hsa-miR-375
—
0.18
—
0.16
—
—
—
—


hsa-miR-376a
—
—
—
—
—
—
—
—


hsa-miR-376b
—
—
—
—
—
—
—
—


hsa-miR-376c
—
—
—
—
—
—
—
—


hsa-miR-376c
—
—
—
—
—
—
—
—


hsa-miR-377
—
—
—
—
—
—
—
—


hsa-miR-378
—
—
—
—
—
—
—
0.10


hsa-miR-379
—
—
—
—
—
—
—
—


hsa-miR-380
—
—
—
—
—
—
—
—


hsa-miR-410
—
—
—
—
—
—
—
—


hsa-miR-421-3p
—
—
—
—
—
—
—
—


hsa-miR-429
—
—
—
—
—
—
—
—


hsa-miR-431
—
—
—
—
—
—
—
—


hsa-miR-432
—
—
—
—
—
—
—
—


hsa-miR-433
—
—
—
—
—
—
—
—


hsa-miR-449a
—
—
—
—
—
—
—
—


hsa-miR-449b
—
—
—
—
—
—
—
—


hsa-miR-450a
—
—
—
—
—
—
—
—


hsa-miR-451
1.68
0.18
—
—
0.30
—
0.25
0.20


hsa-miR-452
—
—
—
—
—
—
—
—


hsa-miR-453
—
—
—
—
—
—
—
—


hsa-miR-454
—
—
—
0.16
—
—
0.12
0.10


hsa-miR-455-5p
—
—
—
—
—
—
—
—


hsa-miR-484
—
—
—
—
—
—
—
—


hsa-miR-485-3p
—
—
—
—
—
—
—
—


hsa-miR-485-5p
—
—
—
—
—
—
—
—


hsa-mir-485_.0s
—
—
—
—
—
—
—
—


hsa-miR-487
—
—
—
—
—
—
—
—


hsa-miR-488
—
—
—
—
—
—
—
—


hsa-miR-490
—
—
—
—
—
—
—
—


hsa-miR-493
—
—
—
—
—
—
—
—


hsa-miR-497
0.30
—
—
—
—
—
—
—


hsa-miR-502
—
—
—
—
—
—
—
—


hsa-miR-503
—
—
—
—
—
—
—
—


hsa-miR-505
—
0.18
0.14
0.16
—
—
—
—


hsa-miR-509-3p
—
—
—
—
—
—
—
—


hsa-miR-514
—
—
—
—
—
—
—
—


hsa-miR-544
—
—
—
—
—
—
—
—


hsa-miR-618
—
—
—
—
—
—
—
—


hsa-miR-619
—
—
—
—
—
—
—
—


hsa-miR-620
—
—
—
—
—
—
—
—


hsa-mir-816
—
—
—
—
—
—
—
—


hsa-mir-817
—
—
—
—
—
—
—
—


hsa-mir-828-3p
—
—
—
—
—
—
—
—


hsa-mir-828-5p
—
—
—
—
—
—
—
—


hsa-mir-831-1
—
—
—
—
—
—
—
—


hsa-mir-840-3p
—
0.18
—
—
—
—
—
—


hsa-mir-840-5p
—
—
—
—
—
—
—
—


hsa-mir-847
—
—
—
—
—
—
—
—


hsa-mir-848
—
—
—
—
—
—
—
—


hsa-mir-849
—
—
—
—
—
—
—
—


hsa-mir-850
—
—
—
—
—
—
—
—


hsa-mir-853
—
0.18
—
—
—
—
—
—


hsa-mir-857
—
—
—
—
—
0.15
—
—


hsa-miR-92b
—
0.36
—
—
—
—
—
—













T-ALL
T-ALL in ramission













miRNA
hsa_turk
hsa_T-ALL3_d0
hsa_T-ALL4_d0
hsa_T-ALL4 d29






hsa-miR-100516
—
—
—
—



hsa-miR-100516
—
—
—
—



hsa-miR-100604
—
—
—
0.65



hsa-miR-100610-5p
—
0.15
—
—



hsa-miR-100631
—
—
—
—



hsa-miR-100732
—
—
—
—



hsa-miR-100514
—
—
—
—



hsa-miR-100815
—
0.36
0.26
0.41



hsa-miR-100816
0.17
—
—
—



hsa-miR-100819
—
—
—
—



hsa-miR-100824
—
—
—
—



hsa-miR-100835-3p
—
0.07
—
—



hsa-miR-100825-5p
—
0.07
—
—



hsa-miR-100829-3p
—
—
—
—



hsa-miR-100835-5p
—
—
—
—



hsa-miR-100842
0.17
—
—
—



hsa-miR-100843-3p
—
—
—
0.08



hsa-miR-100843-5p
—
—
—
0.08



hsa-miR-100846
—
—
—
—



hsa-miR-100851
—
—
—
—



hsa-miR-100852
—
—
—
—



hsa-miR-100854
—
—
—
—



hsa-miR-100855-3p
—
0.15
—
0.16



hsa-miR-100855-5p
—
0.15
—
0.16



hsa-miR-100869-39
—
—
—
—



hsa-miR-100869-5p
—
—
—
—



hsa-miR-100871-3p
—
—
—
—



hsa-miR-100871-5p
—
—
—
—



hsa-miR-100985
—
—
—
—



hsa-miR-100$$
—
—
—
—



hsa-miR-100887-3p
—
—
—
—



hsa-miR-100887-3p
—
—
—
—



hsa-miR-100887-5p
—
—
—
—



hsa-miR-100887-5p
—
—
—
—



hsa-miR-100891-3p
—
—
—
—



hsa-miR-100891-3p
—
—
—
—



hsa-miR-100891-5p
—
—
—
—



hsa-miR-100891-5p
—
—
—
—



hsa-miR-101001
—
—
—
—



hsa-miR-146b
—
—
—
—



hsa-miR-147b
—
—
—
—



hsa-miR-181d
—
—
—
—



hsa-miR-18b
—
0.07
—
—



hsa-mir-18b-3p
—
0.07
—
—



hsa-miR-193b
—
—
—
—



hsa-miR-20b
—
—
—
—



hsa-miR-20b-3p
—
—
—
—



hsa-miR-215b
—
—
—
—



hsa-miR-301b
0.67
0.07
—
—



hsa-miR-329
—
—
—
—



hsa-miR-33b
—
—
0.26
—



hsa-miR-374b
—
—
—
0.16



hsa-miR-375
—
—
—
—



hsa-miR-375a
—
—
—
—



hsa-miR-375b
—
—
—
—



hsa-miR-376c
—
—
—
—



hsa-miR-376c
—
—
—
—



hsa-miR-377
—
—
—
—



hsa-miR-378
—
0.07
0.78
0.05



hsa-miR-379
—
—
0.75
0.08



hsa-miR-380
—
—
—
0.05



hsa-miR-410
—
—
—
—



hsa-miR-421-3p
—
—
—
—



hsa-miR-429
—
—
—
—



hsa-miR-431
—
—
—
—



hsa-miR-432
—
—
—
—



hsa-miR-433
—
—
—
—



hsa-miR-449a
—
—
—
—



hsa-miR-449b
—
0.07
—
—



hsa-miR-450a
—
—
—
—



hsa-miR-451
—
—
—
—



hsa-miR-452
—
—
—
—



hsa-miR-453
—
—
—
—



hsa-miR-454
0.17
—
—
—



hsa-miR-455-5p
—
—
—
0.05



hsa-miR-484
—
—
—
—



hsa-miR-485-3p
—
—
—
—



hsa-miR-485-5p
—
—
—
—



hsa-miR-486_ns
—
—
—
—



hsa-miR-487
—
—
—
—



hsa-miR-488
—
—
—
—



hsa-miR-490
—
—
—
—



hsa-miR-493
—
—
—
—



hsa-miR-497
—
0.22
0.26
0.05



hsa-miR-502
—
—
—
—



hsa-miR-503
—
0.07
—
0.24



hsa-miR-505
—
—
—
—



hsa-miR-509-3p
—
—
—
—



hsa-miR-514
—
—
—
—



hsa-miR-544
—
—
—
—



hsa-miR-618
—
—
—
—



hsa-miR-619
—
—
—
—



hsa-miR-620
—
—
—
—



hsa-mir-816
—
—
—
—



hsa-mir-817
—
—
—
—



hsa-mir-828-3p
—
—
—
—



hsa-mir-828-5p
—
—
—
—



hsa-mir-831-1
—
—
—
—



hsa-mir-840-3p
—
—
—
—



hsa-mir-840-5p
—
—
—
—



hsa-mir-847
—
—
—
—



hsa-mir-848
—
—
—
—



hsa-mir-849
—
—
—
—



hsa-mir-850
—
—
—
—



hsa-mir-853
—
—
—
—



hsa-mir-857
—
—
—
—



hsa-miR-92b
—
—
—
—












AML














miRNA
hsa_kas1
hsa_MLb0
hsa_AML1_d0
hsa_AML2_d0
hsa_AML3_d0






hsa-miR-100516
—
—
—
—
—



hsa-miR-100516
—
—
—
—
—



hsa-miR-100604
—
0.28
0.10
0.14
0.15



hsa-miR-100610-5p
—
—
0.10
—
0.15



hsa-miR-100631
—
—
—
—
—



hsa-miR-100732
—
—
—
—
—



hsa-miR-100514
—
—
—
—
—



hsa-miR-100815
—
—
0.29
0.14
—



hsa-miR-100816
—
—
—
—
—



hsa-miR-100819
—
—
—
—
—



hsa-miR-100824
—
—
—
—
—



hsa-miR-100835-3p
—
—
—
—
—



hsa-miR-100825-5p
—
—
—
—
—



hsa-miR-100829-3p
—
—
—
—
—



hsa-miR-100835-5p
—
—
—
—
—



hsa-miR-100842
—
—
—
—
—



hsa-miR-100843-3p
—
—
—
—
—



hsa-miR-100843-5p
—
—
—
—
—



hsa-miR-100846
—
—
—
—
—



hsa-miR-100851
—
—
—
—
—



hsa-miR-100852
—
—
—
—
—



hsa-miR-100854
—
—
—
—
—



hsa-miR-100855-3p
—
—
0.20
—
—



hsa-miR-100855-5p
—
—
0.20
—
—



hsa-miR-100869-39
—
—
—
—
—



hsa-miR-100869-5p
—
—
—
—
—



hsa-miR-100871-3p
—
—
—
—
—



hsa-miR-100871-5p
—
—
—
—
—



hsa-miR-100985
—
—
—
—
—



hsa-miR-100$$
—
—
—
—
—



hsa-miR-100887-3p
—
—
—
—
—



hsa-miR-100887-3p
—
—
—
—
—



hsa-miR-100887-5p
—
—
—
—
—



hsa-miR-100887-5p
—
—
—
—
—



hsa-miR-100891-3p
—
—
—
—
—



hsa-miR-100891-3p
—
—
—
—
—



hsa-miR-100891-5p
—
—
—
—
—



hsa-miR-100891-5p
—
—
—
—
—



hsa-miR-101001
—
—
—
—
—



hsa-miR-146b
—
—
—
—
—



hsa-miR-147b
—
—
—
—
—



hsa-miR-181d
—
—
—
—
—



hsa-miR-18b
—
—
0.20
—
—



hsa-mir-18b-3p
—
—
0.25
—
—



hsa-miR-193b
—
—
—
—
—



hsa-miR-20b
—
—
—
—
—



hsa-miR-20b-3p
—
—
—
—
—



hsa-miR-215b
—
—
—
0.07
—



hsa-miR-301b
0.71
—
—
—
—



hsa-miR-329
—
—
—
—
—



hsa-miR-33b
—
—
—
—
—



hsa-miR-374b
0.71
0.25
0.10
—
—



hsa-miR-375
—
—
—
0.14
—



hsa-miR-375a
—
—
—
—
—



hsa-miR-375b
—
—
—
—
—



hsa-miR-376c
—
—
—
—
—



hsa-miR-376c
—
—
—
—
—



hsa-miR-377
—
—
—
—
—



hsa-miR-378
—
0.56
—
—
—



hsa-miR-379
—
—
—
0.14
—



hsa-miR-380
—
—
—
—
—



hsa-miR-410
—
—
—
—
—



hsa-miR-421-3p
—
—
—
—
—



hsa-miR-429
—
—
—
—
—



hsa-miR-431
—
—
—
—
—



hsa-miR-432
—
—
—
—
—



hsa-miR-433
—
—
—
—
—



hsa-miR-449a
—
—
—
—
—



hsa-miR-449b
—
—
—
—
—



hsa-miR-450a
—
—
—
—
—



hsa-miR-451
—
—
—
—
0.31



hsa-miR-452
—
—
—
—
—



hsa-miR-453
—
—
—
—
—



hsa-miR-454
—
—
—
—
—



hsa-miR-455-5p
—
—
—
—
—



hsa-miR-484
—
—
—
0.14
—



hsa-miR-485-3p
—
—
—
—
—



hsa-miR-485-5p
—
—
—
—
—



hsa-miR-486_ns
—
—
—
—
—



hsa-miR-487
—
—
—
—
—



hsa-miR-488
—
—
—
—
—



hsa-miR-490
—
—
—
—
—



hsa-miR-493
—
—
—
—
—



hsa-miR-497
—
—
0.20
0.14
—



hsa-miR-502
—
—
—
—
—



hsa-miR-503
—
—
0.29
—
—



hsa-miR-505
—
—
—
—
—



hsa-miR-509-3p
—
—
0.10
—
—



hsa-miR-514
—
—
—
—
—



hsa-miR-544
—
—
—
—
—



hsa-miR-618
—
—
—
—
—



hsa-miR-619
—
—
—
—
—



hsa-miR-620
—
—
—
—
—



hsa-mir-816
—
—
—
—
—



hsa-mir-817
—
—
—
—
—



hsa-mir-828-3p
—
—
—
—
—



hsa-mir-828-5p
—
—
—
—
—



hsa-mir-831-1
—
—
—
—
—



hsa-mir-840-3p
—
—
—
—
—



hsa-mir-840-5p
—
—
—
0.27
—



hsa-mir-847
—
—
—
—
—



hsa-mir-848
—
—
—
—
—



hsa-mir-849
—
—
—
—
—



hsa-mir-850
—
—
—
—
—



hsa-mir-853
—
—
—
—
—



hsa-mir-857
—
—
—
—
—



hsa-miR-92b
—
—
—
—
—














Unrestricted




somatic



Endocrine organs
stem cells















miRNA
hsa_pituitary
SW13
SW13_YFV
hsa_ovary
hsa_testis
hsa_thyroid
hsa_pancreatic_islet
hsa_USSC_d1





hsa-miR-100516
—
—
—
—
—
—
—
—


hsa-miR-100516
—
—
—
—
—
—
—
—


hsa-miR-100604
0.06
—
—
0.23
0.15
—
—
—


hsa-miR-100610-
—
0.13
0.12
—
0.07
—
—
—


5p










hsa-miR-100631
—
—
—
—
—
—
—
—


hsa-miR-100732
—
—
—
—
—
—
—
0.07


hsa-miR-100814
—
—
—
—
—
—
—
—


hsa-miR-100819
0.06
—
—
—
—
—
0.09
—


hsa-miR-100818
—
—
—
—
—
—
—
0.07


hsa-miR-100819
—
—
—
—
—
—
—
—


hsa-miR-100824
—
—
—
—
—
—
—
—


hsa-miR-100825-
0.18
—
—
—
—
—
—
—


3p










hsa-miR-100825-
0.18
—
—
—
—
—
—
—


5p










hsa-miR-100829-
—
—
0.24
—
—
—
—
—


3p










hsa-miR-100835-
—
0.27
—
—
—
—
—
—


5p










hsa-miR-100842
—
—
—
—
—
—
—
—


hsa-miR-100843-
0.06
—
—
0.46
—
—
—
—


3p










hsa-miR-100843-
0.06
—
—
0.46
—
—
—
—


5p










hsa-miR-100846
—
—
—
—
—
—
—
—


hsa-miR-100851
—
—
—
—
—
—
—
—


hsa-miR-100852
—
—
—
—
—
—
—
—


hsa-miR-100854
—
—
—
0.08
—
—
—
—


hsa-miR-100855-
0.12
—
—
0.53
0.51
—
0.19
0.07


3p










hsa-miR-100855-
0.12
—
—
0.53
0.51
—
0.19
0.07


5p










hsa-miR-100859-
—
—
—
—
—
—
—
0.07


3p










hsa-miR-100869-
—
—
—
—
—
—
—
0.07


5p










hsa-miR-100871-
—
0.13
—
—
—
—
—
0.14


3p










hsa-miR-100871-
—
0.13
—
—
—
—
—
0.14


5p










hsa-miR-100385
—
0.13
0.24
—
—
—
0.09
—


hsa-miR-100885
—
0.13
0.24
—
—
—
0.09
—


hsa-miR-100887-
—
—
0.12
—
—
—
—
—


3p










hsa-miR-100887-
—
—
0.12
—
—
—
—
—


3p










hsa-miR-100887-
—
—
0.12
—
—
—
—
—


5p










hsa-miR-100887-
—
—
0.12
—
—
—
—
—


5p










hsa-miR-100891-
—
—
—
—
—
—
—
—


3p










hsa-miR-100891-
—
—
—
—
—
—
—
—


3p










hsa-miR-100891-
—
—
—
—
—
—
—
—


5p










hsa-miR-100891-
—
—
—
—
—
—
—
—


5p










hsa-miR-101001
0.06
—
—
—
0.07
—
—
0.07


hsa-miR-146b
—
—
0.24
—
—
—
—
—


hsa-miR-147b
—
—
—
—
—
—
0.09
—


hsa-miR-181d
—
—
0.12
—
—
—
—
—


hsa-miR-18b
—
0.20
1.09
—
—
—
—
—


hsa-mir-18b-3p
—
0.20
1.09
—
—
—
—
—


hsa-miR-193b
—
—
—
0.23
—
—
—
0.07


hsa-miR-20b
—
1.87
2.91
—
—
—
—
0.04


hsa-miR-20b-3p
—
1.87
2.91
—
—
—
—
0.04


hsa-miR-216b
—
—
—
—
—
—
—
—


hsa-miR-301b
—
0.13
0.61
—
—
—
—
0.07


hsa-miR-329
0.06
—
—
—
—
—
—
—


hsa-miR-33b
—
0.13
—
—
—
—
—
—


hsa-miR-374b
0.06
0.20
—
0.08
—
—
—
0.21


hsa-miR-375
3.05
—
—
—
0.07
—
8.07
—


hsa-miR-376a
0.18
—
—
0.08
—
—
0.09
0.07


hsa-miR-376b
—
—
—
—
—
—
0.09
0.07


hsa-miR-376c
0.18
—
—
—
—
—
0.19
0.07


hsa-miR-376c
0.18
—
—
—
—
—
0.19
0.07


hsa-miR-377
0.24
—
—
0.23
0.15
—
0.19
0.35


hsa-miR-378
0.06
0.53
0.61
—
—
—
—
—


hsa-miR-379
0.24
—
—
0.08
0.22
—
0.38
0.14


hsa-miR-380
—
—
—
—
—
—
—
—


hsa-miR-410
0.43
—
—
—
—
—
0.19
0.07


hsa-miR-421-3p
—
—
—
—
—
—
—
—


hsa-miR-429
0.12
—
—
—
—
—
0.09
—


hsa-miR-431
—
—
—
—
—
—
0.19
0.14


hsa-miR-432
0.06
—
—
—
—
—
0.09
0.14


hsa-miR-433
0.06
—
—
—
—
—
—
—


hsa-miR-449a
—
—
—
—
0.29
—
—
—


hsa-miR-449b
—
0.13
—
—
—
—
—
—


hsa-miR-450a
—
—
—
—
—
—
—
—


hsa-miR-451
1.28
—
—
0.76
0.07
1.92
—
—


hsa-miR-452
—
—
—
—
—
—
—
—


hsa-miR-453
—
—
—
—
—
—
—
—


hsa-miR-454
0.06
—
0.24
—
—
—
—
—


hsa-miR-455-5p
—
—
—
—
—
—
0.19
—


hsa-miR-484
—
—
—
—
—
—
—
—


hsa-miR-485-3p
—
—
—
—
—
—
—
0.07


hsa-miR-485-5p
—
—
—
—
—
—
—
0.07


hsa-miR-486 os
—
—
—
—
—
—
—
—


hsa-miR-487
—
—
—
—
—
—
—
—


hsa-miR-488
—
—
—
—
—
—
—
—


hsa-miR-490
—
—
—
—
—
—
—
—


hsa-miR-493
—
—
—
—
—
—
—
0.14


hsa-miR-497
—
—
—
0.15
0.15
0.52
—
—


hsa-miR-502
—
—
—
—
—
—
—
—


hsa-miR-503
0.06
—
0.12
—
0.58
—
—
—


hsa-miR-505
—
—
—
—
—
—
—
—


hsa-miR-509-3p
—
—
—
—
0.73
—
—
—


hsa-miR-514
0.12
—
—
0.15
0.58
—
—
—


hsa-miR-544
—
—
—
—
—
—
—
—


hsa-miR-618
—
—
0.24
—
—
—
—
—


hsa-miR-619
0.05
—
0.24
—
—
—
—
0.07


hsa-miR-620
—
—
—
—
—
—
—
—


hsa-mir-816
—
0.13
0.12
—
—
—
—
—


hsa-mir-817
—
—
—
—
—
—
—
—


hsa-mir-828-3p
—
—
—
—
—
—
—
—


hsa-mir-828-5p
—
—
0.12
—
—
—
—
—


hsa-mir-831-1
—
0.13
0.12
—
—
—
—
—


hsa-mir-840-3p
—
—
—
—
—
—
—
—


hsa-mir-840-5p
—
—
0.12
—
0.07
—
—
—


hsa-mir-847
—
—
—
—
—
—
—
—


hsa-mir-848
—
—
—
—
—
—
—
—


hsa-mir-849
—
—
—
—
—
—
—
—


hsa-mir-850
—
—
—
—
—
—
—
—


hsa-mir-853
—
—
—
—
—
—
—
—


hsa-mir-857
—
0.13
—
—
—
—
—
—


hsa-miR-92b
0.06
0.13
0.12
—
—
—
—
—















Embryonal derived cell lines/tumors

Cervix carcinoma















hsa_Hela
Placenta
hsa_HeLa
HeLa_HIV
Epididymis
Prestate















miRNA
hsa_NT2/D1
NCCIT
exp
hsa_placenta
susp
infected
hsa_epididymis
hsa-prestate


















hsa-miR-100516
—
—
—
—
—
—
1.18
—


hsa-miR-100516
—
—
—
—
—
—
1.18
—


hsa-miR-100604
0.12
—
0.25
—
—
—
—
—


hsa-miR-100610-5p
0.12
—
—
0.06
—
—
0.08
0.08


hsa-miR-100631
—
—
—
—
—
—
—
—


hsa-miR-100732
—
—
—
—
—
—
—
—


hsa-miR-100814
0.12
—
—
—
—
—
—
—


hsa-miR-100815
0.12
—
0.51
—
—
—
—
—


hsa-miR-100818
—
0.73
—
—
—
—
—
—


hsa-miR-100819
—
—
—
—
—
—
—
—


hsa-miR-100824
—
—
—
—
—
—
—
—


hsa-miR-100825-3p
—
—
—
—
—
—
—
—


hsa-miR-100825-5p
—
—
—
—
—
—
—
—


hsa-miR-100829-3p
—
—
—
—
—
—
—
—


hsa-miR-100835-5p
—
—
—
—
—
1.22
—
—


hsa-miR-100842
0.12
—
—
—
—
—
—
—


hsa-miR-100843-3p
1.70
—
0.25
—
—
—
—
—


hsa-miR-100843-5p
1.70
—
0.25
—
—
—
—
—


hsa-miR-100845
—
—
—
—
—
—
—
—


hsa-miR-100851
0.12
—
—
—
—
—
—
—


hsa-miR-100852
0.36
—
—
—
—
—
—
—


hsa-miR-100854
—
—
—
—
—
—
—
—


hsa-miR-100855-3p
—
—
—
—
—
—
0.16
0.23


hsa-miR-100855-5p
—
—
—
—
—
—
0.16
0.23


hsa-miR-100869-3p
—
—
—
—
—
—
—
—


hsa-miR-100869-5p
—
—
—
—
—
—
—
—


hsa-miR-100871-3p
—
0.73
—
—
0.22
—
—
—


hsa-miR-100871-5p
—
0.73
—
—
0.22
—
—
—


hsa-miR-100855
—
—
—
0.06
—
—
—
—


hsa-miR-100885
—
—
—
0.06
—
—
—
—


hsa-miR-100857-3p
—
—
—
—
—
—
—
—


hsa-miR-100887-3p
—
—
—
—
—
—
—
—


hsa-miR-100887-5p
—
—
—
—
—
—
—
—


hsa-miR-100887-5p
—
—
—
—
—
—
—
—


hsa-miR-100891-3p
—
—
—
—
—
—
—
—


hsa-miR-100891-3p
—
—
—
—
—
—
—
—


hsa-miR-100891-5p
—
—
—
—
—
—
—
—


hsa-miR-100891-5p
—
—
—
—
—
—
—
—


hsa-miR-101001
0.12
—
—
—
—
—
—
—


hsa-miR-146b
—
—
—
—
—
—
—
—


hsa-miR-147b
—
—
—
—
—
—
—
—


hsa-miR-181d
—
—
—
—
—
—
—
—


hsa-miR-18b
—
0.73
0.13
—
—
—
—
—


hsa-mir-18b-3p
—
0.73
0.13
—
—
—
—
—


hsa-miR-193b
—
—
0.25
0.05
0.43
—
—
0.16


hsa-miR-20b
0.36
0.73
0.13
—
—
—
—
0.03


hsa-miR-20b-3p
0.36
0.73
0.13
—
—
—
—
0.03


hsa-miR-216b
—
—
—
—
—
—
—
—


hsa-miR-301b
—
—
—
—
—
—
—
—


hsa-miR-329
—
—
—
—
—
—
—
—


hsa-miR-33b
—
—
0.51
—
0.43
—
—
—


hsa-miR-374b
0.45
1.46
0.25
—
—
0.41
—
0.08


hsa-miR-375
—
—
—
—
—
—
—
0.08


hsa-miR-376a
—
—
—
0.06
—
—
—
—


hsa-miR-376b
—
—
—
—
—
—
—
—


hsa-miR-376c
—
—
—
0.05
—
—
—
—


hsa-miR-376c
—
—
—
0.05
—
—
—
—


hsa-miR-377
—
—
—
0.19
—
—
—
—


hsa-miR-378
—
—
0.25
—
—
—
—
—


hsa-miR-379
—
—
—
0.05
—
—
—
—


hsa-miR-380
—
—
—
—
—
—
—
—


hsa-miR-410
—
—
—
—
—
—
—
—


hsa-miR-421-3p
—
—
—
—
—
—
0.05
—


hsa-miR-429
—
—
—
—
—
—
—
—


hsa-miR-431
—
—
—
0.19
—
—
—
—


hsa-miR-432
—
—
—
—
—
—
—
—


hsa-miR-433
—
—
—
—
—
—
—
—


hsa-miR-449a
—
—
—
—
—
—
0.05
—


hsa-miR-449b
—
—
—
—
—
—
—
—


hsa-miR-450a
—
—
—
—
—
—
—
—


hsa-miR-451
—
—
—
0.51
—
—
0.39
0.15


hsa-miR-452
—
—
—
—
—
—
—
—


hsa-miR-453
—
—
—
—
—
—
—
—


hsa-miR-454
0.12
—
0.25
—
—
—
—
—


hsa-miR-455-5p
—
—
0.25
—
—
—
—
0.03


hsa-miR-484
—
—
—
—
—
0.41
—
—


hsa-miR-485-3p
—
—
—
—
—
—
—
—


hsa-miR-485-5p
—
—
—
—
—
—
—
—


hsa-mir-485_0s
—
—
—
—
—
0.41
—
—


hsa-miR-487
—
—
—
—
—
—
—
—


hsa-miR-488
0.12
—
—
—
—
—
—
—


hsa-miR-490
—
—
—
—
—
—
—
—


hsa-miR-493
—
—
—
—
—
—
—
—


hsa-miR-497
—
—
—
—
—
—
—
0.08


hsa-miR-502
—
—
—
—
0.11
—
—
—


hsa-miR-503
—
—
0.25
0.25
—
—
—
—


hsa-miR-505
—
—
—
—
—
—
—
0.08


hsa-miR-509-3p
—
—
—
—
—
—
—
—


hsa-miR-514
—
—
—
—
—
—
—
—


hsa-miR-544
—
—
—
—
—
—
—
—


hsa-miR-618
—
—
—
—
—
—
—
—


hsa-miR-619
—
—
—
—
—
—
—
—


hsa-miR-620
—
—
—
—
—
—
—
—


hsa-mir-816
—
—
0.25
—
—
—
—
—


hsa-mir-817
—
—
—
—
—
0.82
—
—


hsa-mir-828-3p
—
—
—
—
—
—
—
—


hsa-mir-828-5p
—
—
—
—
—
—
—
—


hsa-mir-831-1
—
—
—
—
—
—
—
—


hsa-mir-840-3p
—
0.73
—
—
—
—
—
—


hsa-mir-840-5p
0.36
—
—
0.06
0.22
0.41
—
—


hsa-mir-847
—
—
—
—
—
—
—
—


hsa-mir-848
—
—
—
—
—
—
—
—


hsa-mir-849
—
—
—
—
—
—
—
—


hsa-mir-850
—
—
—
—
—
—
—
—


hsa-mir-853
—
—
—
—
—
—
—
—


hsa-mir-857
0.12
—
—
—
—
—
—
—


hsa-miR-92b
0.35
—
—
—
—
—
—
—













Breast Carcinoma
Ewino Sarcoma














miRNA
hsa_MCF10A
hsa_MCF7
hsa_HCC38
hsa_5kBr3
hsa_BT474
hsa_T47
hsa_A673





hsa-miR-100516
—
—
—
—
—
—
—


hsa-miR-100516
—
—
—
—
—
—
—


hsa-miR-100604
0.18
—
0.18
—
0.18
0.17
—


hsa-miR-100610-5p
—
—
—
—
—
—
0.09


hsa-miR-100631
—
0.25
—
—
—
—
—


hsa-miR-100732
—
—
—
—
—
—
—


hsa-miR-100814
—
—
—
—
—
—
—


hsa-miR-100815
—
0.13
0.09
—
0.05
—
0.09


hsa-miR-100818
—
—
—
—
0.05
—
—


hsa-miR-100819
—
—
—
—
—
—
—


hsa-miR-100824
—
—
—
—
—
—
—


hsa-miR-100825-3p
—
—
—
—
—
—
—


hsa-miR-100825-5p
—
—
—
—
—
—
—


hsa-miR-100829-3p
—
—
—
—
—
—
—


hsa-miR-100835-5p
—
—
—
—
0.05
—
—


hsa-miR-100842
—
—
—
—
—
—
—


hsa-miR-100843-3p
—
0.13
—
—
0.23
—
0.09


hsa-miR-100843-5p
—
0.13
—
—
0.23
—
0.09


hsa-miR-100846
—
—
—
—
—
—
—


hsa-miR-100851
—
—
—
—
—
—
—


hsa-miR-100852
—
—
—
0.12
—
—
—


hsa-miR-100854
—
—
—
—
—
—
—


hsa-miR-100855-3p
—
—
0.18
—
—
—
—


hsa-miR-100855-5p
—
—
0.18
—
—
—
—


hsa-miR-100859-3p
—
—
—
—
—
—
—


hsa-miR-100859-5p
—
—
—
—
—
—
—


hsa-miR-100871-3p
—
—
—
—
—
—
—


hsa-miR-100871-5p
—
—
—
—
—
—
—


hsa-miR-100885
—
—
—
—
—
—
—


hsa-miR-100885
—
—
—
—
—
—
—


hsa-miR-100887-3p
—
—
—
—
—
—
—


hsa-miR-100887-3p
—
—
—
—
—
—
—


hsa-miR-100887-5p
—
—
—
—
—
—
—


hsa-miR-100887-5p
—
—
—
—
—
—
—


hsa-miR-100891-3p
—
—
—
—
—
—
0.18


hsa-miR-100891-3p
—
—
—
—
—
—
0.18


hsa-miR-100891-5p
—
—
—
—
—
—
0.18


hsa-miR-100891-5p
—
—
—
—
—
—
0.18


hsa-miR-101001
—
—
—
—
—
—
—


hsa-miR-145b
—
—
—
—
—
—
—


hsa-miR-147b
—
—
—
—
—
—
—


hsa-miR-181b
—
—
—
—
0.02
—
—


hsa-miR-18b
—
—
0.18
—
0.02
—
—


hsa-mir-18b-3p
—
—
0.18
—
0.02
—
—


hsa-miR-193b
0.09
0.25
—
0.23
0.05
0.17
0.09


hsa-miR-20b
—
—
—
—
—
—
0.03


hsa-miR-20b-3p
—
—
—
—
—
—
0.03


hsa-miR-216b
—
—
—
—
—
—
—


hsa-miR-301b
—
—
—
—
—
0.59
0.45


hsa-miR-329
—
—
—
—
—
—
—


hsa-miR-33b
0.09
0.13
0.09
—
0.60
0.08
—


hsa-miR-374b
—
—
0.18
—
0.05
0.42
0.63


hsa-miR-375
—
4.26
—
0.12
—
0.17
—


hsa-miR-376a
—
—
—
—
—
—
—


hsa-miR-376b
—
—
—
—
—
—
0.09


hsa-miR-376c
—
—
—
—
—
—
—


hsa-miR-376c
—
—
—
—
—
—
—


hsa-miR-377
—
—
—
—
—
—
0.72


hsa-miR-378
0.46
—
—
0.23
0.28
—
—


hsa-miR-379
—
0.13
—
—
—
—
0.09


hsa-miR-380
—
—
—
—
—
—
—


hsa-miR-410
—
—
—
—
—
—
0.18


hsa-miR-421-3p
—
0.13
—
—
—
0.05
0.18


hsa-miR-429
—
0.25
—
—
0.09
0.25
—


hsa-miR-431
—
—
—
—
—
—
—


hsa-miR-432
—
—
—
—
—
—
—


hsa-miR-433
—
—
—
—
—
—
0.09


hsa-miR-449a
—
—
—
—
—
—
—


hsa-miR-449b
—
—
—
—
—
—
—


hsa-miR-450a
—
—
—
—
—
—
0.09


hsa-miR-451
—
—
—
—
—
—
—


hsa-miR-452
—
—
—
0.12
0.05
—
—


hsa-miR-453
—
—
—
—
—
—
—


hsa-miR-454
—
—
0.18
—
0.97
0.34
—


hsa-miR-455-5p
—
—
—
—
—
—
—


hsa-miR-484
—
—
—
—
—
0.05
—


hsa-miR-485-3p
—
—
—
—
—
—
—


hsa-miR-485-5p
—
—
—
—
—
—
—


hsa-mir-485_0s
—
—
—
—
—
—
—


hsa-miR-487
—
—
—
—
—
—
—


hsa-miR-488
—
—
—
—
—
—
0.27


hsa-miR-490
—
—
—
—
—
—
—


hsa-miR-493
—
0.13
—
—
—
—
0.09


hsa-miR-497
—
0.13
—
—
0.05
0.05
—


hsa-miR-502
—
—
—
—
—
—
—


hsa-miR-503
—
0.50
—
—
—
—
1.53


hsa-miR-505
—
—
—
—
—
—
—


hsa-miR-509-3p
—
—
—
—
—
—
—


hsa-miR-514
—
—
—
—
—
—
—


hsa-miR-544
—
—
—
—
—
—
—


hsa-miR-618
—
—
—
—
—
—
—


hsa-miR-619
—
—
—
—
—
—
—


hsa-miR-620
—
0.25
—
—
—
—
—


hsa-mir-816
0.09
0.13
—
—
—
—
—


hsa-mir-817
—
—
—
—
—
—
—


hsa-mir-828-3p
—
—
—
—
—
—
—


hsa-mir-828-5p
—
—
—
—
—
—
—


hsa-mir-831-1
—
—
—
—
—
—
—


hsa-mir-840-3p
—
—
—
—
0.05
—
—


hsa-mir-840-5p
—
—
—
—
0.55
0.51
0.18


hsa-mir-847
—
—
—
0.23
—
—
—


hsa-mir-848
—
—
—
—
—
—
—


hsa-mir-849
—
—
—
0.23
—
—
—


hsa-mir-850
—
—
—
—
—
—
—


hsa-mir-853
—
—
—
—
—
—
0.09


hsa-mir-857
—
—
—
—
—
—
—


hsa-miR-92b
—
0.50
—
0.12
—
—
0.09









EXAMPLES
Example 1
Materials and Methods
Total RNA Isolation, Cloning and Annotation
Small RNAs were isolated from 100-200 μg of total RNA and cloned as described previously. The annotation was based on information from GenBank (http://www.ncbi.nih.gov/Genbank/), a dataset of human tRNA sequences (http://rna.wustl.edu/GtRDB/Hs/Hs-seqs.html), a dataset of human sn/snoRNA sequences (http://mbcr.bcm.tmc.edu/smallRNA/Database, snoRNA-LBME-db at http://www-snoma.biotoul.fr/index.php and NONCODE v1 at http://noncode.bioinfo.org.cn/), the microRNA registry release version 5.1, and the repeat element annotation of version 17 of the human genome assembly from UCSC (http://genome.ucse.edu).
Cell Lines and Tissues
Pituitary gland was dissected 2 hours postmortal following the written consent of the person's relatives. The identity of the person was obscured for privacy reasons. The human breast cancer cell lines MCF7 and SkBr3 were gifts of Dr. Neal Rosen (Memorial Sloan-Kettering Cancer Center, NY), and were maintained in 1:1 mixture of DME:F12 medium supplemented with 100 units/ml penicillin, 100 μg/ml streptomycin, 4 mM glutamine, and 10% heat inactivated fetal bovine serum, and incubated at 37° C. in 5% CO2. The human neuroblastoma cell line BE(2)-M17 (ATCC:CRL-2267) was maintained in 1:1 mixture of OptiMem:F12 medium supplemented with non essential amino acids, 10% heat inactivated fetal bovine serum, and incubated at 37° C. in 5% CO2.
Example 2
Prediction of Novel miRNA Genes
We predicted microRNA precursors by using conservation filters as well as structural features of the hairpin and folding energy. We compared these predicted sequences to cloning results from human tissues and cell lines, as well as to sequences of experimentally verified microRNAs in other mammals. In applying similarity considerations we followed Rfam, where more than 45% of the human entries are supported by similarity to microRNAs in other mammals. Table 1 demonstrates the verified predictions. FIG. 2A shows the extension of the cluster of miR-200 to include an additional member that was verified by cloning from human tissues, located approximately 1000 nucleotides downstream to miR-200a (Table 1). FIG. 2B demonstrates the identification of two additional microRNA genes in the vicinity of miR-369, one verified by cloning and one supported by its sequence similarity to the mouse homolog (Table 1).







TABLE 1







Supporting evidence for the predicted microRNA genes in the vicinity of known


microRNAs


Predicted microRNA genes supported by cloning









Supporting evidence










Coordinates of cluster founding microRNAs1

By












Cluster

Predicted microRNA
cloning



founding

precursor coordinates
(this
By














microRNAs
Chromosome2
Start
End
Start3
end
study)4
similarity5

















miR-200b, miR-
 1 (+)
1008542
1009390
1010452
1010518
miR-734-
miR-429


200a





3p



miR-191 (MH)
 3 (−)
49017063
49017154
49016591
49016681
miR-425-
Rfam: hsa-








3p,5p
miR-425


miR-127, miR-
14 (+)
99339357
99341161
99337372
99337503
miR-810



136



99338264
99338356
miR-809



miR-299, miR-
14 (+)
99480172
99482195
99483163
99483242
miR-807



323









miR-368
14 (+)
99496068
99496133
99497151
99497236
miR-









376a-3p



miR-134
14 (+)
99511065
99511137
99512568
99512647
miR-812



miR-369
14 (+)
99521976
99522045
99521669
99521773
miR-409-
Rfam:








3p,5p
mmu-miR-









409


miR-144
17 (−)
27334114
27334199
27333954
27334017
miR-806
cand919


miR-224 (MH)
X (−)
149744663
149744743
149745713
149745797
miR-811





1The precursor coordinates are listed. When the predicted miRNA is in the vicinity of an already known miRNA cluster, the coordinates of the whole cluster are listed, from the initial coordinate of the precursor of the first miRNA to the end coordinate of the precursor of the last miRNA.


2The chromosome number, strand and coordinates are taken from the UCSC July 2003 human genome assembly build 34 (hg16) (http://genome.ucsc.edu).


3The coordinates of predicted miRNAs are on the same chromosome and strand as the known cluster member/s.


4Cloned miRNAs were given new names. When miRNAs from both sides of the precursor stem were identified and matched our predictions they are designated with 3p and 5p.


5There are three types of supporting evidence by similarity:






INCORPORATION OF SEQUENCE LISTING
Incorporated herein by reference in its entirety is the Sequence Listing for the application. The Sequence Listing is disclosed on a computer-readable ASCII text file titled, “sequence_listing.txt”, created on Jun. 4, 2010. The sequence_listing.txt file is 145 kb in size.

## Claims

1. An isolated nucleic acid molecule comprising a microRNA having SEQ ID NO: 481, said molecule having no more than 50 nucleotides.

2. An isolated nucleic acid molecule comprising a hairpin precursor microRNA having SEQ ID NO: 496, said molecule having no more than 300 nucleotides.

3. A vector comprising the molecule according to claim 2.

4. A vector comprising the molecule according to claim 1.

5. An isolated molecule according to claim 1, wherein the isolated molecule is a DNA molecule.

6. An isolated molecule according to claim 1, wherein the isolated molecule is a RNA molecule.

7. An isolated molecule according to claim 1, wherein the isolated molecule further comprises a cap.

8. An isolated molecule according to claim 7, wherein the cap is an inverted nucleotide cap.

9. An isolated molecule according to claim 7, wherein the cap is a chemical cap.

10. An isolated molecule according to claim 1, wherein the isolated molecule consists of SEQ ID NO: 481.

11. An isolated molecule according to claim 2, wherein the isolated molecule consists of SEQ ID NO: 496.

12. A molecule according to claim 1, wherein the molecule is modified for increased nuclease resistance.